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SUMMARY 
Studying prospective immune correlates of risk of TB disease following BCG 
vaccination is an important first step towards determining correlates of 
protection against TB, which can be identified only in a placebo-controlled 
randomized controlled trial (RCT) of an effective vaccine. To study correlates of 
risk of TB disease, we collected and stored blood from healthy 10-week old 
infants vaccinated with BCG at birth. During two years of follow up, infants who 
developed lung TB were defined as cases, while those who did not develop TB 
disease were defined as controls. We measured Th1/Th17 cytokine production 
by BCG-specific T cells, release of pro- and anti-inflammatory mediators, 
cytotoxic T cell potential and proliferation in response to BCG as potential 
correlates of risk of TB disease but none of these outcomes were different 
between cases and controls. However, transcriptional profiling of PBMC 
revealed two clusters of infants and interestingly, the gene expression profiles 
from cases and controls in the two clusters were in opposite directions. Based 
on this, we hypothesised that analysing the two clusters of infants separately will 
allow discovery of correlates of risk of TB, which were absent when clustering 
was not taken into account.  
Analysing the two clusters separately, we found several T cell outcomes as well 
as gene expression profiles that were different between cases and controls 
within each cluster. In cluster 1, frequencies of BCG-specific CD4+ T cells 
producing granulysin, granzyme B and perforin in different combinations were 
higher in cases compared to controls while in cluster 2, frequencies of BCG-
specific CD4+ T cells producing perforin only were higher in controls compared 
to cases. Frequencies of BCG-specific CD4+ T cells in producing IL-17 were 
higher in cases compared to controls in cluster 2. We also found that 
inflammatory and innate genes were up-regulated in cases compared to 
controls in cluster 2 with no differential gene expression in cluster 1. Pathway 
analyses by GSEA and IPA also showed up-regulation and down-regulation of 
inflammatory genes in cluster 2 and cluster cases respectively compared to 
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controls.  Based on this, we concluded that too much or too little inflammation 
increases risk of developing TB disease. 
We next compared the two clusters in an attempt to understand the biology. We 
found that cluster 2 infants had higher frequencies of BCG-specific total CD4+ T 
cells producing IFN-γ, TNF-α and IL-2 compared to cluster 1. In addition, 
polyfunctional CD4+ T and CD8+ T cells producing IFN-γ, TNF-α and IL-2 were 
also higher in cluster 2 compared to cluster 1. Several other T cell subsets as 
well as secreted mediators were higher in cluster 2 compared to cluster 1. 
Pathway analysis by IPA showed and IFN-γ dominated pathway with up-
regulation of genes in this pathway in cluster 2 compared to cluster 1. We 
concluded that clustering of gene expression profiles was linked to differential 
response to BCG vaccination and this should be taken into account for 
discovery of host correlates of risk of TB disease. 
To validate these findings in another cohort of cases and controls, we used two 
approaches to define differential response to BCG vaccination. The first 
approach was hypothesis-driven. Firstly, we used a logistic regression model to 
identify the best T cell marker for differential BCG response. A model that 
incorporated the frequencies of total BCG-specific CD4+ producing IFN-γ, TNF-
α and IL-2 gave the best classification. We next used the expression of CXCL9 
transcript as a marker of differential response to BCG. The second approach 
was unbiased where we used a gene expression signature to define differential 
response to BCG vaccination. Correlates of risk of TB disease previously 
identified could not be validated in differential BCG responders defined by these 
three markers.  
The findings in this thesis will contribute significantly in the search for a 
biomarker of risk and/or protection against TB disease. This is the first study 
that has assessed risk of developing TB disease while taking response to BCG 
vaccination into account. Differential response to BCG vaccination was a pre-
requisite for the identification of candidate correlates of risk of TB disease. 
Infants with either too strong or weak myeloid inflammatory responses to BCG 
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vaccination were more at risk of developing TB disease. This therefore suggests 
that heterogeneity in immune responses to BCG vaccination should be taken 
into account in future correlates of risk studies. 
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BCG is known to induce variable immune responses within a given population. 
However, it is still not known if this variability in immune response is associated 
with its poor efficacy. Understanding why certain individuals still develop 
disease despite having a detectable immune response to BCG as well as which 
functions or components of the immune response contributes to protective 
immunity would help in the design and assessment of better vaccines.  
Chapter 2 of this thesis, which contains data produced by others, served as 
background for this study and aimed at identifying correlates of risk of TB in 
BCG vaccinated infants. No correlate could be identified in any of the work 
presented in chapter 2. However, upon further analysis of gene expression 
profiles, two distinct clusters of infants with opposite gene expression profiles 
were observed. The main aim and hypothesis for my thesis was based upon 
identification of these two clusters of infants.  
AIM and HYPOTHESIS 
 
To identify immune responses that correlate with risk of TB disease 
separately in two clusters of BCG vaccinated infants. 
We hypothesised that immune responses that are either too strong or 
weak will associate with risk of developing TB disease in BCG vaccinated 
infants 
SPECIFIC AIMS and HYPOTHESES 
 
1. To identify immune correlates of risk of TB disease in two clusters of 
BCG vaccinated infants. 
 We hypothesised that different immune correlates of risk will be identified 
 separately in two clusters of BCG vaccinated infants. 
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2. To identify biomarkers of clustering in BCG vaccinated infants 
 We hypothesised that clustering of gene expression profiles in BCG 
 vaccinated infants will associate with differential response to BCG 
 vaccination. 
 We further hypothesised that several T cell functions as well as gene 
 signatures will associate with this differential response to BCG 
 vaccination. 
3. To validate prospective immune correlates of risk of TB disease in an 
independent cohort of BCG vaccinated infants. 
 We hypothesised that candidate correlates of risk of developing TB 
 disease can be validated in another cohort of BCG vaccinated infants. 
 
The work presented in this thesis was based on a collaborative study with 
scientists from the Jenner Institute in Oxford and Vaccine and Gene Therapy 
Institute in Florida.   
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CHAPTER 1: LITERATURE REVIEW 
 
1.1) Epidemiology of Tuberculosis 
1.1.1) Definition of Tuberculosis 
Tuberculosis (TB) is a contagious airborne disease caused by infection with the 
bacterium Mycobacterium tuberculosis (M.tb). Although TB can affect almost 
every organ of the body, M.tb primarily infects lungs [1] It is transmitted when an 
uninfected person inhales micro droplets of fluid containing the bacterium from 
an infected person’s cough. Upon inhalation of these droplets containing the 
bacterium, a person may become infected. However, not every infected person 
tends to progress to TB disease. Up to 90% of individuals who become infected 
never progress to disease. Latently infected individuals are usually 
asymptomatic and cannot spread the germs. Only about 10% of infected people 
progress to disease, but this risk is increased up to 20 fold in those infected with 
HIV [2, 3]. These people are said to have active TB disease and they usually 
present with signs and symptoms such as continuous coughing, fever, night 
sweats and weight loss. Because infants and young children (less than 4 years 
old) have an immature immune system compared to older children and adults 
[4, 5], they tend to be more susceptible to TB disease [6]. The work in this thesis 
therefore focuses on infant TB immunology. 
 
1.1.2) Burden of Disease 
In 2012, WHO estimated the global TB incidence to be 8.6 million people and 
13% of this population was co-infected with HIV. There was an estimated 1.3 
million deaths from TB with just under 1 million being HIV-negative [7]. Africa 
accounts for 80% of TB cases living with HIV. The highest TB burden worldwide 
is found in Asia and Africa (Figure 1) and Africa alone has over 27% of the 
world’s cases and the highest rates of cases and deaths [7]. The highest TB 
burden in Africa is found in South Africa, where TB is the first cause of death. 
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WHO estimates show that there were over 0.5 million cases and 74,000 deaths 
amongst children in 2012 worldwide [7].  
Our studies are conducted in the Worcester region of the Western Cape, one of 
the highest TB burden areas in South Africa, recording an incidence of 





Figure 1:Developing countries had highest TB incidence rates in 2012 
(Map Courtesy WHO Global Tuberculosis Report, TB publications, Maps, Global TB incidence 
2013). 
 
1.1.3) Prevention and Control 
Control of the TB epidemic involves active detection of cases, treatment and 
vaccination [9].  
1.1.3.1)  Diagnosis 
Rapid and accurate diagnosis of TB is fundamental to limit its spread. There are 
several diagnostic tools used worldwide to diagnose M.tb infection but the two 
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most widely used are the tuberculin skin test (TST) and, more recently, IFN- 
release assay (IGRA). Both tests rely on the detection of acquired immune 
responses towards mycobacterial antigens, suggestive of current or previous 
infection with M.tb. TST assesses delayed host reaction to M.tb proteins, 
purified protein derivative (PPD) but may also be positive in individuals 
previously exposed to environmental mycobacteria or vaccinated with BCG, as 
many antigens present in PPD are conserved across different mycobacteria. 
TST sensitivity can be reduced by HIV infection [10, 11]. IGRAs measure IFN- 
responses to M.tb-specific antigens, early-secreted antigenic target 6 (ESAT6) 
and culture filtrate protein 10 (CFP10). Since these antigens are not expressed 
by BCG and most environmental mycobacteria, this test is more specific than 
TST. IGRAs may also be influenced by HIV infection although they are more 
sensitive than TST [12, 13]. Reliability of IGRAs in diagnosing children less than 
five years old has not yet been determined [14, 15]. 
As earlier mentioned, TST and IGRAs are useful in diagnosing M.tb infection but 
not TB disease. For diagnosis of disease, a wide range of other tests or assays 
are used which include sputum microscopy, culture, X-ray, epidemiological 
scoring as well as nucleic acid amplification technology (NAAT) method (gene 
Xpert MTB/RIF assay) [9, 16, 17]. Bacteriological confirmation of M.tb presence 
in sputum by microscopy and/or culture is the most definitive way of diagnosing 
TB. However, there is a major limitation in using this method in infants because 
sputum samples are difficult to collect and they usually have very few bacilli 
after collection [18]. For this reason, sputum induction and gastric lavage may 
be used to collect sputum samples from young infants and children. Induced 
sputum is a simple and non invasive process which involves  inhalation of a 
nebulised hypertonic solution, which then liquefies the airway secretion, thus 
promoting  coughing up of sputum [19]. Gastric lavage on the other hand 
involves the insertion of a tube down through the nose or mouth into the 
stomach, followed by addition and removal of small volumes of normal saline. 
Although gastric lavage is mostly used for children under the age of two years, it 
is more invasive and takes more time than induced sputum  [20] . In addition,  it 
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is difficult to perform on out patients [20].  Chest X-rays are also commonly used 
as the first method to diagnose active TB disease. Misdiagnosis is common 
using this method in areas where there is lack of trained radiologists [17] and in 
people co-infected with HIV where there is an overlap with opportunistic 
infections [21]. The latest diagnostic test to be endorsed by WHO for TB 
diagnosis is the gene Xpert MTB/RIF assay [22]. This assay was endorsed at 
the end of 2010. It detects M.tb DNA in sputum samples, with a read out in less 
than 2 hours. This assay may be ideal in areas with high TB incidence but has 
major limitations as it is costly, requires annual servicing and calibration of each 
machine, stable electricity supply, restricted operating temperature and humidity 
as well as limited shelf-life of diagnostic cartridges [9, 21, 23, 24].  
Despite all the diagnostic tools available for TB, diagnosis in children as well as 
sputum smear-negative pulmonary and extra-pulmonary TB in adults remain a 
challenge because of the paubacillary nature of the disease and difficulty in 
obtaining specimens [25, 26]. 
1.1.3.2) Treatment 
The main aims of treating TB are to: cure the patient, prevent death from active 
disease, prevent relapse of TB, reduce transmission to others and prevent 
development and transmission of drug resistance [27]. There are more than 22 
drugs available to treat TB and these drugs are used in different combinations 
based on the circumstance. Drugs used to treat TB can be combined into first 
line (used to treat most new TB cases or patients unexposed to prior TB 
treatment), second or third line regimens (used for treatment of drug resistant 
TB) [27]. TB treatment regimen is similar between children and adults [28] but 
different for latent infection and active disease. Latent TB infection can be 
treated with the first line drug Isoniazid for 6 months or a combination of 
Isoniazid and Rifampicin for 3 months [29]. However, treatment of LTBI in high 
burden settings is limited only to children under 5 years of age and HIV infected 
adults. Patients with active TB disease can be treated with a combination of 
multiple first line drugs for 6 months in two phases [30]. Non-compliance to the 
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treatment program may lead to emergence of resistant strains of TB [31]. 
Treatment of multi drug resistant (MDR) TB is more difficult compared to drug 
susceptible TB [30]. XDR M.tb is resistant to first line and second line drugs, 
therefore third line drugs are used to treat it and these drugs are often less 
effective, more toxic and expensive [32]. 
1.1.3.3)  Vaccination 
An effective vaccine against TB would be the most sustainable intervention to 
control the worldwide epidemic [33]. The only licensed vaccine against TB, 
Bacille Calmette-Guerin (BCG), is effective in preventing severe forms of TB in 
children [34], but has variable efficacy in protection against pulmonary disease 
across all age groups [35, 36]. Due to the variability in protection conferred by 
BCG, there is an urgent need for the development of new and better vaccines 
against TB.  
 
1.2) Bacille Calmette-Guerin (BCG) 
1.2.1) History 
BCG is a live attenuated vaccine containing the non-virulent strain of the 
mycobacterium that causes TB in cows (M. bovis). This vaccine was developed 
early last century by Calmette and Guerin in France, by sub-culturing M. bovis 
for several years until it lost its virulence in animals such as cows and guinea 
pigs. This altered organism was then named Bacille Calmette-Guerin (BCG), 
after the scientists that developed it. This vaccine was used for the first time in 
humans to protect against TB in 1921.  
At first, BCG cultures were only maintained in Paris, but were later sub cultured 
and distributed to several laboratories all over the world for continued sub 
culture. After several years, the strains grown in different laboratories worldwide 
were no longer identical. To limit these variations, the organism is now grown in 
many laboratories using “freeze-dried” (lyophilized) cells so that each batch 
starts with the same cells. 
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Since 1921 when this vaccine was first administered in humans (orally in 
infants), it has been the most widely administered vaccine and estimated to 
have been given over 4 billion times to 1 billion recipients [37]. BCG has been 
part of the expanded programme on immunisation (EPI) from the early 1970s 
and its safety has never been an issue until recently [37]. BCG has been shown 
to cause disseminated disease in infants with HIV, posing a risk in HIV+ 
individuals where TB is highly endemic [38]. For this reason, the WHO 
recommends that BCG should not be given to HIV infected children [37], but the 
reality is in South Africa, BCG is still administered to all infants at birth because 
it protects against severe forms of TB [38]. 
 
1.2.2) Efficacy 
Meta-analyses have shown that BCG efficacy in protecting against lung TB is 
highly variable and ranges from no effect to 80% [35] [36]. Nevertheless, BCG 
has been shown to be consistently efficacious in protecting infants and children 
against disseminated or severe forms of TB (miliary TB and TB meningitis) [34]. 
For this reason, BCG is still commonly used in high TB burden countries and 
even in countries where protective efficacy is negligible, especially in babies.  
Different possible reasons for the variable efficacy of BCG vaccine have been 
proposed but none seem to explain the lack of efficacy in both low and high TB 
burden countries. Some of the reasons include (i) Different BCG strains; (ii) 
Host genetic variation; (iii) Pre-exposure to non-tuberculous mycobacteria 
(NTM); (iv) Interference by parasitic infections.  
 
i) Different BCG strains 
 
BCG vaccine strains used all over the world display different properties, which 
may include genetic variants of the mycobacterial strains as well as the 
preparation of the vaccine. Several studies have thus been conducted to 
determine if these differences could be the reason for the variable efficacy in 
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protection of the vaccine. In a case-control study analysis by Comstock in 
Indonesia and Columbia, it was observed that there was a reduction in 
protection when Paris and Danish strains of BCG were used compared to Japan 
and Glaxo respectively [39]. Also, in another study done in South Africa, 
comparing the effect of the Danish strain to the Japanese strain on induced 
immune response in vaccinated infants, it was found out that different strains 
resulted in different levels of immune responses 10 weeks after vaccination [40]. 
Most recently, in a randomized trial done in Australia, comparing the Danish, 
Japanese and Russian strains of BCG in newborns, significant differences were 
observed in immunity conferred by the different strains [41]. However, the fact 
that certain BCG strains have been shown to be more effective in certain 
populations than others, suggests that efficacy in not only dependent on strain 
variation [42, 43]. To support this observation, a recent meta-analysis has 
shown that BCG efficacy in preventing pulmonary and disseminated TB was not 
affected by vaccine strain [44]. 
ii) Host Genetic Variation  
Several studies have been conducted to investigate the relationship between 
susceptibility to TB and host genetic variation. Some of these studies showed 
that susceptibility to TB and other mycobacterial infections is influenced by 
several genes which control cellular immune mechanisms (including HLA-DR, 
HLA-DQ, vitamin D receptor, IFN-γ receptor polymorphisms, and NRAMP) [45-
48]. Recently in our group variation in toll-like receptor 6 (TLR6) was shown to 
associate with altered innate immune responses and M.tb recognition [49]. In 
another study done by the Hawn Laboratory in collaboration with our group 
(SATVI) on South African infants, it was shown that single nucleotide 
polymorphisms (SNPs) in the innate immune genes, TLR1 and TLR6, were 
associated with altered adaptive immune responses following vaccination with 
BCG [50]. BCG efficacy may at least in part be explained by the difference in 
genetic make-up of different populations.  
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iii) Pre-exposure to non-tuberculous mycobacteria (NTM) 
Most populations in the world are exposed to various NTM, which share similar 
antigens with BCG. This can induce cross-reactive immune responses and 
hence mask the effect of BCG. Pre-clinical studies have shown that BCG 
protection is reduced in mice that have been exposed to M. avium [51]. 
Consistent with this finding is the observation that BCG efficacy tends to be 
lower in populations living in warmer regions of the globe, particularly in rural 
areas [52], probably due to presence of NTM. This becomes a real concern in 
clinical settings where there is high prevalence of NTM. In these settings, pre-
exposure to NTMs may mask the effects of BCG [44]. This hypothesis was 
supported in a BCG efficacy trial in South India, where a certain degree of 
efficacy (29%) was observed in participants that had no prior sensitisation with 
NTMs (M .intracellulae) or who had low tuberculin reactivity at baseline [44]. No 
efficacy was observed in those with tuberculin reactivity. In South Africa, BCG is 
given at birth and this reduces the potential exposure to NTM, therefore 
vaccine-induced responses may be independent of pre-exposure to NTMs.   
iv) Interference by parasitic infections  
Another hypothesis suggests that  simultaneous infection with parasites reduces 
the efficacy of BCG [53, 54]. It has been shown that parasitic infections skew 
the immune system towards a response that does not favour effective control of 
M.tb [53, 54]. However, in the Western Cape, the prevalence of maternal 
helminth infection was found to be very low (<10%), probably suggesting that 
this might have little or no effect on vaccine efficacy [55].  
Understanding determinants of variable immune response elicited by BCG 
remains a very important aspect in evaluating its efficacy.  Although several 
factors  have been shown to influence BCG efficacy such as co-infections with 
parasitic infections, pre-exposure to NTM and host genetic make-up, very few 
studies have investigated the effect of these factors on the variability in BCG-
induced immune responses. Because the work in this thesis investigates 
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variability in immune responses elicited by BCG and correlates of risk of TB 
disease following BCG vaccination, it was very critical to assess the effect of 
these factors in this study in order to rule them out as possible reasons for this 
variability. Section 1.4 below discusses the effects some of these factors have 
on immune responses elicited by BCG vaccination. It was important to note that 
some these factors as well as route of BCG administration did not seem to have  
such an effect in the Western Cape [55, 56]. For these reasons, SATVI clinical 
setting in the Worcester region of the Western Cape is ideal to characterise 
immune responses induced by BCG vaccination and their possible role in 
preventing TB disease in infants. Understanding why BCG-induced immune 
response may protect some individuals but not others may inform rational 
vaccine design and it is the focus of this thesis. For example, our group 
completed a randomised controlled trial in 11, 680 BCG vaccinated infants to 
compare the efficacy of percutaneous versus intradermal BCG vaccination [56]. 
In this study, infants were vaccinated with BCG at birth (Japan strain) either 
percutaneously or intradermally and followed up for a period of two years. 
Within this period, infants who developed TB were identified as well as those 
who did not develop TB despite exposure to TB contacts. In order to assess the 
immune responses elicited by BCG, blood was collected from a subset of 5,674 
infants at 10 weeks of age and stored. These samples form the basis for the 
work in this thesis. 
 
1.3) New TB vaccines pipeline 
As earlier mentioned, the only licensed vaccine against TB is BCG. However, its 
protection against pulmonary disease is variable [35]. There is therefore the 
need to develop better and more effective vaccines against this deadly 
pandemic. The development of new TB vaccines will be accelerated by 
knowledge of correlates of risk of TB disease which could later translate into 
correlates of protection. The work from this study therefore would directly be 
applied to the development of new TB vaccines in the pipeline. In the absence 
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of immunological correlates of risk, what we learn about the variability of 
immune responses induced by BCG may also inform better immunogenicity 
tests to assess new TB vaccines which are currently tested in clinical trials. In 
this light, there are 14 TB vaccine candidates currently in clinical trials (Table 
1;[57]).  Of these, 4 are in phase I for safety testing, 8 are in phase II for safety 
and immunogenicity testing and 2 in phase III [57].  MVA85A has recently been 
tested in the first phase IIb efficacy trial since BCG licensure. MVA85A is a 
modified vaccinia Ankara virus containing antigen 85A from M.tb [58]. This 
vaccine was designed to boost the immune responses induced by BCG but 
results showed that no additional protection was conferred by this vaccine, 
compared to BCG alone [59]. Two other vaccine candidates, M. Vaccae and M. 
indicus pranii which are whole cell mycobacteria vaccines have just recently 
completed phase III trials [57].  In addition to the 14 candidates currently tested 
in clinical trials, there are at least 35 vaccine candidates in preclinical 
development and 21 next generation vaccines in the discovery phase [57]. Next 
generation vaccines are vaccines that are in the research and development 
stage with some preclinical evidence of conferred protection. 
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Table 1: TB vaccine development pipeline in 2013 
 
 
Vaccination strategies have implored the use of different kinds of vaccines. 
Vaccine candidates in clinical trials to date are live attenuated or recombinant, 
viral vectored, whole cell or fragmented mycobacterium and adjuvanted subunit 
vaccines. 
1.3.1) Live attenuated or recombinant vaccines  
These vaccines are designed to replace BCG as prime vaccines. A live 
attenuated vaccine is a vaccine whose virulence has been weakened by 
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deletion of certain genes but can still induce a cellular immune response. An 
example of such a vaccine in clinical trials is MTBVAC, which is a live 
attenuated M.tb vaccine. MTBVAC was constructed by the deletion of two 
virulence genes, phoP and fadD26 and it is the first live attenuated M.tb vaccine 
to have entered clinical trials [60]. This vaccine has been shown to induce an 
immune response that is long lasting in mice compared to BCG [60]. On the 
other hand, another live recombinant vaccine comprises BCG that has been 
designed to over-express key M.tb antigens. VPM1002 is an example of such a 
vaccine and is the most advanced live recombinant vaccine in a clinical trial 
being presently in phase IIa. This vaccine was constructed by knocking out the 
urease gene in BCG and inserting listeriolysin gene from Listeria 
monocytogenes, thereby allowing the recombinant BCG to escape the 
phagosome [61, 62]. This vaccine has been shown to be safe, while inducing 
CD4+ and CD8+ T cell responses similar to BCG in BCG naive, HIV negative 
newborns [63]. Another live recombinant vaccine that reached phase I clinical 
testing in 2004 is rBCG30, but plans for further development have been put on 
hold [37].  
 1.3.2) Viral vectored vaccines  
These vaccines are designed by modifying non replicating viruses which serve 
as transport of M.tb DNA into human cells. Upon entry into cells, the M.tb DNA 
is transcribed into proteins and these proteins can induce immune responses 
[58]. These vaccines have mainly been used in prime-boost strategies to boost 
the immune response induced by BCG. MVA85A, Crucell AD35 and Ad5Ag85A 
are examples of viral vectored vaccines. In a phase IIb trial MVA85A conferred 
no additional protection over BCG alone [59]. Aeras 402, which comprises the 
human adenovirus serotype 35 expressing the M.tb antigens TB10.4, Ag85A 
and Ag85B, had been shown to induce robust CD8+ T cell responses but 
moderate CD4+ responses in a phase I clinical trial [64]. But this vaccine was 
later reduced from a phase IIb to phase II trial (proof-of-concept to safety and 
immunogenicity respectively) after reviewing the preliminary data [57]. The last 
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of the three viral vectored vaccine to be presently in clinical trial is Ad5Ag85A, 
which is a recombinant, replication-deficient adenovirus serotype 5 expressing 
Ag85A. Greater immune responses have been shown with this vaccine in 
individuals who received BCG compared to BCG-naive persons [65]. 
1.3.3) Adjuvanted subunit vaccines 
These vaccines are designed by fusing different M.tb proteins into immunogens, 
which are then formulated with specific adjuvants. In the field of vaccinology or 
immunology, adjuvants are agents that are added to vaccines to provoke the 
immune system to respond to a particular antigen but do not confer immunity 
themselves [66]. Subunit vaccines are also used in prime-boost strategies and 
there are presently five candidates in clinical trials. The most advanced of these 
vaccines is M72, which contains the M.tb proteins 32A and 39A in a fusion 
protein and formulated in the adjuvant AS01. This vaccine has been shown to 
induce good Th1 and Th17 responses in a population of M.tb infected 
individuals in South Africa [67]. In this same study, there was evidence 
suggestive of the fact that this vaccine may boost T cell populations primed by 
natural infection with M.tb [67]. Three other subunit vaccines currently tested in 
clinical trials are all formulated with the adjuvant IC31 [68, 69]. These are Hybrid 
1 (contains Ag85B and ESAT6), Hybrid 56 (Ag85B, ESAT 6 and the latency 
antigen Rv2660) and Hybrid 4 (Ag85B and TB10.4) (Table 1). Although Hybrid 1 
has been shown to induce a robust CD4 T cell response as measured by IFN-γ 
and there are still ongoing studies investigating it, its elimination by H56 is most 
likely as H56 contains antigens in both active disease and latent infection. The 
last of the adjuvanted subunit vaccine in clinical trials is ID93, which contains 
the antigens Rv2608, Rv3619, Rv3620 (active disease antigens) and Rv1813 
(latency antigen) formulated in the adjuvant GLA-SE.  
1.3.4) Whole cell or fragmented mycobacterium vaccines  
These vaccines are made up of replication-deficient, inactivated whole cell or 
fragmented mycobacteria. In combination with chemotherapy, these vaccines 
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may be therapeutic as they work to improve the treatment of either active 
disease or LTBI. Examples of such vaccines are RUTI, Dar 901, M. Vaccae, M. 
indicus pranii.  
New vaccines are designed to: i) prime the immune system prior to M.tb 
infection or environmental NTM exposure ii) boost the already existing immunity 
conferred by BCG iii) prevent transmission or clear the infection.   
i) Prime vaccines 
These vaccines are meant to be used in infants and newborns before they 
become exposed to M.tb or environmental mycobacteria. BCG is still mostly 
used as a prime vaccine but several vaccine candidates have been designed to 
replace BCG. The aim is to use recombinant BCG (rBCG) or attenuated M.tb 
strains as a replacement for conventional BCG [70]. Most prime vaccines are 
live attenuated because they have the ability to replicate and can therefore 
induce immune responses similar to the virulent form. 
ii) Boost vaccines 
These are vaccines designed to enhance the already existing immunity 
conferred by BCG (prime vaccine). Typically, these vaccines consist of 
mycobacteria specific antigens that are coded in viral vectors (viral vaccines) or 
delivered with Th-1-inducing adjuvants (subunit vaccines). There is much 
debate in the field of TB vaccinology with regards to the optimal time to 
administer a boost vaccine. Nevertheless, TB incidence peaks in very young 
children less than 4 years [71] and in adolescence [72], suggesting that these 
populations should be primarily targeted by preventive vaccines. However, more 
recently there is a general consensus that prevention of transmission will make 
the greatest impact on the global epidemic. Since M.tb is most likely transmitted 
by adolescents and adults, the primary targets for vaccination would be 
adolescents just before they get infected [73].  
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iii) Post Infection/therapeutic vaccines  
These can either be vaccines given to latently infected individuals to prevent 
reactivation or to individuals with active disease together with chemotherapy to 
prevent transmission and shortening the treatment regimen [70]. Inactivated 
mycobacteria and the subunit vaccines H56, H1, ID93 and M72 are proposed 
candidates for this kind of approach [70].   
Of the 14 new vaccine candidates in clinical trials, SATVI has conducted clinical 
trials on 7 candidates [74].   
 
1.4) Heterogeneity in immune responses induced by vaccinations  
A major limitation in the design and development of new vaccines is the inter-
individual variation in vaccine-induced immune responses. Variability in immune 
responses may be due to host factors such as genetic factors, environmental 
factors such as demographic distribution, co-infections, pre-exposure to vaccine 
antigens as well as vaccine delivery routes.  
Polymorphisms in key immune response genes have been associated with 
heterogeneity of vaccine-induced responses [75, 76]. For example, HLA genes 
play a pivotal role in determining immune responses to T cell antigens and are 
consequently the most analysed in gene association studies of infectious 
diseases [77]. HLA loci are highly polymorphic, to ensure efficient presentation 
and recognition of a broad range of foreign antigens. Nevertheless, it has been 
hypothesised that individual variability of immune responses induced by 
vaccines may be associated with HLA polymorphism [78, 79]. For example, 
following BCG vaccination in a group of 86 caucasian leprosy patients, lack of 
HLA-D3 was associated with no or low responses measured by skin test 
responsiveness [80]. In another study where BCG was administered to healthy 
caucasians, high or normal responders to BCG were associated with HLA-DR4 
[81]. 
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Pre-exposure to vaccine antigens and/or vectors is another co-factor for 
heterogeneity in vaccine induced responses and this  has been shown in 
various vector-based vaccines [82-84]. An example of such is the STEP trial in 
which high risk HIV individuals were administered with an HIV vaccine made up 
of an adenovirus (Ad5), synthetically modified to contain the nef, gag and pol 
proteins from HIV. The results showed that placebo recipients had lower rates of 
HIV acquisition compared to vaccinees that were seropositive for adenovirus 5 
(Ad5) [85, 86].     
Age as well as gender have also been shown to have an effect on vaccine-
induced immunogenicity or efficacy [87, 88]. BCG has been shown to induce 
variable response in infants vaccinated at birth compared to later time points 
[89-91] . For example, Kagina et al showed higher frequencies of BCG-specific 
Th1 cytokines when BCG vaccine was delayed from birth to 10 weeks of age in 
South African infants [89]. However, the opposite of this was seen by Lutwama 
et al, in Ugandan infants whereby the birth vaccinated group had increased 
frequencies of CD4+ T cells producing IFN-γ compared to those who received 
BCG at 6 weeks [91]. The discrepancy in these results could be accounted for 
by the difference in socio economic status, geographic location as well as study 
design. These data however point to the fact that BCG response may be 
affected by age of administration.  
Co-infection with bacteria, viruses as well as parasites has effects on the human 
immune system and this could consequently affect the immunogenicity of 
several vaccines [92, 93]. For example Elias et al evaluated whether anti-
helminthic therapy prior to BCG vaccination could increase the immunogenicity 
of BCG vaccination in a helminth-infected population. They found that BCG-
induced Th1 immune responses (number of  cells producing IFN-γ and IL-12 
after in vitro stimulation with PPD) were impaired in individuals who received the 
placebo compared to those who received the treatment (dewormed) [53]. 
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1.5)  Immunopathogenesis of Tuberculosis 
1.5.1)  Immunological life cycle of Tuberculosis 
Immune responses against M.tb infection have been shown to control its 
growth. However these responses do not completely clear the bacterium in most 
situations. Understanding these responses has been a major scientific 
challenge and incomplete understanding has been a major limitation in the 
rational design of TB vaccines better than BCG. Despite extensive studies of 
human immune responses to M.tb, there has been no clear understanding of 
correlate of effective immunity against M.tb [94]. A proposed framework for 
understanding and studying TB immunity in both humans and animals is based 
on the assumption that there are multiple stages in human responses to M.tb 
[95]. Understanding these responses at the different stages of the life cycle of 
M.tb may provide a better understanding of the mechanisms involved in 
protection [95].  
1.5.1.1)  Stage 1: Infection stage 
Primary infection occurs when M.tb is transmitted by aerosol and is internalized 
by professional phagocytic cells including macrophages, neutrophils and 
dendritic cells (DCs) recruited in the lungs [96, 97]. This stage is characterized 
by recognition of M.tb components by various pathogen recognition receptors 
(PRRs), such as Toll-like receptors (TLRs) and NOD-like receptors (NLRs) [98]. 
TLRs are believed to be an important recognition system for M.tb mainly 
through TLR2, TLR9 and TLR4 [99]. Polymorphism in TLR genes have been 
shown to increase susceptibility to TB in humans. For example, Chen et al 
reported an association between TB susceptibility and TLR2 genetic 
polymorphism (haplotype A-G-T) [100]. Also, Caws et al have shown an 
association between TLR 2 polymorphism and disseminated TB [101]. Despite 
numerous in vitro data regarding the recognition of mycobacteria by TLR2 and 
TLR4, knock-out mice deficient for these receptors have shown very little 
enhanced susceptibility to infection with M.tb [102]. For example, TLR4−/− mice 
showed variable responses to the challenge with M. tuberculosis, with either 
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normal resistance to infection [103] or chronic pneumonia and increased 
mortality ([104-106]. Also, following low dose infection with M.tb TLR2−/− mice 
showed a decrease in clearance of the bacteria and developed chronic 
pneumonia [107], whereas in other studies only minor effects have been found 
[103, 108]. Studies conducted in MyD88-deficient and TLR2, 4 and 9-deficient  
mice suggest that these mice had increased susceptibility to M.tb and TLR2,4 
and 9 were important in the initial host response but not for the initiation of an 
adaptive response [109]. C-lectin receptors such as mincle, dendritic cell-
specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) and 
mannose receptors (MRs) can also recognise M.tb and initiate pathogen 
internalisation. Recognition through some of these receptors leads to activation 
of macrophages while others allow quiescent entry of M.tb into the cells [110]. 
Recruited and infected cells aggregate leading to formation of early granulomas. 
Granuloma formation is the hallmark of M.tb infection. A granuloma is a well-
organized structured collection of innate and adaptive immune cells that is 
formed to contain the pathogen [94]. Cells that form the granuloma might 
include macrophages, DCs, neutrophils, T and B cells [94, 111, 112]. M.tb can 
persist in hypoxic conditions within the granuloma by altering gene transcription 
patterns and adopting a dormant lifestyle and may continue to replicate when 
host immunity wanes [113, 114]. Resident lung DCs take up M.tb or infected 
apoptotic cells and migrate to the local draining lymph node where naive T cells 
are primed through antigen presentation. The primed T cells migrate back to the 
lung and secrete IFN-, which activates infected macrophages to kill M.tb 
through the production of nitric oxide (NO). TNF- is important in activating 
macrophages and maintaining the granuloma structure. Macrophages 
containing M.tb may undergo apoptosis or necrosis releasing viable M.tb [115]. 
However, other macrophage mechanisms aimed at killing M.tb in humans are 
mediated by TLR-induced vitamin D-dependent induction of the antimicrobial 
peptides cathelicidin and β-defensin 2 (DEFB4) [116-120].  When M.tb is not 
effectively killed or controlled within the granuloma, M.tb can eventually be 
transmitted. Transmission of M.tb occurs when the caseous granuloma breaks 
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and the caseum with viable bacilli is deposited into the airways. The bacilli are 
then coughed up into the air and are inhaled by another host either uninfected 
or with an existing infection [121]. However, the formation of caseum and 
eventual calcification of the granuloma may also be an indication of successful 
containment of the bacilli. 
During the early stages of the infection, the recruitment of phagocytic cells to the 
site of infection may be of benefit to the pathogen as it provides additional 
cellular targets to infect [122, 123]. M.tb has evolved multiple mechanisms to 
survive and multiply inside specialized phagocytes, which include: a) Prevention 
of phagosomal trafficking and maturation, to allow escape from lysosomal-
mediated mechanisms of restriction, killing and degradation [124-126]; b) 
Expression of several virulence factors, to enable cell to cell spread [122]; c) 
Inhibition of host cell apoptosis, which would enhance antigen presentation to T 
cells, in favour of necrosis, an inflammatory process that supports mycobacterial 
spread [115, 127, 128]. 
 
 




Figure 2: Stages in the immunological life cycle of tuberculosis. 
The framework for the life cycle is based on clinical, epidemiological and immunological studies 
in humans. Included are examples of some of the immunological mechanisms and functions that 
characterize each stage, in cases where they are known. PAMP, pathogen-associated 
molecular pattern; TB, tuberculosis; TNF, tumour necrosis factor. (Ernst, 2012).  
 
1.5.1.2) Stage 2: Immunological Balance 
The adaptive immune response to M.tb is characterized by a delay in onset 
compared to other pathogens in humans. Studies that have evaluated immune 
responses following M.tb exposure of naive individuals to an active case of 
pulmonary TB have shown that measurable immune responses (measured as 
skin test reactivity using Pirquet or TST) in  humans appear approximately after 
42 days following M.tb exposure [129, 130]. A similar delay in onset of activation 
of antigen-specific T cells has been reported in mice following aerosol infection 
with M.tb [110, 111, 117, 118]. Lin et al showed a 1.5 fold decrease in bacterial 
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burden in lung granulomas including sterilisation of lung granulomas in 
macaques infected with M.tb from 4 to 11 weeks, which suggests killing at the 
onset of the adaptive immune response [131]. Studies in mice and non-human 
primate models have demonstrated that these responses occur earliest in the 
lymph node that drains the lungs [124, 132-134]. This has been attributed to a 
delay in transport of the bacterium by myeloid DCs from the lungs to the 
draining lymph nodes [125, 133]. After the onset of the adaptive response, 
about 90% of humans control bacterial growth and never progress from this 
latent, asymptomatic infection to active TB disease [95]. In mice, accumulation 
of effector CD4+ and CD8+ T cells in the lungs upon M.tb challenge is essential 
for long-term survival, but only marginally decreased bacterial load in the lungs 
[135]. Other studies in mice and non-human primates have shown continuous 
bacterial replication despite overall control of bacterial growth [136, 137]. This 
therefore suggests that latent TB is a state of bacterial and immunological 
equilibrium rather than a state of bacterial stasis. 
Adaptive immune responses to M.tb largely depend on CD4+ T cells in humans, 
mice, cattle and non-human primates [138-140]. MHC class II deficient mice 
were more susceptible to disease due to lack of control of bacterial growth 
[141]. In humans, HIV-infected individuals with low CD4+ T cell counts are more 
susceptible to TB disease [142]. CD8+ T cells secrete IFN-γ, which activates 
macrophages to kill the bacteria [143]. Although CD8+ T are involved in fighting 
against M.tb, they cannot compensate for the lack of CD4+ T cells [143, 144].    
1.5.1.3) Stage 3: Postprimary TB  
In low endemic settings, most cases of TB in adults are due to reactivation of 
latent M.tb probably due to very little transmission and must be distinguished 
from a secondary infection, which can occur even in immunocompetent 
individuals. However, in high endemic countries, where there is ongoing 
transmission of the bacteria, most cases of TB are due to repeated infection 
[145].  Reactivation TB is characterized by bacteria shedding in cough and it 
usually reflects progression to active, symptomatic disease [146]. Reactivation 
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of TB can occur decades after infection [147] and this reactivation can be 
attributed to a weakened immunity [95].  
Two main mechanisms have been described in humans as potential reasons for 
reactivation of TB. The first mechanism relies on quantitative and qualitative 
defects in CD4+ T cells driven by HIV infection [138]. Studies in humans have 
suggested that before CD4 counts reach a very low level following HIV infection, 
there is faster depletion of M.tb specific CD4+ T cells compared to CD4+ T cells 
specific for other infections [148]. In addition, depletion of CD4+ T cells by SIV in 
non-human primates has been shown to cause reactivation and progression of 
TB [139]. However, the exact mechanism used by CD4+ T cells to maintain and 
control M.tb in the latent state is unknown. The second mechanism is the 
therapeutic neutralization of TNF [149], especially by monoclonal antibodies 
[150]. Although the effect of blocking TNF has not been fully characterized, it 
has been linked to a) Decreased in macrophage-mediated antimicrobial activity 
[151] b) Induction of higher frequency of Treg cells [152] c) Depletion of a 
subset of CD45RA+ effector memory CD8+ T cells that secrete granulysin and 
have been shown to kill M.tb in vitro [153]. Diabetes mellitus [154] and treatment 
with glucocorticoids [155] have also been linked with an increased risk of TB 
reactivation. Other conditions such as silicosis, haematological malignancies, 
cancer chemotherapy, gastrectomy, uraemia as well as age have all been linked 
to increased reactivation of M.tb [156] though the underlying mechanisms have 
not been fully elucidated. These two mechanisms are somehow "modern" 
mechanisms of reactivation. However, the main risk factor for TB reactivation, 
which also happens to be common between the mechanisms described above, 
is relative immunocompromise. 
 
1.6) Role of T cells in immune mediated control of TB 
The role of T cells in the protective immunity against TB has been well 
established. Within granulomas, the effective control of M.tb has been 
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associated with recruitment of mycobacteria-specific T cells and activation of 
macrophages. Different T cell subsets including cytotoxic T lymphocytes (CD8+) 
and CD4+ T cells (Th1, Th17, Th22, Th2, and regulatory T cells (Tregs) have 
been reported to play roles in protecting against TB [125, 143, 144, 157, 158]. 
1.6.1) Th1 cells  
CD4+ T cells likely play a more important role in TB immunity compared to 
CD8+ T cells. This is because CD4+ T cells have been shown in animal as well 
as human studies to control M.tb infection and progression to active TB disease 
[94, 144]. In murine models, it has been shown that protective immunity against 
TB is achieved in RAG mice (deficient in B and T cells) that received adoptively 
transferred CD4+ T cells [159]. In humans, individuals infected with HIV are 
more likely to progress to TB disease compared to HIV negative [142].  
CD4+ T cells can be further divided into multiple lineages with significantly 
different immune responses to M.tb infection [160]. Protective immunity by 
CD4+ T cells is mediated by Th1 cells that secrete cytokines, mainly IFN- 
[144]. This protective immunity has been shown to be dependent on IL-12p40 in 
mice [125, 141, 144, 161].  In humans, polymorphisms in the IL-12/IFN- 
pathway genes have been linked to susceptibility to pulmonary TB and 
mycobacterial disease [162] and the function responsible for these associations 
is IFN-γ. Treating rheumatoid arthritis patients with anti-TNF therapy increased 
their risk of developing TB disease [163].  In humans, IFN-  has been shown to 
induce autophagy [164] while M.tb induced TNF-α production leads to apoptosis 
of infected alveolar macrophages [165]. These two mechanisms function to 
reduce bacterial burden.  
IL-2 has been shown to be pivotal in enhancing immune responses by driving 
proliferation of antigen-specific T cells, which is required for these cells to carry 
out their effector functions as well generation of memory T cells [166].  
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CD4+ T cells co-expressing IFN-γ, TNF-α and IL-2 together (polyfunctional 
cells) have been shown to be more protective against TB in mice [167]. These 
polyfunctional cells have also been shown to correlate with vaccine-induced 
protection against L. major in a mouse model [168].  In humans, increased 
frequencies of these cells have been observed in latently infected individuals 
compared to TB patients [169, 170] supporting the supposedly protective role of 
these cells postulated in animal models. However, the opposite has been 
reported by Caccamo et al., where they found increased frequencies of these 
cells in TB disease patients compared to LTBI [171].  
1.6.2) Th17 cells 
Th17 cells, which produce the pro-inflammatory cytokines IL-17 [172] and IL-22 
[173], have also been studied in immunity against TB. Two SNPs in the IL-17F 
gene have been associated with susceptibility to both pulmonary and extra 
pulmonary TB disease [174]. Kagina et al showed that BCG vaccination induces 
low levels of IL-17 in children [175] whereas Scriba et al reported higher levels 
of BCG-specific IL-17 and IL-22 producing CD4+ T cells in adults [176]. Scriba 
et al also showed lower frequencies of mycobacteria-specific Th17 cells in 
individuals with active TB compared to healthy controls [176]. Compared to 
active TB disease patients, latently infected individuals have been associated 
with increased frequency of IL-17+ T cells [177]. At the site of disease, higher 
levels of IL-22 have been reported compared to IL-17 [178]. The role of IL-17 in 
TB has been extensively described in mice [179-183]. This cytokine has been 
shown to be induced in both M.tb infection and challenge models [182, 183]. 
Gopal et al showed that vaccine-induced protection is diminished in mice 
deficient of IL-17 but not IFN-γ [179]. In addition, mice receiving early IL-17 
cytokine therapy have been shown to have an enhanced vaccine-induced 
protection against TB in M.tb mice challenge models [179]. Recently, Gopal et al 
showed that wild type mice controlled infection compared to IL-17-/- mice 
following infection with the virulent M.tb strain HN878, suggesting a protective 
role of IL-17 [184]. All these show that Th17 cells may contribute to immunity 
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against TB. However, the function of IL-17 is not fully understood and further 
studies are required.  
1.6.3) Regulatory T cells (Tregs)  
Evidence of the role of Tregs in immunity against TB has been reported in mice, 
whereby there was a decrease in protection conferred by BCG with the 
appearance of Tregs [185]. Tregs have also been shown to impair Th1 
responses [186]. IL-10 and TGF- are produced mainly by Tregs and these 
have been shown to inhibit proliferation and production of cytokines by other T 
cells [187]. In humans, higher frequencies of Tregs have been reported in 
patients with TB disease compared to healthy uninfected individuals [188]. 
Whether Tregs are induced to counter balance excessive inflammation during 
disease or their pre-existing enrichment may affect protective immune 
responses, predisposing to disease, has not been established. 
1.6.4) Cytotoxic T lymphocytes 
Intracellular control of mycobacteria and intracellular infections has been linked 
with cytotoxic T lymphocytes (CTLs). One of the ways that CTLs carry out this 
effector function is through the secretion of cytolytic molecules such as 
granzymes, granulysin and perforin [189]. In M.tb infection, cytotoxic CD4+ [189] 
and CD8+ [190] have been shown to play key roles in TB immunity. More 
recently, it has been shown that some of these cytotoxic proteins such as 
granzyme B, granulysin and perforin are expressed by BCG-specific memory T 
cells following newborn vaccination with BCG [191]. However, these cytolytic 
molecules may have different roles in mediating immunity against M.tb. For 
example, perforin has been shown to perforate the cell membrane of M.tb 
infected cells, allowing  entry of granzymes that either kill the M.tb directly or kill 
the infected cell [192]. M.tb target cell death by granulysin is through  disruption 
of the cell membrane which leads to  release of cytochrome c and the apoptosis 
inducing factor (AIF) as well as influx of extracellular calcium [193, 194]. 
However, the effector function of granulysin is dependent on perforin [195]. 
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Similar to granulysin, granzymes depend on perforin for their cytotoxic activity. 
Granzyme B induces apoptosis of target cell by activating caspases 3 and 7 
[196]. T cell cytotoxic potential may be critical in controlling M.tb and therefore 
was assessed in our study of immune correlates of risk of TB disease.  
1.6.5) CD8+ T cells  
CD8+ T cells recognise M.tb antigens presented on MHC I molecules by 
infected cells. Mice deficient in β2-microglobulin (no MHC I) have been shown to 
be more susceptible to M.tb [197]. Also, depletion of CD8+ T cells in non-human 
primates is associated with impaired BCG induced immunity against TB [198].  
Although the main function of CD8+ T cells is to eliminate infected cells through 
cytotoxicity, they also produce TNF- and IFN- [199, 200]. Soares et al showed 
that following routine BCG vaccination of newborns, CD8+ T cell responses 
measured at 10 weeks of age were characterized by IFN- and IL-2 production 
[201]. Also, IFN- production by M.tb specific CD8+ T cells in young children has 
been associated with an immunologic signature of primary M.tb infection 
resulting in disease [202]. 
1.7) Spectrum of Human Tuberculosis 
From a clinical point of view, diagnosis and treatment of TB are based on the 
fact that following infection with M.tb, an individual may develop either active 
disease or may become latently infected. However, recent understanding and 
interpretation acknowledges that M.tb infection does not result in this binary 
outcome but rather in a heterogeneous spectrum of clinical states [113, 203] 
(Figure 3A).  
Following initial infection with M.tb, some individuals develop active disease, 
referred to as primary or primary progressive disease with distinct clinical 
presentation and possibly different host genetic susceptibility [204, 205]. The 
clinical presentation can range from systemic responses which include fever, 
weight loss, night sweats to local responses such as cough, lymphadenopathy 
and lung cavities [206]. These symptoms may represent the host response to 
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the pathogen which has been suggested to be inadequate, hence development 
of disease. The imbalance between pro and anti-inflammatory responses has 
been suggested to be one of the causes for progression to active TB disease 
(Figure 3B) [207].  
Latent TB on the other hand represents a diverse response to M.tb infection 
with different clinical outcomes (Figure 3A). As earlier mentioned, diagnosis of 
latent infection is made based on the presence of recall immune responses 
against M.tb antigens. This suggests that latent TB reflects a heterogeneous 
group of individuals which include: i) those who have subclinical disease, ii) 
progress to active disease, iii) those who at first suppress infection but later go 
on to develop disease, iv) those who maintain life-long infection, v) those who 
effectively clear the infection [113, 208] (Figure 3A). Heterogeneity in lung 
lesions following M.tb infections has been demonstrated in both humans and 
nonhuman primates [113, 209, 210], but the lack of data hampers accurate 
interpretation of the immunological responses needed for the establishment of 
latency [207]. However, a balance between pro and anti-inflammatory 
responses has been suggested to be important in the establishment of latency 
[207] (Figure 3B).   
The need for better diagnostic tools that differentiate the complete spectrum of 
immune responses to M.tb [113, 203, 211] has been brought to light by the 













Figure 3: Heterogeneous outcomes following M.tb infection. (O'Garra et al., 2013; Lin et 
al., 2010) 
A) Infection status based on tuberculin skin test (TST) and IFN-γ release assay (IGRA). Positive 
TST and/or IGRA results are shared by individuals who have subclinical infection, cleared the 
infection but have detectable T cell responses and those who have an immune response but still 
remain infected. Negative TST and/or IGRA shared by those individuals who have cleared the 
infection with no detectable T cell responses, those who remain uninfected and those who have 
cleared the infection with also no detectable immune responses. B) The clinical outcomes of 
active (red line) and latent (blue line) infection. Bacteria burden shown by the dashed orange 
line. The seesaws reflect the pro- (P) and anti-inflammatory (A) mediators and the purple line 
reflects the risk of reactivation in latency. 
A 
B 
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1.8) Immunological correlates of Risk of TB disease 
An immune correlate of protection is a measureable response to a vaccine that 
indicates a person is protected from being infected or developing a disease 
[212]. The ability to assess the protective efficacy of a vaccine by measuring the 
proportion of vaccinees who generate a particular immune response without 
having to measure clinical outcomes provides significant advantages and is 
important for vaccine development, monitoring of effectiveness and licensure. A 
better understanding of the interrelationship between vaccination, immune 
response, protection and clinical outcomes is of great interest not only to 
immunologists or vaccinologists but also to regulatory authorities. Without a 
clear knowledge of protective immunity, vaccine effectiveness can only be 
determined in large phase III clinical trials. 
Correlates of protection have been of significant advantage in facilitating clinical 
trials of new vaccines against several infectious diseases. For example, 
following vaccination against Hepatitis B, antibody titres ≥10  mIU/ml have been 
shown to correlate with the induction of the T helper cell responses that mediate 
memory B cell responses such that there is an anamnestic response that 
prevents disease and/or infection  in the vaccinee after exposure to the Hepatitis 
B virus [213, 214]. This antibody titre is used as the cut-off for vaccine induced 
response in hepatitis B vaccine clinical trials [215]. In influenza, the 
haemagglutination- inhibition (HAI) antibody titre is the universally accepted 
correlate of protection[216]. However, a  number of novel approaches to the 
design of new influenza vaccines are under consideration  and the development 
of these new vaccines have focused on  HAI as a correlate of protection [216-
218]. In Europe, post vaccination HAI titres are used as the basis for the 
approval of the annual updated  influenza vaccine and also for the licensure of 
new haemagglutinin based vaccines  [219]. 
An effective vaccine that prevents pulmonary TB disease would be an ideal tool 
to impact the global epidemic [37]. One of the main reasons that hamper the 
development of efficacious vaccines is the lack of or limited knowledge on 
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correlates of protection after vaccination. Without a clear correlate of protective 
immunity against TB, potential vaccine candidates have to undergo large and 
expensive phase III efficacy trials [220]. Vaccine-induced correlates of 
protection can only be identified in randomised controlled trials of an effective 
vaccine but, as earlier mentioned, the only licensed vaccine against TB, BCG, is 
only partially effective. In alternative, we are studying prospective correlates of 
risk of TB disease upon BCG vaccination, to inform future studies of correlates 
of protection [221]. Correlates of risk are immunological markers that correlate 
with the rate or level of clinical end point used to measure vaccine efficacy in a 
given population [221].   
Optimal cohort selection, appropriate definition of TB cases as well as 
delineation of adequate follow up period are all critical aspects in designing 
studies aimed at investigating correlates of risk of TB disease. By definition, 
correlates of risk may be addressed only before disease occurs, therefore a 
prospective study, involving thousands of high-risk healthy participants, and at 
least two years of follow-up are required. Cross sectional comparisons of 
immunological markers in participants with latent/asymptomatic M.tb infection 
and active TB disease have been performed in many relevant studies [94, 222-
226], and generated useful knowledge about immune responses occurring 
during different stages of the infection and disease. These responses are not 
necessarily predictive of vaccine efficacy or protection from disease upon 
natural infection. 
Design of immune correlate studies should also take into account the collection 
of appropriate biological samples to measure host parameters (biomarkers), and 
try to foresee which technologies may be used at the time of analyses. 
Biomarkers generally are measurable characteristics, which may be used as an 
indicator of a biological state or condition. They can be applied in many scientific 
fields, but in relation to our study, this may be a gene expression signature that 
identifies individuals more likely to develop disease. Biomarker discovery can 
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rely on both hypothesis-driven approaches, which rely on assumptions based on 
current knowledge, or be unbiased and hypothesis generating.   
Based on our knowledge of TB immunobiology, we have previously assessed 
biomarkers that are thought to play a role in fighting against TB, but were not 
able to identify potential correlates of risk of TB disease [175]; Scriba and 
Keyser et al., In prep). In this thesis, we also applied unbiased approaches, in 
the form of gene expression profiling, to discover biomarkers of risk of TB 
disease. 
Biomarkers associated with protection against primary M.tb infection and 
development of TB disease could serve as surrogate endpoints in efficacy trials 
of new TB vaccines. This would allow more rational selection of vaccine 
candidates in the preclinical and early stages of clinical development as well as 
shortening of clinical trials [57]. Complexity of the dynamic interaction between 
M.tb and the immune system suggests that a single biomarker of efficacy may 
never exist (Figure 4). Different biomarkers will have to be identified for different 
stages of infection and disease. Ideally, an effective vaccine against TB should 
confer protection across all populations and stages of TB; that is prevent 
infection of healthy individuals, clearance of M.tb in infected individuals and 




Chapter 1: Literature Review Page 32 
 
   
Figure 4: Biomarkers for different stages of M.tb’s immunological life cycle. (Image 
courtesy of TB vaccine pipeline report, July 2013). 
B=Biomarker. B1= Biomarker for exposure to infection, B2 and B4= Biomarkers for progression to 
active disease, B3 and B5= Biomarkers for latent infection, B6= Biomarker for reactivation  
 
Continuous performance of efficacy trials without a clearer knowledge of what is 
a protective immunity against TB may lead to research fatigue among donors, 
policy makers, host countries and even TB affected communities. Validated 
biomarkers are urgently needed to avoid this, as well as reducing cost and time 
for vaccine candidates to get into large phase III trials.   
 
1.9) Systems Biology 
1.9.1) Approaches 
Systems biology is an emerging research strategy that focuses on complex 
interactions within biological systems using a holistic approach, rather than a 
reductionist approach. The overall aim of systems biology is to understand the 
dynamic aspects of networks [228]. To understand complex biological systems, 
integration of experimental as well as computational research is necessary 
[229]. Systems biology is often studied by monitoring relevant pathways after 
perturbation of biological systems [230]. This is followed by integration of large 
data sets to formulate mathematical models that describe the system’s structure 
and its response to perturbations [230].  
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Systems biology has been applied in different areas of study and, for each of 
these, different technology platforms have been used. Some of these areas 
include: 
 Genomics – Sequencing of deoxyribonucleic acid (DNA), including intra-
organism cell specific variations e.g. Telomere variation. 
 Epigenomics – Identification of cell specific gene expression regulating 
factors not empirically coded in the genomic sequence e.g. DNA methylation. 
 Transcriptomics – Gene expression profiling. 
 Proteomics – Measurement of proteins and peptides. 
 Metaboloics – Organismal, tissue or cell level measurements of small 
molecules known as metabolites. 
 Phenomics – Variation in phenotypes as they change in disease 
progression and over lifespan. 
1.9.2) Gene Expression Profiling 
The role of T cells in immunity against TB has been the main reason why they 
are studied as potential correlates of risk against TB. Nevertheless, unbiased 
approaches, which do not limit what may comprise protective immunity against 
TB have been used to identify potential correlates of risk of TB disease. 
Genome-wide transcriptional profiling is one of such approaches, which has  
been used to identify these correlates as well as to depict novel molecular 
mechanisms involved in host control of pathogens [221, 223, 231]. For these 
reasons, genome-wide transcriptional profiling was used to identify potential 
biomarkers of risk of TB disease in this study.      
The measurement of the activity (expression) of thousands of genes at once to 
create a global picture of cellular functions is known as gene expression 
profiling [232, 233]. It examines the expression level of mRNAs in a given cell 
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population and, while knowledge of the proteins a cell expresses (proteomics) 
may be more functionally relevant than knowing how much mRNA is made from 
each gene, gene expression profiling provides the most global picture possible 
in a single experiment.. This approach assumes that genes that share a 
common pattern of expression under certain conditions are functionally related 
and that change in these gene expression pathways reflects the physiological 
changes in a cell. This therefore makes it possible to define physiological states 
and infer phenotypes based on these gene expression patterns [234].  
Gene expression profiling usually involves the use of high-throughput 
techniques and several methods have been used to measure thousands of 
transcripts simultaneously. Some of these methods include: serial analysis of 
gene expression (SAGE), massively parallel signature sequencing (MPSS), 
oligonucleotide arrays, cDNA microarrays and most recently RNA sequencing 
(RNA-Seq) [234, 235]. Microarrays are currently the most widely used 
technique. 
Microarray analysis is regarded as a hypothesis generating approach: it allows 
identification of relevant genes and expression pathways that can be further 
investigated in future studies. For this reason, microarrays have been used in: 
 Description of genes involved in developmental, pathological and 
physiological processes (gene discovery) [236, 237]. 
 Description of regulatory networks (gene regulation) [238, 239]  
 Identification of gene expression patterns that represent prognostic 
indicators and define disease states (diagnosis) [240] . 
 Drug discovery and toxicology [241] . 
 Identification of a whole blood gene expression signatures of active TB 
disease [223]. 
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The workflow of microarray analysis is quite simple (Figure 5). This involves the 
generation of messenger RNA (mRNA) from two samples/conditions under 
investigation. Each mRNA molecule is then transcribed to a complementary 
DNA (cDNA) with a reverse transcriptase enzyme. This process allows 
incorporation of fluorescent nucleotides to the cDNA, as both samples are 
labelled with different dyes. The labelled cDNA generated from the mRNA is 
loaded onto a DNA microarray plate where it hybridises or binds to its synthetic 
cDNA attached on the microarray plate. The fluorescent intensity of the 
hybridisation is then measured on a scanner and downstream analysis to 
identify differential gene expression is performed by a bioinformatician. 
However, the over simplicity of this concept tends to hide the potential problems 
as each step in the experiment is a potential source of error.  
 
Figure 5: Course of typical microarray experiment  (Murphy, 2002). 
 
Microarray experiments usually produce large amounts of data making it critical 
to analyse. There is no standardised statistical approach to analyse microarray 
data, despite continuous effort to define optimal procedures for data analysis 
Chapter 1: Literature Review Page 36 
 
and presentation [242]. Following data processing and normalisation, different 
analysis strategies are used to analyse microarray data (Figure 6).  
 
 
Figure 6: Different approaches used for microarray data analysis 
 
Some of the commonly used methods of analyses include:  
i) Low level analysis 
 Before any downstream analysis on microarray data, a low level analysis is 
performed which involves the exclusion of poor quality spots and normalisation 
to remove systematic errors [243].  
To bring up-regulated and down-regulated values to the same scale for easy 
comparison, the fluorescent intensities of the spots are firstly log transformed. A 
Spot is excluded from analysis if its intensity is lower than the background plus 
two standard deviations [244].  
The process of normalisation involves balancing the fluorescent intensities of 
the two labelling dyes to remove systematic errors. Some of the common 
methods of normalisation are [244]: 
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- Global normalisation, which uses all the genes on the array. 
- Housekeeping genes normalisation, which uses those that are constantly 
expressed. 
- Internal controls normalisation, which uses exogenous controls added during 
the hybridization step. 
Despite the use of all these methods, they have been proven to be inadequate 
for data normalisation of microarrays. Reasons for this are that housekeeping 
genes are not constantly expressed as previously thought and dye fluorescence 
can be influenced by spot intensity and spatial location on the array [245]. 
Recently, different methods have been used to normalize array data. One of 
such methods thought to be more superior to other methods uses non-linear 
normalisation on the basis of gene intensity and spatial location [244, 246]. The 
most common and widely used non-linear normalisation method is the quantile 
normalisation [247]. This method was derived from quantile-quantile plots and it 
adjusts the distribution of gene expression pooled from each array to be the 
same [248]. This method is the default normalisation method in Bioconductor 
[249], which is the most widely used and open source platform for analysing 
microarray data in R (R core team, 2006).    
ii) High level analysis 
Following low level analysis, a high level analysis is performed which involves 
the application of several statistical methods as well as data mining techniques 
to uncover patterns of gene expression. The commonly used high level 
analyses are (Figure 6): 
a) Exploratory analysis: This involves understanding the similarities and/or 
dissimilarities of the gene expression levels among all samples. The aim of this 
analysis is to find genes with similar gene expression profiles using a clustering 
technique [247]. There are two types of clustering analyses: Supervised and 
unsupervised. While unsupervised classification requires no pre-defined test, 
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supervised analysis on the other hand requires known biological information 
about the gene sets to guide the clustering algorithm. There are two categories 
of unsupervised clustering which are hierarchical and non-hierarchical analyses 
with the former being commonly used [250]. The K-means clustering (centroid)  
[251] and self-organisation maps (SOM) [252] are other types of clustering 
analyses used.  
b) Identifying differentially expressed genes: A two-fold increase or decrease in 
expression is usually used to identify differentially expressed genes using a 
fixed threshold cut-off. Systemic and biological variation in microarray 
experiments makes this method statistically inefficient [247] and might increase 
the risk of getting false positives or negatives. To complement this analysis, 
statistical methods are applied which rank genes according to their probability of 
differential expression [247]. Examples of such statistical methods include: 
student t test, Analysis of variance (ANOVA), Bayesian method and the Mann-
Whitney test [253-255]. To control for type I errors such as false discovery rate 
(FDR) and family wise error rate (FWER), which may arise when comparing 
thousands of outcomes, the resulting p-values generated from the statistical 
analysis are adjusted for multiple comparison [256] . 
c) Class prediction analysis: This involves using genes expression profiles to 
classify samples. A classifier algorithm is trained using gene expression profiles 
in a given set of samples and used to assign groups in a new set of samples 
[247]. This kind of analysis is also called supervised analysis, and includes 
linear discriminant analysis (LDA) [257] and k-nearest neighbour [258]. 
However, generalising the classifier for all situations and over-training on the 
same data set resulting in “over-fitting” are the major challenges when using this 
model. Validation of the trained classifier is essential to create a balance 
between accuracy and generalisation. Cross-validation is often used for this and 
the most common method used is called the leave-one-out in which one sample 
is taken from the training set to be a validation sample for each round of 
analysis [259].    
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d) Pathway analysis: Analysing microarray data in pathways could lead to better 
understanding of the system as genes never act alone in biological systems, but 
rather as a cascade of networks [247]. There are three approaches to 
performing pathway analyses: 
The first is further exploratory analysis of the cluster analysis to see if genes that 
cluster together might be involved in the same pathway [260]. 
The second is to reverse engineer the global genetic pathways followed by the 
identification of global regulatory networks [261]. This method assumes that by 
perturbing the system there will be a change in expression of other proteins in 
the network and this change in expression is an image of the underlying 
network. Examples are Boolean and Bayesian networks [262, 263]  . 
The last approach is studying the expression from a pathway perspective itself. 
Expression data can be linked to metabolic pathways and evaluated to identify 
which metabolic pathways are affected by transcriptional changes. Examples 
include gene set enrichment analysis (GSEA) and integrated pathway analysis 
(IPA).  
1.9.3 Statistical and biological validation of microarray results 
Validation of microarray results is necessary because of the statistical issues 
that come with analysing the data [264, 265].  Microarrays are often used as a 
first step to identify genes that associate with an outcome under investigation. 
However, the amount of false positives that can be generated during the 
analyses process can be very high especially with small sample sizes and the 
small differences in gene expression between the conditions [266]. Validation is 
therefore usually performed on independent groups of samples from which the 
original transcriptomic profiles were identified to overcome these false positive 
rates [267]. The group of samples on which microarrays are performed for gene 
identification are usually referred to as the discovery or training set while the 
group of samples on which the validation of these genes are performed are 
referred to as the validation or test set. After identification of a smaller subset of 
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differentially expressed genes by microarray in the training set, validation can be 
performed using quantitative real time polymerase chain reaction (qRT-PCR) in 
the validation set. This technique has been shown to be very sensitive and very 
rapid to accurately quantify results generated by microarray [266].   
The qPCR method, however, can be an expensive and relatively low throughput 
technique. For these reasons, the Fluidigm Dynamic Array Integrated Fluidic 
Circuits (IFC) and the Biomark HD system offers more throughput and is ideal 
for validation of microarray results [268, 269]. This technique can be used to 
measure expression of up to 96 transcripts from 96 different samples, allowing 
for a total of 9216 reactions to be performed in a single experiment. The IFC has 
tens of thousands of microfluidic controlled valves and interconnected channels 
to move both the reagents and samples in several patterns [268]. The 
elastometric material that makes up these valves deflects under pressure, 
creating a tight seal, which controls the flow of fluids in the IFC. The samples 
(DNA) are partitioned and randomly distributed in small volumes into the 
different chambers followed by PCR amplification in the presence of a 
fluorophore-containing probe. A positive fluorescence is indicative of DNA in the 
chamber while no fluorescence or blank is indicative of no DNA in the chamber 
[270]. This new qPCR technology makes it possible to perform high throughput 
gene expression analyses with very small amounts of both reagents and sample 
volumes because the IFCs reduce the 10-20ul volume used in a normal qPCR 
down to 10 nanolitres [268, 269].  
For the validation analysis performed in this thesis, we first selected the most 
differentially expressed genes by microarray in the training set. Using a 
multiplex quantitative real time PCR (Fluidigm) we then measured the 
expression of these genes in the training set. This was to validate gene 
expression profiles between microarray and the Fluidigm. For validation, the 
expression of these genes was measured by Fluidigm in the validation set 
(Figure 7). 
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Figure 7: Schematic representation of validation procedure 
 
1.10 Assays used to measure vaccine immunogenicity 
In most TB vaccine clinical trials, immunological assays are designed to 
measure vaccine-specific T cell immunity. In humans, the majority of these 
assays evaluate the magnitude and/or quality of vaccine-specific memory T 
cells in the peripheral blood because it is easier and less invasive to obtain 
compared to lymph nodes, lung tissue or bronchial alveolar lavage. Typically,  
peripheral whole blood or peripheral blood mononuclear cells (PBMC) are re-
stimulated with vaccine antigens in vitro  [271] and the responding cytokine-
producing cells can be measured by Elisa, Elispot or by flow cytometry [272]. 
The choice of method to use largely depends on the selected outcomes of 
interest and the resources available. 
Samples used for these assays may be fresh (just after collection), 
cryopreserved or both. The assay duration is very critical and this usually varies 
depending on the questions being addressed and the feasibility of the 
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performance. The assay durations usually include; (i) short-term assay (less 
than 24 hours) (ii) medium-term assay (one to three days), or (iii) long-term 
assay (four or more days) [271].  
In this thesis, we used all three assays depending on the T cell function we were 
investigating. We used the short term whole blood intracellular cytokine staining 
assay (12 hrs) to investigate the magnitude and cytokine profile of BCG-specific 
T cells by flow cytometry; as well as levels of secreted mediators in the plasma 
(7hrs) by luminex technology. Long term re-stimulation assays were used to 
assess the cytotoxic potential (3 days) and proliferative capacity (6 days) of 
BCG-specific T cells respectively by flow cytometry.  
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CHAPTER 2: CORRELATES OF RISK OF TB DISEASE IN BCG 
VACCINATED INFANTS 
 
All studies reported in this chapter, partially published, were performed by 
other members of SATVI (Benjamin Kagina, Alana Keyser, Brian Abel, 
Thomas Scriba). The results generated from the studies in this chapter led 
to the primary work presented in this thesis. In order to convey a clear 
understanding of this thesis work, it was necessary to present a brief 
report on these studies. This chapter therefore serves as the background 
for this thesis work.  
 
2.1) Rationale and approach 
As previously mentioned, the most effective intervention against TB would be 
the widespread use of an efficacious vaccine [273]. Unfortunately, the only 
licensed vaccine against TB, BCG, has variable efficacy in protection against 
pulmonary TB [36], and this accounts for high TB rates worldwide. Therefore, 
there is urgent need to develop a new effective vaccine against TB, but this has 
proven difficult to achieve, partially because of lack of immunological correlates 
of protection. Identification of immunological determinants of protection against 
TB may be guided by studies of correlates of risk of developing TB disease 
[221]. As children are particularly susceptible to TB, we aimed to identify 
immunological correlates of risk of TB disease following newborn BCG 
vaccination. Blood was collected from 10 week old infants following BCG 
vaccination at birth, processed and cryopreserved. After a two year follow-up 
period, infants who developed TB disease (at risk of TB, defined cases) and 
those who did not develop disease (not at risk of TB, defined controls) were 
identified (see materials and methods). Blood stored at 10 weeks of age was 
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thawed and different immunological parameters investigated to identify potential 
correlates of risk of developing TB disease in these infants. 
We hypothesised that frequencies of BCG-specific T cells producing Th1/Th17 
cytokines as well as cytotoxic and proliferative capacity of T cells will correlate 
with risk of developing TB disease. Using this hypothesis-driven approach, we 
evaluated immune responses thought to be important for protection against TB. 
We focused on Th1/Th17 cytokine production by BCG-specific T cells, their 
proliferative and cytotoxic potential, and release of pro-inflammatory mediators 
in response to BCG.  
We complemented these studies with an unbiased, hypothesis generating 
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2.2) Materials and Methods 
2.2.1) Participants 
Ten-week old infants vaccinated with BCG at birth were enrolled at the SATVI 
field site in the Worcester area, near Cape Town, South Africa into a 
randomized controlled trial (RCT) [56] which aimed to determine whether 
percutaneous or intradermal delivery of Japanese BCG resulted in similar 
protection against TB. 5,724 from 11,680 infants enrolled for this RCT study 
were then recruited into our correlates of risk study. Exclusion criteria at 10 
weeks of age were: BCG not received within 24 hours of birth, HIV-infected 
mother, any acute or chronic disease at the time of enrolment, significant 
perinatal complications in the infant, clinically anaemic, and household contact 
with any person with TB disease, or any person who was coughing. The 
protocol for this study was approved by the University of Cape Town Research 
Ethics Committee (271/2000) and written informed consent was obtained from 
parents or legal guardian. The study was conducted according to the US 
Department of Health and Human Services and Good Clinical Practice 
guidelines.  
2.2.2) Participant follow up and TB case definition 
Blood was collected from infants at 10 weeks of age and participants were 
followed up for a period of 2 years. Community-wide passive surveillance 
systems identified children with possible TB disease, those with symptoms 
suggestive of TB disease, or from households where an adult had TB disease 
[56]. These infants were admitted to a dedicated research ward for clinical 
examination, chest radiography, tuberculin skin testing, two early morning 
gastric aspirations and two sputum inductions for M.tb smear and culture [56]. 
All infants admitted to the research ward were also tested for HIV infection: a 
positive antibody test resulted in exclusion. The median time from vaccination to 
TB diagnosis was 12.3 months with minimum and maximum times being 1.1 
and 23.9 months respectively. 
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For TB case definition, only pulmonary TB patients were included in this study. 
The reason for this was because this was the primary endpoint for TB diagnosis 
to assess correlates of risk of TB and in addition other forms of TB are relatively 
more difficult to diagnose. However, Hawkridge et al reported a total of 5 out of 
the 11,680 recruited in the study to have other forms of TB but the sample size 
was too small to perform any statistical comparisons [56]. Cases included were 
culture positive for M.tb after investigation (definite TB) or culture negative for 
M.tb but either had strong positive chest x-ray and clinical and/or 
epidemiological evidence of TB (probable TB). We included 2 groups of 
controls: infants who were living in the same TB endemic area but didn’t meet 
criteria for TB investigation (community controls) or those who were exposed to 
patients with active TB in the household but found not to have TB after 
investigation (household controls). 
2.2.3) Whole blood assay and intracellular cytokine staining 
For logistic reasons, the Danish BCG strain was used for all experiments as 
opposed to the Japanese strain used for vaccination. The main reasons being 
that at the time when experiments were done, there was a shift in the country to 
the use of the Danish strain and almost all immunological assays implored the 
use of this strain. Heparinised blood was collected from all infants at 10 weeks 
of age and 1mL was incubated with BCG (Danish strain, Statens Serum Institute 
(SSI), used at 1.2 x 106 organisms/mL), as previously described [271]. Briefly, 
1ml of blood was incubated with BCG and the co-stimulatory antibodies anti-
CD28 and anti-CD49d (BD Biosciences, 1µg/mL each) for 7hrs at 37oC. Blood 
was also incubated with co-stimulatory antibodies alone as negative control or 
with Staphylococcal Enterotoxin B (SEB, Sigma-Aldrich, 10μg/mL) as a positive 
control. After this incubation time, plasma was collected and cryopreserved (to 
measure release of soluble molecules) and Brefeldin-A (Sigma, 10g/mL) was 
then added to the blood for intracellular cytokine capture, followed by incubation 
for an additional 5 hours at 37°C. After incubation, 2mM of EDTA (Sigma) was 
added, followed by vortexing for 10s and incubating at room temperature for 
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15mins. This was followed by addition of FACS lysing solution (BD Biosciences) 
to lyse red cells and fix white cells for 10mins at room temperature. Cells were 
then cryopreserved by pelleting and re-suspending in 10% DMSO in foetal calf 
serum (FCS) followed by step wise freezing to -70°C in a “Mr Frosty” (Nalgene) 
and transferred to liquid nitrogen the following day. Multiple vials of each sample 
were cryopreserved to avoid repeated freeze-thaw cycles. Cryopreserved cells 
were later thawed, washed and permeabilised using Perm/Wash solution (BD 
Biosciences). Cells were incubated for 1 hour with fluorescence-conjugated 
antibodies against surface antigens as well as intracellular cytokines at 4°C in 
the dark. Antibodies used were: anti-CD3 Pacific Blue (clone UCHT1), anti-CD4 
QDot605 (S3.5, Invitrogen), anti-CD8 PerCP-Cy5.5 (SK-1), anti-γδ-TCR APC 
(B1), anti-IFN- Alexa 700 (B27), anti-TNF- PE-Cy7 (Mab11), anti-IL-2 FITC 
(5344.111, all from BD Biosciences) and anti-IL-17 PE (eBio64CAP17, 
eBioscience). An LSRII flow cytometer (BD Biosciences) configured with 3 
lasers and 12 fluorescence detectors, using FACS Diva 6.1 software, was used 
to acquire cells. Optimal photomultiplier tube (PMT) settings were established 
prior to sample analysis. Cytometer Setting and Tracking (CST) beads (BD 
Biosciences) were used to record the target MFI values for the baseline settings 
each day prior to sample acquisition. Compensation settings were set using 
anti-mouse kappa-beads (BD Biosciences) labelled with the individual 
fluorochrome-conjugated antibodies.  
2.2.4) PBMC isolation and cryopreservation 
PBMC were isolated from peripheral blood of 10-week old infants by ficoll 
density gradient centrifugation (Sigma), and cryopreserved in RPMI 1640 
(Biowhittaker). Briefly, 10mL of blood was diluted with 20mL RPMI in a 50mL 
tube, capped and inverted to mix. 15mL of ficoll was placed in another 50mL 
tube and 30mL of the diluted blood was slowly layered on top of the ficoll.  The 
blood was then centrifuged at 400g for 30mins at room temperature without 
brake and PBMC from the buffy coat carefully aspirated at the ficoll interface 
with a pipette and transferred into another tube. PBS was added to 50mL and 
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then centrifuged at 350g for 10mins at 22°C. Supernatant was decanted and 
cells resuspended in 1mL of 1X PBS by pipetting up and down. 1X PBS was 
added to 50mL, tube inverted 2-3 times and centrifuged at 350g for 10mins at 
22°C. Supernatant was decanted and cells resuspended in 1mL RPMI and kept 
on ice. For cryopreservation, cells were pelleted and resuspended in RPMI 
containing 10% DMSO in FCS followed by step wise freezing to -70°C in a “Mr 
Frosty” (Nalgene) and transferred to the vapour phase in liquid nitrogen the 
following day.  Because repeated freeze-thaw cycles can have serious effects 
on immunological as well as genetic findings, multiple vials of PBMCs were 
cryopreserved so as to avoid repeated freeze-thaw cycles and each vial was 
thawed only once.   
2.2.5) Lymphoproliferation assay  
Cryopreserved PBMC were thawed in culture medium (12.5% v/v AB+ serum in 
RPMI) containing 10g/mL DNase (Sigma-Aldrich). After 2 washes, cells were 
stained with 1g/mL Oregon Green (Molecular Probes) and rested in 5% CO2 at 
37C overnight. PBMC were then incubated at 2 x 105 cells/well in 200L 
culture medium with BCG at a multiplicity of infection (MOI) of 0.01 or 0.5g/mL 
of SEB (positive control) in 5% CO2 at 37C for 6 days. Medium alone served as 
negative control.  Four hours before the end of the incubation period, cells were 
re-stimulated with phorbol 12-myristate 13-acetate (PMA, Sigma-Aldrich 
20ng/mL) and ionomycin (Sigma-Aldrich, 10µg/mL) to induce cytokine 
expression and Brefeldin-A (Sigma-Aldrich, 2µg/mL) added for intracellular 
cytokine capture. After incubation, cells were harvested with 2mM EDTA 
(Sigma-Aldrich) in PBS, followed by staining with 1g/mL LIVE/DEAD® Fixable 
Violet Dead Cell Stain (Invitrogen). Cells were then fixed with FACS Lysing 
Solution (BD Biosciences) before cryopreservation. Cells were later thawed, 
washed and stained for 1 hour at 4°C with anti-CD3 Qdot605 (clone UCHT1) 
and anti-CD8 PerCP-Cy5.5 (Sk1) and acquired as described above. Re-
stimulation with PMA and Ionomycin down regulates CD4 expression so CD4+ 
T cells were identified as CD3+CD8- cells [274, 275] 
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2.2.6) Cytotoxic marker assay 
PBMC were thawed, washed and plated at 2 x 105 cells/well in 200L RPMI 
containing 10% AB serum and incubated with either BCG at MOI of 0.1 or 
0.05g/ml SEB (positive control) in 5% CO2 at 37C for 72 hours.  Medium alone 
served as negative control. Cells were then harvested, stained for viability with 
1g/mL LIVE/DEAD® Fixable Violet Dead Cell Stain (Invitrogen), fixed and 
cryopreserved as described above. Cryopreserved fixed cells were later thawed, 
washed and permeabilized with Perm/Wash solution (BD Bioscences). After 
permeabilization, cells were stained with the following antibodies for 1h at 4C: 
anti-CD3 Qdot605 (clone UCHT1), anti-CD8 Cy5.5PerCP (SK1), anti-granzyme 
B Alexa 700 (GB11), anti-perforin FITC (G9; all from BD Biosciences) and anti-
granulysin PE (eBioDH2, eBioscience). Cells were acquired as described 
above.  
2.2.7)  Secreted mediators measurement 
Supernatant collected from whole blood assays (plasma) was thawed once and 
levels of 29 cytokines/chemokines were determined with the human cytokine 
LINCOplex 29-bead array assay kit (LINCO Research, Millipore). 
Cytokines/chemokines measured were: interleukin-1 (IL-1), IL-1, IL-1RA, IL-
2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12p40, IL-12p70, IL-13, IL-15, IL-17, 
soluble CD40-ligand (sCD40L), epidermal growth factor (EGF), eotaxin, 
fractalkine, granulocyte-colony stimulating factor (G-CSF), granulocyte-
macrophage colony-stimulating factor (GM-CSF), interferon- (IFN-), interferon-
gamma-induced protein (IP-10), monocyte chemotactic protein-1 (MCP-1), 
macrophage inflammatory protein- (MIP-1-, MIP-1), transforming growth 
factor- (TGF-), tumor necrosis factor- (TNF-), and vascular endothelial 
growth factor (VEGF) according to manufacturer”s instructions. The Luminex 
100 IS instrument with Luminex software (xMAP technology, Luminex 
Corporation) was used to detect fluorescence. 
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2.2.8) Gene expression profiling 
Cryopreserved PBMC were thawed, washed in RPMI and rested for 6 hours at 
1X106 cells/ml in RPMI 1640 containing 10% human AB serum and 1% L-
glutamine in 5% CO2 at 37°C. After resting, PBMC were incubated in culture 
with BCG (Danish strain, SSI, reconstituted as previously described) at an MOI 
of 0.18 in 5% CO2 at 37°C for either 4 or 12 hours. Medium alone served as 
negative control. Cells were then harvested and QIAmp RNA Blood Mini kit 
(Qiagen) was used to isolate RNA according to the manufacturer’s instructions. 
Isolated RNA was stored at -80°C, later thawed and amplified using the Illumina 
RNA Amplification Kit (Ambion) as previously described [276]. 
Amplified RNA (750ng per array) was hybridized to the Illumina HumanRefSeq-
8 BeadChip (version 2) according to the manufacturer's instructions. An Illumina 
bead array reader confocal scanner was used to scan the arrays.  
 
2.2.9) Data analysis 
FlowJo (Treestar) was used to compensate and to analyze the flow cytometric 
data. Boolean gates were generated to assess combinations of markers. 
For whole blood intracellular cytokine staining assays, frequencies of cytokines 
from the negative control were subtracted from BCG-specific responses. Median 
absolute deviations (MADs) were calculated as follows: for each sample, the 
absolute deviation from the median was obtained by subtracting the frequencies 
of cytokine expressing cells of each sample from the median expression in the 
negative control for all unstimulated samples. The MAD was then calculated as 
the median of the absolute deviations of each sample from the median.  
Participants were included in the analysis if they meet the following criteria: (1) a 
positive control (SEB) CD4 T cell response higher than the median plus 3 MADs 
of the CD4 T cell response in the negative control, (2) number of CD3+ T cell 
events counted > 75,000.  
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For the proliferation assay, frequencies of proliferating cells from the negative 
control were subtracted from the BCG stimulated frequencies and infants were 
included in the analyses only if frequencies of Oregon Greenlow CD4+ T cells in 
the positive control were greater than the median frequency plus 3 MAD of the 
negative control. 
For the cytotoxic marker assay, frequencies of cytotoxic molecule+ T cells in the 
negative control were subtracted from frequencies of BCG stimulated responses 
and infants were included in the analyses only if frequencies of cytotoxic 
molecule-expressing CD4+ or CD8+ T cells in the positive control were greater 
than the median frequency plus 3 MAD of the negative control.  
For the Luminex assay, cytokine data were imported directly into Microsoft 
Excel from the Luminex software. For analysis, standards were used to 
generate standard curves in duplicate for each cytokine; these curves were 
used to calculate cytokine levels. Cytokine levels from medium alone were 
subtracted from BCG stimulated levels to obtain final BCG-specific cytokine 
levels. Negative values and values below limit of detection were assigned a zero 
value. 
For assessment of differences between cases and controls, a Mann-Whitney U 
test was performed, using Prism 4.0 (GraphPad Software Inc.).  
For Microarray data analysis, raw Illumina probe data was first exported from 
Beadstudio followed by screening for quality. Probe set intensities were pre-
processed, quantile-normalized and expression values transformed to log2 
using Bioconductor (www.r-project.org). Genes with low expression and 
insufficient variation in expression across all samples were excluded using 
Bioconductor’s gene filter package. Following gene filtering, only expression 
values with intensities greater than 200 units in at least 2 samples and an 
interquartile range of 0.2 (log 2 scale) across all samples were included for 
analysis. Unsupervised hierarchical clustering was used to obtain unbiased 
clusters of infants independent of clinical outcome. 




A total of 13,338 pregnant women were approached for the initial RCT study 
and 11,860 infants were vaccinated and recruited into the study. Reasons for 
exclusion were: still birth, prematurity, perinatal infection as well as withdrawal 
from study. 1578 mothers were therefore excluded from the study and from this 
number, only 11 withdrew consent [56]. From the 11,680 infants vaccinated with 
BCG at birth in the randomized controlled trial [56], we enrolled a total of 5,724 
infants for this study. Different groups of babies were used for different assays 
reported in this chapter. Figure 8A below shows a summary of the enrolment 
into the various arms of the study. Firstly, the infants were divided into a training 
and validation set (Figure 8B). All infants included into this part of the study 
were from the training set, except for studies involving the cytotoxic potential of 
T cells that had infants from both training and validation sets. For infants in the 
training set, a total of 29 infants were identified as definite TB (microbiological 
confirmation) and were included as cases. For gene expression studies, a total 
of 26 definite TB cases were included for analysis. Controls in the training set, 
were divided into two: 55 community controls and 55 household controls (see 
section 2.2.2 for definitions) and both groups were used for all assays. However 
because not all samples from the various control groups were always available 
to perform the different assays, only community controls and household controls 
were used for release of secreted mediators and transcriptional profiling 
respectively. For infants in the validation set (cytotoxic potential), a total of 29 
infants were identified as probable TB (see section 2.2.2 for definition) because 
there were not enough culture positive infants to form a validation set. Controls 
in the validation set were community controls that were never investigated for 
TB (n=55). 
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Figure 8: Participant enrolment into the different groups and cohorts of the study 
(Modified from Kagina et al., 2010).  
A) Study design and participant enrolment into case/control groups.  Controls were randomly 
selected using a random selection program on STATA. 185 probable/possible TB cases as well 
as 153 TB-negative cases were not analysed in order to make sample size more feasible and 
practical. B) Cases and controls included in the different assays and different cohorts of the 
study. Highlighted in red are cases while blue and green are household and community controls 
respectively. For transcriptional profile analysis in the training cohort, 26 cases and 18 
household controls were used.  
 
2.3.2) Frequency and cytokine profile of BCG-specific CD4+ and CD8+ T 
cells 
As earlier mentioned, cytokines produced by T cells are measured as vaccine 
endpoints in clinical trials [253] and are also thought to be important in TB 
immunity [121, 144]. We therefore investigated these cytokines as potential 
correlates of risk of childhood TB disease development, following BCG 
vaccination at birth. An intracellular cytokine assay was used to evaluate 
frequencies and cytokine expression profiles of these T cells and these 
outcomes were compared between cases and controls. Figure 10 shows a 
representative flow cytometry plot of cytokine co-expression in CD4+ T cells in 









Figure 9: Representative flow cytometry plots of cytokine co-expression (Kagina et al., 
2010).  
Whole blood was incubated with BCG, SEB or left unstimulated for 12 hours and cytokine 
detected using an intracellular cytokine assay and flow cytometry. 
 
There were no differences between the 3 groups in the frequencies of BCG-
specific CD4+ T cells expressing any of the 4 cytokines (Figure 10A). 
Frequencies of CD4 T cells expressing different combinations of IFN-, TNF-, 
IL-2 or IL17 were also similar in cases and controls (Figure 10B). 
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Figure 10: Frequency and cytokine expression profile of BCG-specific CD4+ T cells 
(Kagina et al., 2010).  
Whole blood was incubated with BCG for 12 hours and cytokine detected using an intracellular 
cytokine assay and flow cytometry. (A) Frequencies total CD4+ T cells expressing IL-2, IFN-, 
TNF- and IL-17 upon BCG stimulation. (B) Frequencies of BCG-specific CD4+ T cell-
expressing different combinations of cytokines. Boolean gating was used to generate 15 distinct 
cytokine expressing subsets following selection of CD4+ T cells. Results are shown in box and 
whiskers plots with whiskers representing the maximum and minimum value; the box 
representing the interquartile range and the horizontal line in the box representing the median. 
No significant differences between the groups (all p>0.05) were observed using the Kruskal-
Wallis test. Red boxes represent TB cases (n=29), green boxes represent community controls 
(n=55) and blue boxes represent household controls (n=55). 
  
Similarly to CD4+ T cells, cases and controls did not differ in terms of 
frequencies of total cytokine-expressing BCG-specific CD8+ T cells (data not 
shown), nor cytokine combinations thereof (data not shown). Of note, CD8+ T 
cell responses to BCG were lower than those observed in CD4+ T cells, and 
mainly restricted to IFN- production.  
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2.3.3) Proliferative capacity of BCG-specific T cells 
We have recently shown that newborn BCG vaccination induces mycobacteria-
specific T cells endowed with proliferative capacity [191].  Proliferation capacity 
of BCG-specific T cells was assessed as potential correlate of risk of developing 
TB disease in BCG vaccinated infants. The in vitro lymphoproliferative capacity 
of these cells was measured as dilution of the intracellular dye Oregon Green 
upon cell division in response to BCG. Although BCG-specific proliferating T 
cells were detected in most of the infants, there were no differences in the 
proliferative responses between cases and the 2 control groups (Figure 11). 
 
 
Figure 11: Proliferative capacity of BCG-specific T cells (Scriba and Keyser et al, 
manuscript in preparation). 
PBMCs were stained with Oregon Green (OG) and stimulated for 6 days with BCG or left 
unstimulated. Proliferating cells were identified as OGlow CD8+ or CD8- (mainly CD4+) T cells. 
Proliferation index was calculated as the frequency of proliferating cells upon BCG stimulation, 
divided by the frequency of proliferating cells in unstimulated cells. Lines in the middle denote 
medians. Differences between the three groups were assessed using the Kruskal-Wallis test 
followed by Mann-Whitney test between any two groups. No significant differences were 
observed. TB cases (n=29), community controls (n=55) and household controls (n=55). 
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2.3.4) Cytotoxic potential of BCG-specific T cells 
The cytotoxic markers granzyme B, granulysin and perforin are expressed by 
mycobacteria-specific memory T cells in newborns vaccinated with BCG [191]. 
The importance of these cytotoxic T cells in control of M.tb has been 
demonstrated in several studies through their cytolytic activity [189] or cytotoxic 
protein-mediated anti-mycobacterial activity [153]. We therefore sought to 
determine if proportions of BCG-specific T cells expressing the cytotoxic 
markers granzyme B, granulysin and perforin were associated with risk of TB. 
Following in vitro stimulation of PBMCs with BCG, expression of these markers 
by BCG-specific T cells was measured by flow cytometry. BCG-specific T cells 
were identified as CD8+ or CD8- (mainly CD4+) T cells expressing these 
cytotoxic molecules upon in vitro stimulation with BCG. This is because cells 
were restimulated with PMA and Ionomycin which has been shown to down-
regulate CD4 T cells. Proportions of BCG-specific CD4+ T cells expressing 
granulysin were higher in cases, compared to household controls only (Figure 
12A). In particular, proportions of CD4+ T cells co-expressing granulysin and 
granzyme B, or granzyme B and perforin, were higher in cases, compared to 
both controls (Figure 12B).  
Among BCG-specific CD8+ T cells, cases showed higher proportions of 
granzyme B-expressing cells, compared to both control groups (Figure 12C). 
Proportions of CD8+ cells co-expressing granzyme B and granulysin were also 
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Figure 12: Cytotoxic potential of BCG-specific CD4+ and CD8+ T cells (Scriba and Keyser 
et al, manuscript  in preparation). 
PBMCs were stimulated with BCG or left unstimulated for 3 days and T cells expressing 
cytotoxic molecules were defined as BCG-specific T cells. Flow cytometry was used to detect 
BCG-specific CD4+ and CD8+ T cells expressing granzyme B, granulysin and/or perforin. 
Proportions of total BCG-specific CD4+ (A) or CD8+ (C) T cells expressing granzyme B, 
granulysin or perforin in cases and controls. Frequencies of BCG-specific CD4+ (B) or CD8+ (D) 
T cell subsets co-expressing combinations of the 3 cytotoxic molecules. Horizontal lines denote 
medians. The Kruskal Walis test was used to compare differences between the three groups 
and the Mann-Whitney test was used to compare the two groups. Only p-values below 0.05 are 
shown. TB cases (n=29), community controls (n=55) and household controls (n=55). 
A major limitation in studies in which outcomes are determined by measuring 
multiple parameters is the increased likelihood of false positive results. 
Nevertheless, these false positives can be overcome by validating the findings 
on another set of participants. To validate the findings described above, these 
outcomes were measured in another set of 29 TB cases and 55 Community 
controls. Proportions of BCG-specific CD4+ and CD8+ T cells expressing the 
different cytotoxic markers that were candidate correlates of risk of developing 
TB disease in infants in the training set were not significantly different in the 
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validation set (data not shown). We therefore could not validate our initial results 
that frequencies of cytotoxic CD4+ or CD8+ T cells were associated with risk of 
developing TB disease. 
2.3.5) Secreted mediators measurement  
Levels of pro-inflammatory mediators measured in supernatant of BCG 
stimulated whole blood were also compared between cases and controls. Apart 
from the Th-1 promoting cytokine intereukin-12-p40 (IL12p40), which was higher 
in cases compared to household controls, no other lymphokines were 
significantly different between the two groups (Figure 13). However, after 




Figure 13: Soluble levels of secreted mediators (Scriba and Keyser et al., manuscript  in 
preparation). 
Levels of 29 chemokines/cytokines were measured in plasma by multiplex bead array after 
incubation of whole blood with BCG or medium alone for 7 hours. The following selected 
cytokines are shown: IFN-, TNF-, IL-13, Fractalkine, EGF and IL-12p40. BCG-specific levels 
were determined by subtraction of levels in plasma from whole blood incubated with medium 
alone, from those in BCG-stimulated blood. Horizontal lines denote medians. The Mann-
Whitney U test was used to compare the two groups and p-values  shown. Only IL-12p40 levels 
were different between cases and controls of all secreted mediators measured. TB cases (n=29) 
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 2.3.6) Gene signature of risk of developing TB disease 
For over ten years now, transcriptional profiling has been applied in several 
human diseases to provide surrogate markers for clinical phenotyping [277] and 
to accurately predict prognosis [278]. It has been used to identify potential 
therapeutic targets as well as diagnostic and prognostic biomarkers in patients 
with autoimmune diseases [279]. Recently, Berry et al identified a blood 
signature of active TB disease using genome wide transcription profiling of 
whole blood [223]. To determine if a gene expression signature correlates with 
prospective risk of developing TB disease, we used genome-wide transcription 
profiling of PBMCs stimulated with BCG. RNA was extracted from PBMCs 
stimulated with BCG or left unstimulated, hybridized to Illumina HumanRefSeq-8 
BeadChip (version 2) and gene expression measured using an Illumina bead 
array reader confocal scanner. We observed greater differential response in 
PBMC stimulated for 12 hours compared to 4 hours stimulation in our 
preliminary analysis. We therefore focused our downstream analysis on the 12 
hour stimulation time point. Following unsupervised hierarchical clustering 
analysis in the BCG stimulation condition only, 25 genes were differentially 
expressed between cases and controls with a fold change > 1.3 and a nominal 
p value of 0.05 (Figure 14). However, after adjusting for multiple comparisons 
and setting the false discovery rate (FDR) p-value at 0.05, there was no 
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Figure 14: Heatmap showing differential gene expression between cases and controls. 
PBMC stimulated with BCG for 12 hours and gene expression analysis performed by 
microarray. Unsupervised hierarchical analysis was performed and 25 genes were differentially 
expressed between cases (red, n=26) and controls (black, n=18) with FC>1.3 and nominal p-
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2.4) Discussion 
We aimed to identify correlates of risk of TB disease in infants vaccinated with 
BCG at birth. Two approaches were used: hypothesis-driven and unbiased or 
hypothesis-generating approaches. We were not able to identify correlates of 
risk of TB disease using either of the approaches.  
Frequencies of Th1/Th17 BCG-specific CD4+ and CD8+ T cell did not correlate 
with risk of developing TB disease in infants, following BCG vaccination at birth  
[175], nor did the frequencies of  polyfunctional T cells. Several studies have 
shown that Th1 cytokines play key roles in TB immunity [280-283]. Darrah et al 
showed that polyfunctional CD4+ T cells correlated with vaccine-induced 
protection against Leishmaniasis in mice [168]. IL-17 expression by CD4+ T 
cells has also been shown to play a role in protection against TB; this is why we 
also investigated this cytokine as a correlate of risk of TB disease [181]. 
Experimental and clinical studies have all demonstrated roles of CD8+ T cells in 
TB immunity. For example Bruns et al showed that patients undergoing anti-
TNF therapy, had decreased numbers of antigen-specific effector memory 
CD8+ T cells, which led to a decrease in antimicrobial activity against M.tb, 
which was associated with an increase in incidence of TB disease [153]. No 
differences between cases and controls were observed when these markers 
where measured as potential correlates of risk of TB disease. 
Because T cell responses to mycobacteria are very complex [284, 285], we 
sought to investigate other T cell outcomes as potential correlates of risk of TB 
disease. We investigated the cytotoxic and lymphoproliferative capacity of BCG-
specific T cells. Our results showed that these markers do not correlate with risk 
of developing TB disease in infants. Silva et al suggested a key role in 
protection against TB by granule mediated cytotoxicity of CD4+ and CD8+ T 
cells [286]. We also investigated plasma levels of 29 chemokines/cytokines after 
stimulation with BCG, which also did not correlate with risk of developing TB 
disease. These results however do not mean that T cells are not essential in TB 
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immunity. On the other hand, our data suggest that T cell function by itself might 
not be sufficient to prevent TB disease. As earlier mentioned, the immune 
system is very complex and so is the immune response following M.tb infection 
which involves different cell types. Recently, Kozakiewicz et al showed that in a 
mouse model, B cells can regulate neutrophilia following M.tb infection and 
vaccination with BCG by modulating IL-17 responses [287]. Studies such as 
these suggest that measuring other immunological outcomes should be 
considered in future correlates of risk of TB disease studies.  
T cell outcomes investigated as potential correlates of risk of TB disease in this 
study were based on our current knowledge of what we think is important in 
immunity against M.tb.  However, we also used genome wide transcriptional 
profiling, an unbiased approach which does not rely on previous knowledge. We 
observed similar PBMC gene expression between cases and controls. 
Transcriptional profiling has been used in several human diseases to 
understand the molecular mechanisms which lead to pathogenesis and identify 
markers that correlate with clinical phenotypes. For example in cancers, 
transcriptional profiling has been used to accurately predict prognosis leading to 
effective and directed treatment [277]. In this study, transcriptional profiling was 
used to differentiate between acute myeloid leukaemia (AML) and acute 
lymphoid leukaemia (ALL) as well as between B-cell ALL and T-cell ALL, which 
could all have similar clinical presentations. The application of gene expression 
profiling in TB has been widely used recently [222-226]. Berry et al., compared 
gene expression profiles between persons with latent TB and those with active 
disease and identified a blood signature of active disease [223]. In another 
study carried out in South African and Malawian HIV-infected and uninfected 
individuals, a 27 and 44 gene signature could distinguish TB from LTBI and 
other diseases, respectively [222]. The aim of this study was to identify gene 
transcripts that could be used to diagnose TB in HIV-infected individuals [222]. 
However, in all these studies reported above, gene expression was compared 
between TB disease and latently infected individuals. In our study, all analyses 
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were performed when infants were healthy and most likely not infected with 
M.tb. The phenotype of healthy BCG vaccinated infants who ultimately progress 
to TB or remain healthy is a very challenging phenotype to analyse.  
We observed high heterogeneity in the response to BCG vaccination within this 
study population. In our study, known factors that could influence BCG 
immunogenicity, such as helminth infection or route of BCG administration, were 
unlikely to account for such heterogeneity, according to previous studies 
conducted by our group [55, 56]. For example, Hatherill et al found that maternal 
infection with helminths in the Western Cape was less than 10%, suggesting it 
has negligible effect on BCG variability [55].  
Post immunization variability in immune responses has been used as marker of 
disease susceptibility [75]. For example, in measles vaccine trials, vaccine 
recipients have been categorised into "low" or "non responders" and "high" or 
"responders", respectively based on the level of antibody responses [288, 289]. 
Chen et al showed that low responders to measles vaccine post immunization 
were not protected from measles when exposed to the virus compared to high 
responders [288]. Similarly, Mathias et al also showed that non responders to a 
single dose of measles vaccine in whom a measurable response was detected 
only after a second dose were six times more likely to develop measles after 
exposure compared to responders [289]. These two examples show an 
association between vaccine response and development of disease in that 
individuals with a weak vaccine-induced response are more likely to develop 
disease compared to those with a strong response. However, there are several 
pathogens and/or vaccines that can cause diseases at the extremes of both 
weak and strong immune responses such, as Aspergillus spp and Vaccinia virus 
(used as vaccine against small pox) [290]. Casadevall et al proposed that host 
damage can be depicted by the nature of the immune response and that both 
the host and the pathogen can contribute to virulence (Figure 15). Host-
pathogen interaction can confer a certain degree of benefit to the host. In as 
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much as the pathogen can lead to host damage, host responses could also 
contribute to host damage. The "U" shape on the graph shows that host 
damage can be maximal if host immune responses are either too weak or 
strong (Figure 15). This model fits well with the known importance of CD4 T 
cells in TB, whereby too low CD4 T cell count, observed in progressive HIV 
infection is associated with increased risk of TB, while on the other hand, 
cavitation is mainly observed in the presence of normal CD4 count [138]. We did 
not consider such complex host responses in the analyses performed in this 
chapter. In the next chapters, our further investigations considered non-linear 
associations between immunity and clinical outcome, under this hypothesis that 
marked heterogeneity in immune responses within a given population could 
mask potential correlates of risk of TB disease. 
 
Figure 15: Damage-Response framework (Adapted from Casadevall et al., 2003).  
 




Our results suggests that BCG-induced T cell functions as well as PBMC gene 
expression profiles in healthy 10-week-old infants do not correlate with risk of 
developing TB disease during the first 2 years of life. Further analysis and 
investigation of other T cell outcomes may be considered for identification of 
these correlates. 
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CHAPTER 3: CORRELATES OF RISK OF TB DISEASE ACCORDING TO 
CLUSTERING OF GENE EXPRESSION PROFILES 
In this chapter, re-analyses of microarray data was by our collaborators in 
VGTI and Jenner Institute while all other re- analyses were done by 
Samuel Njikan.   
 
3.1) Introduction 
In the previous chapter, we reported that no correlate of risk of TB disease could 
be identified among BCG-specific T cells functions as well as gene expression 
profiles investigated following routine BCG vaccination in infants. However, the 
analyses did not take into account the complex nature of host responses 
proposed in a damage-response framework which suggests that very strong 
and weak host immune responses to infections can predispose to disease [290]. 
We therefore hypothesised that heterogeneity in immune responses may mask 
correlates of risk of TB disease. In this chapter, we sought to acknowledge this 
heterogeneity in immune responses and further identify potential correlates of 
risk of TB disease 
To address our aims, further analyses were performed on gene expression 
profiles as well as BCG-specific T cell outcomes measured in the previous 
chapter. Different analysis strategies are frequently used to mine data 
generated from microarray experiments. Some of these analyses include 
unsupervised clustering, identification of differentially expressed genes, class 
prediction analysis and pathway analysis. These kinds of analyses are useful in 
generating new hypotheses and the validity of such analyses is based on both 
biological knowledge and statistical significance [291]. 
Hierarchical clustering analysis is one method used to explore microarray data. 
It can be performed with either supervised or unsupervised methods. In 
supervised analysis, prior knowledge on biological/clinical outcomes is 
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considered during the process while no prior knowledge is needed for 
unsupervised clustering. This analysis strategy has been used to uncover gene 
expression patterns in acute myeloid leukaemia [292]. Following clustering 
analysis, different analysis strategies can be performed to identify differentially 
expressed genes between the conditions under study to uncover potential 
biomarkers. Linear models for microarray analysis (LIMMA) and prediction 
analysis for microarrays (PAM) are methods used to identify differentially 
expressed genes and subsequent biomarkers. These two analysis platforms are 
found in Bioconductor’s R analysis software. 
Understanding the biology of biomarkers or gene expression-based classifiers is 
an important step in fully appreciating their significance. Pathway analyses are 
usually performed to understand the biological significance of the gene 
expression in the classifier. Gene set enrichment analysis (GSEA) as well as 
integrated pathway analysis (IPA) are commonly used to identify the most 
differentially expressed biological pathways across the conditions under study. 
These methods have been used in several studies [293-295] and have been 









Chapter 3: Correlates of Risk of TB Disease According to Clustering of Gene Expression 
Profiles   Page 70 
 
3.2) Materials and Methods 
This chapter mainly focuses on further analysis of the results generated in the 
previous chapter.  
3.2.1) Whole blood assay and intracellular cytokine staining 
See section 2.2.3 
3.2.2) Lymphoproliferation assay 
See section 2.2.5 
3.2.3) Cytotoxic marker measurement 
See section 2.2.6 
3.2.4) Secreted mediators measurement 
See section 2.2.7 
3.2.5) Gene expression profiling 
See section 2.2.8 
3.2.6) Data analysis 
See section 2.2.9 
Bioinformatic data analysis (Figure 17) was performed in collaboration with 
Helen Fletcher (University of Oxford, UK), Rafick Sekaly and Ali Filali (Vaccine 
and Gene Therapy Institute, FL, USA). 
3.2.6.1) Hierarchical clustering analysis 
Firstly, the probe intensities were normalised across all samples. Following this 
normalisation, probe intensities from unstimulated samples were subtracted 
from probe intensities in BCG stimulated. Background subtracted probe 
intensities were used to perform clustering analysis. This analysis was 
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performed using R’s cluster package [249], which makes use of the hierarchical 
clustering algorithm. Unsupervised hierarchical clustering followed by semi-
supervised hierarchical clustering analyses were used to identify clusters of 
infants and following identification of clusters, their stability and validation were 
determined by altering pre-clustering conditions to include different numbers of 
genes (5000 to 20000 genes).The Euclidean distance as well as Pearson’s and 
Spearman’s correlations were also used to assess stability of the different 
clusters.  
3.2.6.2) Identification of differentially expressed genes 
Differentially expressed genes were identified using Bioconductor's limma 
package [296]. Briefly, the fold change in gene expression between cases and 
controls was determined (up or down-regulated in cases compared to controls). 
An empirical Bayes method was used to moderate the standard error of the log 
fold change for expression values from each gene. This was followed by 
adjusting for multiple comparisons using the Benjamini and Hochberg method, 
which also controls the false discovery rate (FDR). The FDR was set at 0.05. 
3.2.6.3) Class prediction analysis    
A nearest-neighbour centroid method in Bioconductor’s pamr package [297] 
was used for class prediction as well as selection of biomarkers. Briefly, the 
optimal shrinkage threshold used to build the centroid was determined by using 
an internal k-fold cross validation. After estimating the cross-validation error for 
each threshold, the optimal threshold that gave the lowest cross-validation error 
rate was chosen.   
3.2.6.4) Pathway analysis 
Analysis of pathways of gene expression was performed using Gene Set 
Enrichment Analysis (GSEA) [298], which is a non-parametric statistical method. 
This analysis makes use of a list of ranked genes to determine if a particular 
phenotype is associated with a known biological pathway or sets of genes. An 
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enrichment score (ES) is used to evaluate this association and an empirical 
phenotype-based permutation method is used to assess the statistical 
significance of each gene set’s ES. The GSEA accounts for multiple 
comparisons by normalising the ES for each gene and calculates a false 
discovery rate (FDR) for each normalised ES. 
We systematically tested gene sets from the Molecular signature Database 
(MsigDB, http://www.broad.mit.edu/gsea/msigdb) canonical pathways (cp) 
version c2.cp.v3.0. within the C2 collection which contains 913 gene sets  to 
which we added a collection of 28 immune related gene sets described in 
Chaussabel et al [299]. A total of 220 gene sets were filtered out because they 
were either very small (less than 15 genes) or very high (more than 500 gene 
sets). Briefly, genes found to be differentially expressed between cases and 
controls (up or down-regulated in cases compared to controls) were ranked 
according to fold change in expression. The GSEA was then used to compare 
this list of ranked genes to known datasets of genes housed in the GSEA C2:cp 
molecular signature database (739 data set). Gene expression in cases and 
controls were ranked with specific pathways in the GSEA and FDR was set at 
0.05. 
In addition to GSEA, integrated pathway analysis (IPA) was used to identify 
genes that have been shown to correlate with several diseases from the 
ingenuity biological database (www.ingenuity.com). Briefly, genes were inserted 
into ingenuity’s IPA and a search was performed to identify defined molecular 
interactions between genes. This was then used to generate a network of 
genes. For network analysis, IPA computed a score (p-score=-log10(p-value)) 
according to a list of focus genes stored in the ingenuity database and the set of 
input genes. This score is derived from a p-value and takes into account the 
size and number of genes in the network to approximate how relevant this 
network is to the original list of genes. A score of 1 indicates there is a 1 in 10 
(p<0.1) and 2 indicates a 1 in 100 (p<0.01) chance that the genes in a network 
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are together by chance. Therefore the higher the score, the more likely that 
genes found in a network are together not by chance. The network identified is 
presented as a graph indicating the molecular relationships between 
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3.3.1) Clustering of gene expression profiles 
Following quantile normalisation, background gene expression values (UNS) 
were subtracted from BCG stimulated values (BCG-UNS). Figure 16 shows a 
summary of the different analysis performed. Using unsupervised hierarchical 
clustering analysis after background subtraction, we observed two distinct 
clusters of infants according to gene expression profiles induced by in vitro BCG 
stimulation (Cluster 1, n=20; Cluster 2, n=24; Figure 17A). Differential gene 
expression between cluster 1 and cluster 2 identified 461 genes in opposite 
directions with an FDR p value <0.05 and a FC>1.3.  Within the two different 
clusters, there was equal distribution of cases and controls (Figure 17B). In 
cluster 1, there were 11 cases and 9 controls, while cluster 2 had 15 cases and 
9 controls (Figure 17B). 
   
Figure 16: Flow chart of different bioinformatics analysis performed. 
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Figure 17: Clustering of gene expression profiles. 
Normalized probe intensity from PBMC stimulated with media only (UNS) was subtracted from 
the normalized probe intensity from PBMC stimulated with BCG. Unsupervised hierarchical 
clustering was performed (Pearson correlation with 20,000 probes) resulting in two distinct 
clusters of infants (cluster 1 and cluster 2). A) Heat map showing 461 differentially expressed 
genes between the two clusters with a FC> 1.3 and FDR <0.05. Up-regulated and down-
regulated genes denoted by orange and blue respectively. B) Distribution of cases (red, n=26) 
and controls (black, n=16) within clusters 1 (green) and 2 (blue). 
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3.3.2) Correlates of risk of TB disease  
We observed two distinct clusters of infants with opposite gene expression 
profiles in response to in vitro BCG stimulation with each cluster including both 
cases and controls. This observation could be explained by the damage-
response framework proposed by Casadevall et al [290]. We hypothesised that 
cases and controls may also display different transcriptional profiles in different 
clusters of infants. We therefore separately compared cases and controls in the 
two clusters of infants, to uncover potential correlates of risk of TB disease in 
each cluster. 
3.3.2.1) Gene signature of risk of TB disease   
Further analysis of both clusters separately showed groups of cases and 
controls in each. However, case and control groups in cluster 2 were more 
pronounced and clear than cluster 1. 
To identify a gene signature of risk of TB disease, analysis was performed in 
BCG stimulated and unstimulated conditions separately. Differential gene 
expression was already present in the unstimulated samples (data not shown) 
but it was not strong enough to attain statistical significance. However, it seems 
like stimulation with BCG enhanced these differences, which attained 
significance when cases and controls were compared. Subtracting the 
background lead to loss in differential gene expression. For this reason, 
correlates were identified only in the BCG stimulation condition. Semi-
supervised analysis of both clusters separately revealed two clusters of cases 
and controls in each. In cluster 1, 341 genes were differentially expressed 
between cases (11 infants) and controls (9 infants) (Figure 18A). However, this 
differential gene expression was not seen after adjusting the p-value for multiple 
comparisons (FDR <0.05) when linear models for microarray analysis (LIMMA) 
was performed. Cases (15 infants) and controls (9 infants) from cluster 2 
showed differential expression of 206 genes, determined by LIMMA analysis 
(Figure 18B), where a fold change (FC) >1.5 was used to identify differentially 
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expressed genes at a false discovery rate (FDR) <0.05. A total of 5 infants were 
misclassified with these criteria (3/15 cases and 2/9 controls) (Figure 18B). Of 
these 206 transcripts, 74 were able to predict cases and controls determined by 
prediction analysis for microarray (PAM) upon cross-validation. Among these 
genes, S100A8 (S100 calcium binding protein A8) and CD14 were the most up-
regulated in cases compared to controls with a fold change> 3.5.  
 
 
Figure 18: Differentially expressed genes between cases and controls. 
Gene expression profiles of PBMCs stimulated with BCG for 12hrs. Semi-supervised clustering 
followed by LIMMA analysis was performed in BCG stimulated samples only to identify 
differential gene expression between cases and controls. A) Semi-supervised clustering 
analysis showing 341 genes differentially expressed between cases (n=11) and controls (n=9) in 
cluster 1. B) LIMMA analysis with an FDR of 0.05 following semi-supervised clustering analysis 
showing 206 genes differentially expressed between cases (n=15)  and controls (n=9). Cases 
are shown in red and controls in black. Orange colour on heat maps denote genes up-regulated 
in cases compared to controls while blue colour denotes genes down-regulated in cases 
compared to controls. 
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3.3.2.2) T cell correlates of risk of TB disease 
We next assessed the T cell outcomes measured in the previous chapter 
between cases and controls in the two clusters of infants separately. We 
hypothesised that analysing the two clusters separately will uncover differences 
in BCG-specific T cells between cases and controls that were absent when the 
data was analysed together.  
Firstly we assessed if frequencies and cytokine profiles of BCG-specific CD4+ 
and CD8+ T cells were different between cases and controls in the two clusters 
of infants. No differences were observed in frequencies and cytokine profiles 
between cases and controls in cluster 1. However, cases in cluster 2 were 
associated with higher frequency of IL-17-producing CD4+ T cells compared to 
controls (Figure 19). However, after adjusting for multiple comparison using 
Bonferroni, this significant difference was lost. No other differences were 
observed between cases and controls in CD4+ T cells and CD8+ T cells (Table 
2). 
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Figure 19: Frequencies of BCG-specific IL-17-expressing CD4+ T cells between cases and 
controls. 
Whole blood was incubated with BCG for 12 hours and cytokine detected using an intracellular 
cytokine assay and flow cytometry. Frequencies of total CD4+ T cells expressing IL-17 upon 
BCG stimulation. Mann-Whitney U test was used to compare differences between groups. 
Cases (red) and controls (black). Horizontal lines denote median and whiskers denote 
interquartile range. A p value < 0.05 was considered significant (purple). Cluster 1 (cases, n=6 
and controls, n=7). Cluster 2 (cases, n=12 and controls n=5). 
We next assessed the cytotoxic capacity of CD4+ and CD8+ T cells between 
cases and controls in the two clusters. In cluster 1, cases had higher CD4+ T 
cells co-expressing granulysin, granzyme B and perforin (Figure 20A), or co-
expresing granulysin and granzyme B (Figure 20B) as well as granzyme B and 
perforin (Figure 20C) compared to controls. In cluster 2, cases were associated 
with lower expression of CD4+ T cells producing perforin only (Figure 20D).  
When we compared cases and controls between the two clusters, we observed 
that cluster 2 controls had higher CD4+ T cells co-expressing granulysin and 
granzyme B (Figure 20B) as well as granzyme B and perforin (Figure 20C) 
compared to cluster 1 controls. However, after adjusting for multiple comparison 
using Bonferroni, this significant difference was lost. There were no other 
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differences observed in both CD4+ and CD8+ T cells between cases and 
controls in cluster 1 and cluster 2 (Table 2). 
 
 
Figure 20: Cytotoxic potential of BCG-specific CD4+T cells in the two clusters. 
PBMCs were stimulated with BCG or left unstimulated for 3 days and flow cytometry was used 
to detect BCG-specific CD4+ T cells expressing granzyme B, granulysing and/or perforin. BCG-
specific T cells were defined by subtracting the unstimulated value from the BCG stimulated 
value. Frequencies of CD4+ T cells co-expressing  (A) granulysin, granzyme B and perforin (B) 
granulysin and granzyme B (C) granzyme B and perforin or  (D) perforin only. The Kruskal 
Wallis test was used to assess differences in any of the groups. Mann-Whitney test was used to 
compare any two groups (cases in red and controls in black). Horizontal lines on graphs 
represent median and whiskers represent interquartile ranges. P-values < 0.05 were significant 
(purple). Cluster 1 (cases n=6 and controls n=7). Cluster 2 (cases n=12 and controls n=4). 
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We next compared levels of secreted mediators between cases and controls 
within the two clusters separately. Cases were associated with lower levels of 
IL-8 in cluster 1 (Figure 21A) and TGF-α in cluster 2 (Figure 21B) compared to 
controls. Comparing cases and controls between the two clusters, we observed 
that cluster 2 controls had increased levels of TGF-α compared to cluster 1 
controls (Figure 21B). There was also increased levels of IL-1β in cluster 2 
cases compared to cluster 1 cases (Figure 21C). No other differences in 
secreted mediators were observed (Table 2).  
There were no differences observed in the proliferative capacity of either CD4+ 
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Figure 21: Levels of secreted mediators in cases and controls from clusters 1 and 2. 
Whole blood was incubated with BCG or no antigen for 7 hrs and secreted molecules were 
measured by luminex bead array. Values measured in unstimulated controls were subtracted 
from BCG-stimulated samples and are shown. Levels of (A) IL-8 (B) TGF-α (C) IL-1β. Horizontal 
lines and whiskers on graphs denote median and interquartile range respectively. The Kruskal 
Wallis test was used to assess differences in any of the groups and the Mann-Whitney test was 
used to compare any two groups (cases in red and controls in black). Only p-values below 0.05 
were considered significant (purple). Cluster 1 (cases, n=5  and controls, n=7). Cluster 2 (cases, 
n=10 and controls n=4). 
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Table 2: BCG-specific T cell outcomes not significantly different between 
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3.3.3) Biological processes associated with risk of TB disease 
Differential gene expression between cases and controls was observed when 
cluster 1 and 2 were analysed separately. We now want to investigate if unique 
biological pathways will associate with cases and controls in each cluster when 
the two clusters are analysed separately. We hypothesised that cases and 
controls within the two clusters will have differential expression of biological 
pathways. Using Gene Set Enrichment Analysis (GSEA), we observed different 
biological pathways associated with cases and controls in the two clusters 
separately. In cluster 1, the majority of the pathways associated with cases 
where pathways involved in protein synthesis (green) and glucose metabolism 
(grey) (Table 3). There were a few pathways associated with T (pink) and B 
cells (blue) as well as mitogen activated protein kinase (MAPK) (orange) 
signalling in cases (Table 3). Cluster 1 controls were associated with myeloid 
cells (purple), inflammation (red) and MAPK signalling pathways (orange) (Table 
4). The majority of genes up-regulated in controls compared to cases were 
myeloid cell and inflammatory genes suggesting that diminished immune 
activation might increase risk of developing TB disease. 
In cluster 2, pathways associated with controls and not cases were pathways 
involved in protein synthesis (green), glucose metabolism (grey) and CD4 T cell 
signalling (pink) (Table 5). MAPK signalling (orange), inflammatory (red) and 
myeloid cell activation pathways (purple) were the main pathways identified and 
the majority of these pathways were over represented in cases compared to 
controls (Table 6). These pathways were therefore associated with risk of TB 
disease in this group of infants. B cell signalling pathways (blue) as well as 
glucose metabolism (grey) were also identified and found to associate with risk 
of TB disease (Table 6).  The majority of genes up-regulated in cases compared 
controls were myeloid and inflammatory genes. This data suggests that 
excessive immune activation increases risk of developing TB disease. 
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Table 3: GSEA pathways associated with cluster 1 cases 
 
Cluster 1 cases FDR 
Protein synthesis (Reactome_ Viral_ MRNA_ Translation) 0.0000 
Protein synthesis (Reactome_ Translation) 0.0000 
Protein synthesis (Reactome_ Peptide_ Chain_ Elongation) 0.0000 
Protein synthesis (Reactome_ GTP_ Hydrolysis_ And_ Joining_ Of_ The_ 60s_ 
Ribosomal_ Subunit) 
0.0000 
Protein synthesis (Reactome_ Gene_ Expression) 0.0000 
Protein synthesis (Kegg_ Base_ Excision_ Repair) 0.0000 
Protein synthesis (Kegg_ Aminoacyl_ tRNA_ Biosynthesis) 0.0000 
Protein synthesis (Reactome_ tRNA_ Aminoacylation) 0.0000 
Protein synthesis (Reactome_ Cytosolic_tRNA_Aminoacylation) 0.0000 
Protein synthesis (M_ 3.7_ Spliceosome_ Methylation_ Ubiquitin) 0.0000 
Protein synthesis (M_204_ Ribosomal proteins) 0.0000 
Protein synthesis (Reactome_ Formation_ of_ a_ Pool_ of_ Free_ 40s_ Subunits) 0.0014 
Protein synthesis (Reactome_ Influenza_ Viral_RNA_ Transcription_ And_ 
Replication) 
0.0042 
Protein synthesis (Kegg_ Ribosome) 0.0056 
Protein synthesis (M_ 1.7_ MHC_ Ribosomal_ Proteins) 0.0058 
Protein synthesis (Kegg_ Cytosolic_ DNA_ Sensing_ Pathway) 0.0075 
Protein synthesis (ABC_ Transporters) 0.0078 
Protein synthesis (Reactome_ Influenza_ Life_ Cycle) 0.0078 
Glucose Metabolism (Reactome_ Integration_ Of_ Energy_ Metabolism) 0.0000 
Glucose Metabolism (Reactome_ Glucose_ Regulation_ Of_ Insulin_ Secretion) 0.0000 
Glucose Metabolism (Reactome_ Regulation_ Of_ Beta_ Cell_ Development) 0.0014 
Glucose Metabolism (Reactome_ Regulation_ Of_ Gene_ Expression_ In_ Beta_ 
Cells) 
0.0014 
Glucose Metabolism (Kegg_ Pentose_ Phosphate_ Pathway) 0.0048 
Glucose Metabolism (Reactome_ Regulation_ Of_ Insulin_ Secretion) 0.0049 
Glucose Metabolism (Kegg_ One_ Carbon_ Pool_ By_ Polate) 0.0098 
T Cell (M_ 3.8_ CDC_ TCR_ Creb_ Glycosylase) 0.0000 
B Cell (M_ 1.3_ B cells) 0.0000 
MAP Kinase Signalling (Kegg_ Parkinsons_ Disease) 0.0056 





Chapter 3: Correlates of Risk of TB Disease According to Clustering of Gene Expression 
Profiles   Page 86 
 
 
Table 4: GSEA pathways associated with cluster 1 controls 
 
Cluster 1 controls FDR 
Myeloid cells (M_ 2.6_ Myeloid Lineage) 0.0000 
Myeloid cells (M_ 1.5_ Myeloid Lineage) 0.0000 
Myeloid cells (M_ 1.2_ Platelets) 0.0000 
Myeloid cells (Kegg_ Haematopoietic_ Cell_ Lineage) 0.0000 
Inflammation (M_ 3.3_ Inflammation II) 0.0000 
Inflammation (M_ 3.2_ Inflammation I) 0.0000 
Inflammation (Kegg_ Systematic_ Lupus_ Erythematosis) 0.0000 
Inflammation (Kegg_ Sphingolipid_ Metabolism) 0.0028 
MAP kinase signalling (Reactome_ Metal_ Ion_ Transporter) 0.0000 
MAP kinase signalling (Reactome_ JAak_ STAT_ Signalling_ Pathway)  0.0000 
MAP kinase signalling (Reactome_ RNA_ Polymerase_I_ Promotion) 0.0032 
MAP kinase signalling (Reactome_ FRS2_ Mediated_ Cascade) 0.0057 
 
Table 5: GSEA pathways associated with cluster 2 controls 
 
Cluster 2 controls FDR 
Protein synthesis (Reactome_ Peptide_ Chain_ Elongation) 0.0000 
Protein synthesis (Reactome_ Translation) Protein synthesis (Reactome_ 
Formation_ of_ a_ Pool_ of_ Free_ 40s_ Subunits) 
0.0003 
Protein synthesis (Reactome_ Translation) 0.0005 
Protein synthesis (Kegg_ Ribosome) 0.0007 
Protein synthesis (Reactome_ GTP_ Hydrolysis_ And_ Joining_ Of_ The_ 60s_ 
Ribosomal_ Subunit) 
0.0008 
Protein synthesis (Reactome_ Viral_ MRNA_ Translation) 0.0020 
Protein synthesis (Reactome_ Formation_ Of _ The_Ternary_ Complex_ And_ 
Subsequently_ The_ 43S_ Complex) 
0.0093 
Protein synthesis (Reactome_ Translocation_ Of_ Zap70_ To_ Immunological_ 
Synapse) 
0.0207 
Protein synthesis (M_ 1.7_ MHC_ Ribosomal_ Proteins) 0.0243 
Protein synthesis (Reactome_ Metabolism_ of_ Proteins) 0.0271 
Protein synthesis (Reactome_ Influenza_ Viral_RNA_ Transcription_ And_ 
Replication) 
0.0307 
Protein synthesis (Reactome_ Transloation_ Initiation_ Complex_ Formation) 0.0387 
Glucose Metabolism (Reactome_ Regulation_ Of_ Beta_ Cell_ Development) 0.0009 
Glucose Metabolism (Reactome_ Regulation_ Of_ Gene_ Expression_ In_ Beta_ 
Cells) 
0.0022 
T Cell (Reactome_ Phosphorylation_ Of_ CD3_ And_ TCR_ Zeta_ Chains) 0.0090 
T Cell (M_ 3.8_ CDC_ TCR_ Creb_ Glycosylase) 0.0155 
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Table 6: GSEA pathways associated with cluster 2 cases 
 
Cluster 2 cases FDR 
Myeloid cells (M_ 2.6_ Myeloid Lineage) 0.0000 
Myeloid cells (M_ 1.5_ Myeloid Lineage) 0.0000 
Myeloid cells (Kegg_ Lysosome) 0.0031 
Myeloid cells (Kegg_ FC_ Gamma_ R_ Mediated_ Phagocytosis) 0.0032 
Myeloid cells (Kegg_ Glycosaminoglycan_ degradation) 0.0059 
Myeloid cells (M_ 2.3_ Erythrocytes) 0.0130 
Myeloid cells (Reactome_ Platelet_ Activation_ Triggers) 0.0150 
Myeloid cells (Kegg_ Other_ Glycan_ Degradation) 0.0180 
Myeloid cells (Kegg_ Acute_ Myeloid_ Leukaemia) 0.0182 
Myeloid cells (Biocarta_ NK_ Cell_ Pathway) 0.0210 
MAP kinase signalling (Biocarta_ RAS_ Pathway) 0.0000 
MAP kinase signalling (Biocarta_ ECM_ Pathway) 0.0026 
MAP kinase signalling (Biocarta_ SPP_ Pathway) 0.0027 
MAP kinase signalling (Reactome_ FRS2_ Mediated_ Cascade) 0.0028 
MAP kinase signalling (Reactome_ Semaphorin_ Interactions) 0.0030 
MAP kinase signalling (Reactome_Nuclear_Events_Kinase_And_Transcription_ 
Factor_ Activation) 
0.0030 
MAP kinase signalling (Biocarta_ ERK_ Pathway) 0.0031 
MAP kinase signalling (Reactome_ ERK_ MAPK_ Targets) 0.0034 
MAP kinase signalling (Reactome_ MAPK_ Activation_ In_ TLR_ Cascade) 0.0035 
MAP kinase signalling (Reactome_ SEMA4D_ In_ Semaphorin_ Signalling) 0.0063 
MAP kinase signalling (Reactome_ Signalling_ To_ ERKS) 0.0083 
MAP kinase signalling (Biocarta_ CDC42RAC_ Signalling) 0.0091 
MAP kinase signalling (Reactome_MAPK_Targets_Events_Mediated_ By_ MAPK) 0.0104 
MAP kinase signalling (Reactome_ Signalling_ To_ RAS) 0.0116 
MAP kinase signalling (Biocarta_ HER2_ Signalling) 0.0116 
MAP kinase signalling (Reactome_ GSK3_ Pathway) 0.0257 
MAP kinase signalling (Reactome_ Signalling_ By_ NGF) 0.0363 
Inflammation (M_ 3.3_ Inflammation II) 0.0191 
Inflammation (M_ 3.2_ Inflammation I) 0.0027 
Inflammation (Biocarta_ Il-12_ Pathway) 0.0114 
Inflammation (Kegg_ Chemokine_ Signalling_ Pathway) 0.0180 
Inflammation (Reactome_ Toll_ Receptor_ Cascades) 0.0000 
Inflammation (Reactome_ Toll_ Like_ Receptor_ 3_ Cascade) 0.0253 
Inflammation (Biocarta_ IL-17_ Pathway) 0.0378 
Inflammation (Reactome_ Innate_ immunity_ Signalling) 0.0448 
Inflammation (Kegg_ Sphingolipid_ Metabolism) 0.0469 
B Cell (SA_ B_ Cell_ Receptor_ Complexes) 0.0000 
B Cell (Biocarta_ BCR_ Pathway) 0.0187 
B Cell (ST_ B_ Cell_ Antigen_ Receptor) 0.0283 
Glucose Metabolism (Kegg_ Amino_ Sugar_ And_Nucleotide_Sugar_ Metabolism) 0.0441 
Glucose Metabolism (Kegg_ Glyoxylate_ And_ Dicarboxylate_ Metabolism) 0.0450 
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We next evaluated whether functional gene networks were associated with 
differential gene expression between cases and controls in the two clusters 
separately using IPA with all 20,000 genes. IPA is a web- based software that 
constructs networks based on known interactions and/or associations from 
literature. Similar to what we observed with the GSEA, we found that cases in 
cluster 2 were associated with gene networks that were involved in 
Inflammatory Response, and Post-Translational Modification (Figure 22). This 
network generated a score of 44 and comprised of 35 genes. This score is 
calculated from the p-value and gives the probability that the genes in this 
network are together by chance. A score of 2 and above represents a 99% 
probability (p<0.001) that gene co-regulation is not by chance and the higher the 
score the higher this probability. Of these 35 genes, 17 were up-regulated (red) 
and 7 were down-regulated (green) in cases compared to controls while 11 
transcript had no differential expression between cases and controls. Most 
importantly, transcripts up-regulated in cases compared to controls (red) were 
associated with inflammatory responses.  
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Figure 22: Gene network identified by IPA between cases and controls in cluster 2. 
Visual representation of principal network generated using 20,000 genes.  Network shows 35 
genes involved in Inflammatory Response, Ophthalmic Disease and Post-Translational 
Modification. Genes highlighted in red are up-regulated and in green are down-regulated in 
cases compared to controls. Solid lines denote direct interactions while dashed lines represent 
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Following the observation that cases in cluster 2 infants were associated with 
myeloid cell pathways as well as higher expression of CD14 gene, we sought to 
confirm this finding by flow cytometry. We observed trends of higher frequencies 
of CD14+ cells (Figure 23A) and lower frequencies of CD3+ cells (Figure 23B) 
in cases compared to controls in cluster 2 (unpublished data). When we 
compared myeloid to lymphoid ratio between cases and controls in cluster 2, we 
also found a trend suggesting that cases had higher myeloid to lymphoid ratios 
compared to controls (Figure 23C, unpublished data). However, there was no 
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Figure 23: Frequencies of myeloid and lymphoid cells in cluster 2 cases and controls. 
Cryopreserved  PBMC  were thawed, washed, and immediately stained for myeloid and 
lymphoid markers. The frequencies of (A) CD14+ monocytes and (B) CD3+  lymphocytes were 
expressed as relative proportions of live CD45+ leukocytes. Percentage of myeloid cells was 
calculated by adding together % CD14+ cells and % myeloid DC. Percentage of lymphoid cells 
was calculated by adding together % CD3+ and % CD19+ cells. (C) The ratio between myeloid 
and lymphoid cells was calculated by dividing total myeloid by total lymphoid cell populations. 
Cases (n=15) are shown in red while controls (n=8) are shown in black. Horizontal lines depict 
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3.4)  Discussion 
In the previous chapter, we reported that no correlate of risk of TB disease could 
be identified according to the outcomes we measured in healthy 10-week-old 
infants. Using unsupervised hierarchical clustering analysis, we identified two 
clusters of infants based on their gene expression profiles after in vitro 
stimulation of PBMC with BCG. Unsupervised hierarchical clustering analysis 
has been used in several studies to mine microarray data [300-302]. It is one of 
the most widely used methods to analyse this kind of data by generating 
clusters based on highly differentially expressed genes whose pattern of 
expression are similar [303]. Gene expression profiles in the two clusters of 
infants was in opposite direction. Following this observation, we hypothesised 
that analysing the clusters separately would allow identification of correlates of 
risk of TB. Analysing the two clusters of infants separately, allowed identification 
of differential gene expression signatures and T cell functions in infants who 
ultimately developed TB disease or remained healthy in each cluster. This 
finding was very important in that, for the first time, we were able to identify 
markers that were different between 10-week old BCG vaccinated infants who 
later on developed disease and those who remained healthy. However, this was 
only possible after the observation of two different clusters of infants by gene 
expression profiles as these correlates were absent when the infants were 
analysed together. An explanation for this can be that given the analysis 
approach we applied which rely on analyses of group averaging differences, the 
opposite gene expression in the two clusters cancel out distinct patterns when 
the infants are analysed together, hence no differential expression were 
apparent between cases and controls.   
A 74-gene expression signature for risk of TB disease was identified in infants 
who clustered in the second group (cluster 2). This signature mainly comprised 
myeloid, innate and inflammatory genes. Among these genes, S100A8 (S100 
calcium binding protein A8) and CD14 were the most up-regulated in cases 
compared to controls with a fold change> 3.5. S100A8 is a calcium and zinc 
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binding protein that has been shown to play a key role in innate immunity to 
infections [304, 305]. Recently, this protein has been shown to play a major 
pathologic role in TB by mediating accumulation of neutrophils in the lungs and 
inflammation in humans, non human primates and mice [306]. In humans and 
non human primates, increased levels of S100A8-producing neutrophils were 
found in inflammatory lung lesions of active TB individuals compared to those 
latently infected [306]. Interestingly, in humans increased levels of this protein 
were found in serum of active TB patients compared to serum obtained from 
latently infected individuals and healthy controls [306]. Following M.tb infection 
in mice, S100A8-producing monocytes were found in mice that had increased 
inflammation [306]. CD14 is a monocyte differentiation antigen and forms an 
important component of the innate immune system [307]. It is required for the 
TLR-4 mediated recognition of M.tb and has been shown to elicit lung 
inflammation in M.tb infected mice [308]. Soluble levels of CD14 have been 
shown to be a specific marker of monocyte/macrophage activity [309]. Although 
the role of CD14 in TB has not been fully investigated in humans, elevated 
levels of this protein have been found in BAL and serum of active TB patients 
[310]. Our data suggests that there is enrichment of myeloid cells (monocytes) 
in cases compared to controls in cluster 2 infants. This finding was confirmed by 
showing a trend in higher frequencies CD14+ cells and lower frequencies of 
CD3+ cells in cases compared to controls in cluster 2 infants. Although there 
was no statistical significance between the two groups, the trends in the 
frequencies of these cells reflected what we observed at the gene expression 
level. The association between risk of TB disease and myeloid/lymphoid cell 
ratio has also been described recently by Naranbhai et al in HIV-positive adults 
before and after starting anti-retroviral therapy [311]. In this study, it was 
observed that there was a higher risk of HIV-infected individuals to develop TB 
disease over time if they had either too high or low myeloid to lymphoid cell ratio 
[311]. In our study however, all infants were HIV-uninfected at time of 
enrolment. 
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IL-17 and IFN-γ are pro-inflammatory cytokines that are induced during primary 
TB. Among other functions, they act as chemotactic mediators, recruiting cells 
to site of infection and thus help in stabilisation of the granuloma. However, a 
balance of both Th1 and Th17 cells during infection is essential to avoid 
immunopathology. A shift towards IL-17 may cause too much influx of 
neutrophils, which might lead to tissue damage [158]. In an M.tb infection model 
in IFN-γ-/- mice, there was increased expression of IL-17 in the lungs, which 
induced S100A8, which in turn mediated influx of neutrophils leading to 
exacerbated lung inflammation [306]. In our study,   IL-17 producing cells were 
higher in cases compared to controls in cluster 2, with no difference in IFN-γ 
producing cells. However, cases and controls were compared at 10 weeks of 
age when they were all healthy and had no exposure to M.tb.    
Cytotoxic molecules produced by CD4+ T cells in cases and controls was found 
to be opposite in the two clusters of infants. In cluster 1, cases were associated 
with higher frequencies of BCG-specific CD4+ T cells producing granulysin, 
perforin and granzyme B, while in cluster 2 cases showed similar or lower 
frequencies of these cells compared to controls. Pitabut et al showed that TB 
patients have increased granulysin and perforin in circulation compared to 
healthy controls [312]. This suggests that infant response to BCG stimulation in 
the two clusters might be different, confirming our hypothesis of identifying 
correlates of risk of TB disease separately. We hypothesised that because we 
observe these two clusters of infants with opposite gene expression profiles, 
analysing them separately would allow for identification of correlates of risk of 
TB disease in each cluster.   
In cluster 1 infants, plasma levels of IL-8 was higher in controls compared to 
cases. IL-8 is a chemokine that plays a role in regulating leucocyte influx in TB 
disease [313]. Elevated levels of this protein have been found in BAL [314-316], 
pleural fluid [317] and plasma [318] of TB patients. This is however opposite to 
what we see in our study. In the studies reported above, IL-8 levels were 
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assessed in patients with TB disease but in our study, IL-8 was measured when 
infants were all healthy (10 weeks of age) hence the possible reason for the 
disparity in results. Transforming growth factor-alpha (TGF-α) is known to 
stimulate neural cell proliferation in the human adult brain [319]. However, its 
role in TB has not yet been established. Nevertheless, the fact that this 
chemokine as well as IL-1β were different between clusters 1 and 2 controls as 
well as cluster 1 and 2 cases respectively, further supports our hypothesis of 
identifying correlates of risk of TB disease in the two clusters separately.  
GSEA showed that enriched (cluster 2) or decreased (cluster 1) expression of 
inflammatory as well as myeloid gene pathways were associated with risk of 
developing TB disease. In cluster 2 infants, cases had increased expression of 
pathways associated with myeloid cells, inflammation as well as type I/II 
interferons while there was decreased expression of T cell pathways compared 
to controls. These transcriptomic patterns have been reported in several other 
studies [223, 226, 320]. For example, Berry et al showed up-regulation of 
inflammatory, myeloid cells and type I/II interferon gene pathways and down-
regulation of T cell pathways in TB disease compared to latent infection [223]. 
This finding was also supported by a study performed by other members of our 
laboratory aimed at identifying correlates of risk of TB disease in adolescents 
(Penn-Nicholson, Hanekom, Scriba et al., unpublished data). In this study, these 
patterns associated with risk of TB disease in M.tb infected adolescents as far 
as 18 months before they developed disease. Nevertheless, the fact that we 
see a similar pattern of gene expression may indicate innate responses to 
mycobacteria, suggesting that this may be due to persistence of BCG. It has 
been suggested that myeloid genes specifically up-regulated in TB disease are 
expressed by macrophages and dendritic cells and this may reflect innate cells 
trafficking to the inflammed lungs [320]  
Casadevall et al have proposed that host immune responses to pathogens that 
are too strong or weak can lead to host tissue damage [290]. Following BCG 
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vaccination, there can be several factors that account for this dichotomy in 
inflammatory responses which can be environmental, genetic or even 
persistence of the BCG itself. To address these hypotheses, other members of 
our laboratory are currently studying the effects of delaying BCG from birth to 10 
weeks. In this study, a group of infants will be vaccinated with BCG at birth and 
in another group, BCG vaccination will be delayed to 10 weeks of age. Blood 
will be collected from both groups of infants at 10 weeks of age just before the 
delayed group receive BCG. Gene expression profiles will be compared 
between the two BCG vaccinated groups of infants. If BCG persistence is the 
reason for this dichotomy in inflammatory response, then the signatures 
previously identified should be found only in the BCG birth vaccinated arm and 
not the delayed group. However, if this dichotomy is genetic and not dependent 
on BCG persistence, then this signature should be present in both groups of 
BCG vaccinated infants.    
Up- or down-regulation of MAPK signalling was also associated with risk of 
developing TB in both clusters. Immunohistochemical analysis of lung biopsies 
of TB patients has shown phosphorylation of p38MAPK in macrophages 
surrounding the granulomas and in vitro studies have shown that p38 activity 
regulates matrix degradation by macrophages [321]. Yang et al also showed 
that this pathway is essential for inflammatory responses in TB through toll-like 
receptors [322]. These also support our findings suggesting that too much or too 
little inflammation might increase the risk of developing TB disease. Gene 
network analysis using IPA also showed up-regulation of inflammatory genes in 
cases compared to controls confirming what was observed with the gene 
signature of risk of TB disease as well as GSEA.   
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3.5) Conclusion 
Taken together, we showed that cases and controls are associated with 
different patterns of immune response to BCG in the 2 clusters of infants, but a 
consistent pattern could not be identified. Our data suggest that excessive or 
inadequate inflammation in response to BCG, possibly driven by myeloid cells, 
is associated with prospective risk of developing TB disease in different groups 
of infants. However, taking into account differential gene expression in response 
to BCG stimulation (clustering) was a key factor in identifying correlates of risk 
of TB disease. Indeed, we saw opposite gene expression profiles between 
cases and controls in the two clusters. We also observed different T cell 
correlates of risk, at times in opposite directions, in the two clusters. The next 
chapter focuses on understanding the biology of this clustering. 
Our findings are limited by the small sample sizes, especially considering the 
variability in some of the groups. For this reason, this finding requires further 
validation in an independent cohort of infants. 
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CHAPTER 4: ASSOCIATION BETWEEN CLUSTERING OF GENE 
EXPRESSION AND DIFFERENTIAL RESPONSE TO BCG VACCINATION  
In this chapter, re-analyses of microarray data was by our collaborators in 
VGTI and Jenner Institute while all other re-analyses were done by Samuel 
Njikan.   
 
4.1)  Introduction 
In the previous chapter, we observed complex models of immunity as proposed 
by the damage-response framework whereby either too much or too little 
inflammatory responses associated with increased risk of developing TB 
disease in BCG vaccinated infants. However, clustering of infants into two 
groups based on their gene expression profiles was a pre-requisite for 
discovering potential biology-related correlates of risk of TB. Since accounting 
for this clustering allowed identification of biological correlates of risk of TB 
disease, it is important to understand the biological processes that underlie it.   
The work in this chapter aimed to investigate the association between clustering 
of gene expression profiles and differential response to BCG vaccination. Since 
the two clusters of infants had differential gene expression profiles, we 
hypothesised they will also have differential response to BCG vaccination 
measured as frequency of BCG-specific T cells. For this, we re-analysed and 
compared BCG-specific T cell responses between the two clusters of infants.  
Following this analysis, we performed several mechanistic investigations to 
further understand the biology of this clustering. Using GSEA and IPA, we 
investigated weather transcriptional profiles associated with biological pathways 
known to be important in immune responses were also associated with 
clustering of gene expression profiles.   
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4.2)  Materials and Methods  
4.2.1) Whole blood assay and intracellular cytokine staining 
See section 2.2.3 
 4.2.2) Lymphoproliferation assay 
See section 2.2.5 
4.2.3) Cytotoxic marker measurement 
See section 2.2.6 
4.2.4) Secreted mediators measurement 
See section 2.2.7 
4.2.5)  Gene expression profiling 
See section 2.2.8 
4.2.6) Data analysis 
T cell outcomes measured in chapter 2 where compared between clusters 1 and 
2. A Mann Whitney test was used to compare the two clusters and a significant 
difference was determined by a p-value of <0.05. 
Biological pathways differentially expressed in the two clusters was assessed as 
described in section 3.2.6.4. 
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To understand what underlies the clustering of infants into two groups based on 
their gene expression profiles, we sought to look for differences between 
clusters 1 and 2. For this, we first assessed whether technical parameters, 
demographic, epidemiological or biological conditions of either the mother or the 
child associated with the observed clustering. The parameters collected at time 
of enrolment and sample processing that were assessed included: birth weight, 
weeks of gestation, age at first bleed (day of sample procession), RNA quality, 
gender, ethnicity and vaccination route (Figure 24A-G). None of these 
parameters collected at enrolment were co-variates of clustering as there was 
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Figure 24 (previous page): Co-variates of clustering 
Demographic and technical parameters investigated as co-variates of clustering of infants. 
Mann Whitney test was used to compare A) birth weight, B) gestation period, C) age at first 
bleed and D) RNA quality between cluster 1 (green, n=20) and cluster 2 (blue, n=24). Fischer's 
exact test used to compare E) gender (clear bars=males and shaded bars=females), F) ethnicity 
(clear bars=coloureds and shaded bars=blacks) and G) route of BCG administration (clear 
bars=percutaneous and shaded bars=intradermal) between cluster 1 and 2. Horizontal lines and 
whiskers in graphs A-D denote median and interquartile range respectively. All p values were 
>0.05.  
 
4.3.1) Association between clustering and BCG-specific T cell responses 
Following the observation that certain infants clustered together by gene 
expression profiles after in vitro stimulation of PBMC with BCG, we sought to 
investigate underlying biological processes. Results of all T cell assays 
described in the previous chapter we re-analysed and compared between the 
two clusters. Among the 44 infant samples on which the microarray was 
performed, there were only 30 or less samples that had both microarray and T 
cell data. Analyses in this chapter are therefore on the 30 infants that had data 
from all analyses. 
Firstly, we compared frequencies of Th-1 cytokine-expressing CD4+ and CD8+ 
T cells upon in vitro re-stimulation with BCG between the two clusters. 
Frequencies of BCG- specific CD4+ T cells expressing each IFN-γ, TNF-α and 
IL-2 (total cytokine+ CD4+ T cells) were higher in cluster 2 compared to cluster 
1 (Figure 25A). In addition to this, polyfunctional CD4+ T cells co-expressing 
IFN-γ, TNF-α and IL-2, was more frequent in cluster 2 compared to cluster 1 
(Figure 25B). 
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Figure 25: Frequencies of BCG-specific CD4+ T cells. 
Whole blood was incubated with BCG for 12 hours and cytokine-expressing CD4+ T cells 
detected using an intracellular cytokine staining assay and flow cytometry. (A) Frequencies of 
total CD4+ T cells expressing IFN-, TNF-and IL-2 upon BCG stimulation. (B) Frequencies of 
BCG-specific CD4+ T cells co-expressing IFN-, TNF-and IL-2. Mann-Whitney U test was 
used to compare differences between clusters 1 (green, n=13) and 2 (blue, n=17). Horizontal 
lines represent median while whiskers represent the interquartile range. A p value of < 0.05 was 
considered significant.  
 
Infants from cluster 2 also had higher frequencies of BCG-specific CD4+ T cells 
expressing: IFN-γ only (Figure 26A), IFN-γ and TNF-α (Figure 26B), TNF-α and 
IL-2 (Figure 26C) as well as TNF-α, IL-2 and IL-17 (Figure 26D), when 
compared to infants from cluster 1. No other T cell subsets were different 
between the two clusters (Table 7).  
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Figure 26: Cytokine profile of BCG-specific CD4+ T cells. 
Whole blood was incubated with BCG for 12 hours and cytokine-expressing CD4+ T cells 
detected using an intracellular cytokine staining assay and flow cytometry. Frequencies of BCG-
specific CD4+ T cells expressing (A) IFN- only. (B) IFN-, and TNF-together, (C) IL-2 and 
TNF-together (D), IL-2, IL-17 and TNF-together. Mann-Whitney U test was used to compare 
differences between clusters 1 (green, n=13) and 2 (blue, n=17). Median and interquartile range 
are denoted by horizontal line and whiskers respectively. A p value of < 0.05 was considered 
significant.  
 
As described before, CD8+ T cells predominantly expressed IFN-γ , while IL-2, 
TNF-α and IL-17 expressing CD8+ T cells were relatively infrequent. Also, BCG-
specific CD8+ T cell responses were generally lower than CD4+ T cell 
responses. Similarly to CD4+ T cells, frequencies of BCG-specific CD8+ T cells 
expressing IL-2 and those co-expressing IFN-γ, TNF-α and IL-2 together were 
higher in infants from cluster 2 compared to cluster 1 (Figure 27A and B). No 
Chapter 4: Association Between Clustering of Gene Expression and Differential Response to 
BCG Vaccination  Page 105 
 
other BCG-specific CD8+ T cell cytokine or subset was different between the 
two clusters of infants (Table 7). 
 
 
Figure 27: Frequencies of BCG-specific CD8+ T cells. 
Whole blood was incubated with BCG for 12 hours and cytokine-esxpressing CD8+ T cells 
detected using an intracellular cytokine staining assay and flow cytometry. Frequencies of total 
CD8+ T cells expressing (A) IL-2, (B) IFN-, TNF-and IL-2. Mann-Whitney U test was used to 
compare differences between clusters 1 (green, n=13) and 2 (blue, n=17). Horizontal lines and 
whiskers denote median and interquartile range respectively. A p value of < 0.05 was 
considered significant.  
 
Analysis of levels of secreted mediators released in the supernatant of whole 
blood stimulated with BCG for 7 hours showed some differences between the 
two clusters. The Th-1 promoting cytokine, IL-12p70 (Figure 28A) as well as T 
cell homeostatic cytokine IL-15 (Figure 28B) were higher in cluster 2 compared 
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Figure 28: Secreted mediators. 
Whole blood was incubated with BCG or no antigen for 7 hrs and soluble molecules were 
measured by luminex bead array. Values measured in unstimulated samples were subtracted 
from BCG-stimulated samples. Levels of IL12-p70 (A) and IL-15 (B) differed between cluster 1 
(green, n=12) and cluster 2 (blue, n=13). Horizontal lines show medians while whiskers show 
interquartile range. The Mann-Whitney U test was used to compare the two groups. 
 
Analysis of the proliferative capacity (figure 29) and up-regulation of the 
cytotoxic molecules granzyme B, granulysin and perforin by BCG-specific CD4+ 
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Figure 29: BCG-specific T cell proliferative capacity. 
PBMCs were stained with Oregon Green (OG) and stimulated for 6 days with BCG or left 
unstimulated. Proliferating cells were identified as OGlow CD8+ or CD8- (mainly CD4+) T cells. 
Proliferation index was calculated as the frequency of proliferating cells upon BCG stimulation, 
divided by the frequency of proliferating cells in unstimulated cells. Differences in proliferative 
capacity of (A) CD4+ and (B) CD4+ T cells between cluster 1 (green, n=11) and cluster 2 (blue, 
n=17) were assessed using the Mann-Whitney test. Horizontal line on graphs denotes the 
median while whiskers denote interquartile range.  No significant differences were observed. 
 
 
Figure 30: Cytotoxic capacity of BCG specific T cells. 
PBMCs were stimulated with BCG or left unstimulated for 3 days and flow cytometry was used 
to detect BCG-specific CD4+ T cells expressing granzyme B, granulysing and/or perforin. BCG-
specific T cells were defined by subtracting the unstimulated value from the BCG stimulated 
value. Frequencies of (A) CD4+ T and (B) CD8+ cells expressing total cytototxic molecules. 
Mann-Whitney test was used to compare cluster 1 (green, n=13) and cluster 2 (blue, n=17). 
Horizontal lines on graphs represent median and whiskers represent interquartile range.  
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Taken together, these data show that the clusters identified by unbiased 
analysis of global gene expression associated with the magnitude of BCG-
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Table 7: BCG-specific T cell outcomes not significantly different between 




of CD4+ T cells  
Frequency and 
cytokine profiles 
of CD8+ T cells  
Cytotoxic  and 
proliferation capacity 
of CD4+ T cells  
Cytotoxic  and 
proliferation capacity 














γ+α+  (p=0.063) 
Total TNF-α  
(p=0.053) 
Total granzyme B 
(p=0.379)  




γ+  (p=0.189) 






IL-4 (p=0.363)  
IL-2+IL-17+ (p-













TNF-α+ (p=0.320) Granulysin+Granzyme 
B+ (p=0.312)  
Granulysin+Granzyme 
B+ (p=0.674)  
IL-6 (p=0.897)  




































γ+  p(=0.149) 
Granzyme B+  
(p=0.188) 








Perforin+  (p=0.260) Perforin+  (p=0.677) IL-1β  
(p=0.446) 








TNF-α+ (p=0.835) IL-2+TNF-α+  
(p=0.897) 
  IFN-γ 
(p=0.227) 
 IL-2+IFN-γ+   
(p=0.122) 





  GM-CSF 
(p=0.341)  
 IL-17+IFN-γ+  
(p=0.101) 




  Eotaxin  
(p=0.626) 
    Fractackline  
(p=0.083) 
    MIP-1β 
(p=0.316) 
    MIP-1α  
(p=0.463) 
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4.3.2) Gene expression pathways associated with clustering 
We next assessed which gene expression pathways were differentially 
expressed in the two clusters by GSEA and IPA.  
For GSEA analysis, a rank metric score for each gene was obtained within the 
two clusters. A rank metric score is the signal to noise ratio (BCG-UNS) used to 
position the gene in the ranked list. This ranked list was then compared to 
known datasets of genes housed in the GSEA C2:cp molecular signature 
database (MsigDB, http://www.broad.mit.edu/gsea/msigdb). Differentially 
expressed gene pathways included those associated with myeloid cells (mostly 
monocytes and dendritic cells in PBMCs), with IFN-γ, IFN-α and 
proinflammatory cytokine activity, lysosomal and cytototoxic T cell activities. In 
cluster 1, gene sets associated with myeloid cells, lysosomal activity and 
inflammation II (molecules inducing or inducible by inflammation and lysosomal 
enzymes) [299] had an increased expression compared to cluster 2 (Figure 31). 
Gene sets enriched in cluster 2 compared to cluster 1 were associated with 
inflammation (genes encoding molecules involved in inflammatory processes 
and regulation of apoptosis) [299], cytokine activity, interferon response (type I 
and II) and cytotoxic T cells (Figure 31). FDR was set at 0.05. 
Chapter 4: Association Between Clustering of Gene Expression and Differential Response to 
BCG Vaccination  Page 111 
 
                                                                                
Figure 31: GSEA of differentially expressed pathways between clusters 1 and 2. 
The most differentially expressed genes between cluster 1 (green) and cluster 2 (blue) in 
representative immune pathways. Gene rank metric score is signal to noise ratio for each gene 
(BCG-UNS). Inflammation included genes encoding molecules involved in inflammatory 
processes and regulation of apoptosis and inflammation II included molecules inducing or 
inducible by inflammation and lysosomal enzymes (Chaussabel et al., 2008). 
 
When we evaluated the functional gene networks associated with differential 
gene expression between the two clusters using IPA with all 20,000 genes, a 
network of 35 genes with a score of 39 was generated (Figure 32). This network 
comprised genes that are co-expressed to regulate cellular growth and 
proliferation, haematological system development and function as well as tissue 
development (Figure 32). Of this 35 genes, 15 were down-regulated in cluster 1 
compared to cluster 2 (red,) 15 were up-regulated in cluster 1 compared to 
cluster 2 (green) and 5 genes had no differential expression between the two 
clusters. 25 of these transcripts were found in our list of 461 genes differentially 
expressed between the two clusters identified by LIMMA analysis. Most 
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importantly, this pathway seems to be largely dominated by IFN-γ, as all the 
other focus molecules are directly or indirectly connected to it. 
 
Figure 32: Gene network identified by IPA between cluster 1 and cluster 2. 
Visual representation of principal network generated using 20,000 genes (BCG-UNS). Network 
shows 35 genes that work together for cell growth and proliferation, haematological system 
development and function as well as tissue development. Genes highlighted in green are up-
regulated in cluster 1 compared to cluster 2, while those highlighted in red are down-regulated in 
cluster 1 compared to cluster 2. Solid lines denote direct interactions while dashed lines 
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As seen from the IPA analysis, IFN-γ mRNA was upregulated in stronger 
responders compared to weaker responders. Interestingly, IFN-γ produced by 
CD4+ T cells was also higher in stronger responders compared to weaker 
responders. In order to back up this finding,  a correlation analysis on IFN-γ 
mRNA expression and frequencies of IFN-γ-expressing CD4+ T cells was 
performed, and a significant positive correlation between the two was found 
(r=0.605, p=0.0002) (Figure 33A). To further support this finding, when we 
correlated CXCL9 mRNA expression (CXCL9 is a monokine induced by IFN-γ) 
to IFN-γ-expressing CD4+ T cells, this strong positive correlation was also 




Figure 33: Correlation of IFN-γ and CXCL9 mRNA expression and IFN-γ-expressing CD4+ 
T cells. 
PBMCs were stimulated with BCG or left unstimulated for 12 hrs. RNA was extracted, 
transcribed to cDNA and IFN-γ and CXCL9 expression were measured by microarray. Whole 
blood was incubated with BCG or left unstimulated for 12 hours and frequencies of IFN-γ-
expressing CD4+ T cells measured by intracellular cytokine staining assay and flow cytometry. 
Following background subtraction, correlation between A) IFN-γ mRNA expression and 
frequencies of IFN-γ+CD4+ T cells and B) CXCL9 mRNA expression and frequencies of IFN-
γ+CD4+ T cells were determined using spearman rank correlation.  
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4.4) Discussion 
Following the observation of clustering of infant gene expression profiles upon 
in vitro BCG re-stimulation, we aimed to understand the biology associated with 
this phenomenon. After exclusion of demographic and sample processing 
factors that could have influenced our results, we compared BCG-specific T cell 
responses as well as expression of gene pathways between these two clusters. 
We consistently observed higher frequencies of BCG-specific T cells, mainly 
Th1, in cluster 2 compared to the cluster 1. Frequencies of CD4+ T cells 
expressing total IFN-γ, TNF-α, IL-2 and CD8 + T cells expressing total IL-2 were 
higher in cluster 2 compared to cluster 1. Th1 cytokines, especially IFN-γ, 
produced by CD4+ T cells are often measured as vaccine endpoints in clinical 
trials [323]. The magnitude of these responses is usually used to assess the 
immunogenicity of a vaccine. Importantly, frequencies of CD4+ and CD8+ T cell 
co-expressing IFN-γ, TNF-α and IL-2 (polyfunctional cells) were also higher in 
cluster 2 compared to cluster 1. Darrah et al showed that polyfunctional cells 
could be an additional measure of the quality of a T cell response, which 
correlated with Leishmania vaccine efficacy in a mouse model [168]. In addition 
to vaccine efficacy, these polyfunctional cells are also measured as 
immunogenicity end points in new TB vaccine trials [64, 324]. Despite this, no 
differences in frequencies of polyfunctional T cells were observed between 
cases and controls within cluster 2 (see chapter 3). 
In our study, all participants received BCG at birth. Though all infants had 
detectable T cell responses measured at 10 weeks of age, the frequencies of 
BCG-specific T cells were higher in some infants compared to others. Our data 
show that infants from cluster 2 had a stronger antigen-specific T cell response 
to BCG than infants in cluster 1. Based on this data, we linked clustering of 
gene expression profiles in these infants to differential response to BCG 
vaccination where infants in cluster 2 are “stronger BCG responders” and those 
in cluster 1 are “weaker BCG responders”. This association between innate 
gene signature and magnitude of adaptive immune responses has been 
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described in several other vaccines. For example, Zak et al have reported a 
similar association between innate gene signature and magnitude of adaptive 
responses to MRKAd5/HIV vaccine [325]. In this study, 35 healthy HIV-
uninfected adults were vaccinated with MRKAd5 Vaccine. Blood was collected 
immediately pre-vaccination and at 4-6, 24, 72 and 168 hours post-vaccination. 
Transcriptional profiling was used to identify differentially expressed genes 
between pre-vaccination and post vaccination time points. Using systems 
analysis, they found innate immune signatures that associated with 
immunogenicity of MRKAd5/HIV vaccine [325]. Immunogenicity was defined by 
the magnitude of gag-specific CD8+ T cell responses and participants were 
stratified as high or low responders based on this parameter. In yellow fever 
vaccine, Querec et al have shown that early innate gene signatures correlate 
with the magnitude of both CD8+ T cell and neutralising antibody responses 
[326]. Blood was collected at 0, 1, 3, 7 and 21 days post vaccination from 15 
healthy volunteers. Differential gene expression between days 0 and 3 as well 
as days 0 and 7 was identified. Post vaccination (3 and 7 days) innate gene 
signatures were found to correlate with the magnitude of vaccine-induced CD8+ 
T cell and antibody responses measured at 60 days post vaccination [326]. This 
approach was also used by Tan et al  whereby they showed that enrichment of 
signatures corresponding to proliferating B cells accurately defined antibody 
responses to influenza vaccine [327]. 
There could be several reasons underlying differential BCG immunogenicity and 
efficacy within a population. In our group, several factors that may play a role in 
BCG-induced immunity in our community have been studied. Davids et al 
compared the effect of Danish and Japanese BCG strains on the immune 
responses in infants vaccinated at birth and showed that infants who received 
the Japanese strain of BCG had significantly higher Th1 responses compared to 
those who received the Danish strain [40]. However, all 5,724 infants enrolled 
into our study received the Japanese BCG strain. Hawkridge et al reported no 
effect on BCG immunogenicity and efficacy when BCG is administered using 
Chapter 4: Association Between Clustering of Gene Expression and Differential Response to 
BCG Vaccination  Page 116 
 
two different vaccination routes (percutaneous vs intradermal) [56]. Also, in 
South Africa, BCG is widely given to all infants at birth, before any exposure to 
non-tuberculous mycobacteria, suggesting that this in an unlikely cause of 
differential responsiveness to the vaccine [44]. Shey et al also reported that 
single nucleotide polymorphism (SNP) of TLR6 gene (G1083C and C746T) in 
South African adults who had received BCG at birth was associated with 
impaired mycobacteria specific responses [49]. This therefore suggests that 
polymorphisms in certain immune related genes within our community might 
influence response to BCG. However, when we investigated the association 
between SNP of TLR1 and TLR6 genes and response to BCG vaccination in 
these infants, no conclusion could be reached, as there were not enough 
individuals with this polymorphism to analyse (Shey, Hawn, Hanekom et al., 
unpublished observation). Overall, the frequency of these SNPs reported by 
Shey et al was very rare in our study population, and therefore these genetic 
polymorphisms are unlikely to underlie the differential response to BCG 
vaccination we observed. However, we cannot rule out that SNPs in other 
genes or regions of the genome may underlie this differential response.  
Analysis of gene expression profiles of these infants showed that several 
pathways were differentially expressed between stronger and weaker BCG 
responders. Pathways involved in lysosomal activity, myeloid lineage and 
“inflammation II” were enriched in weaker responders compared to stronger 
responders while pathways up-regulated in stronger responders were 
associated with “inflammation I”, cytokine, cytotoxic T cells and interferon 
pathways (type I and II). Our results are at odds with published literature. For 
example, Teles et al showed that type I interferons suppress type II interferons 
in infected lesions of M.leprae infected individuals [328]. In this study, 
transcriptional profiling performed on skin lesions showed that a score that 
reflected the expression of several genes associated with both type I and II 
interferons was always in opposite direction [328]. In our study, we found that 
several genes associated with both type I and II interferons were up-regulated in 
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stronger responders. Also, Zak et al showed that MRKAd5/HIV vaccine 
response was associated with increased expression of inflammatory, myeloid 
and interferon pathways and suppression of pathways associated with lymphoid 
lineage, cytotoxicity and T cells [325]. Other members of our laboratory found 
that upregulation of inflammatory pathways was also associated with 
upregulation of myeloid as well as interferon pathways in M.tb infected 
adolescents at prospective risk of developing TB disease  (Penn-Nicholson, 
Hanekom, Scriba et al., unpublished data). However in our study, we had two 
groups of BCG vaccinated infants both made up of healthy M.tb uninfected 
infants at prospective risk of developing TB disease  and those not at risk. 
“Inflammation II” gene set included molecules inducing or inducible by 
inflammation, such as IL-18, SERPINB1, ALOX5, ANPEP and AOAH while 
“inflammation I” included genes encoding molecules involved in inflammatory 
processes such as IL-8, ICAM1, C5R1, IL1A, and CD44 [299]. The observation 
of differential mechanism of inflammation in the two groups of infants might be a 
confirmation of the differential response to BCG vaccination. In the previous 
chapter, we found that inflammatory pathways in weaker responders were 
down-regulated in cases, while in stronger responders they were up-regulated in 
cases compared to controls. This might imply that the inflammation signature we 
observed in weaker responders is mainly driven by control samples, while in 
stronger responders is due to the cases. This supports our findings in the 
previous chapter suggestive of too little inflammation, as seen in cases in 
weaker responders, or too much inflammation, as seen in cases in stronger 
responders, increases the risk of developing TB disease.  Pathways associated 
with myeloid lineages were also higher in weaker responders compared to 
stronger responders. However this was observed only when the background 
expression values were subtracted. Separate analysis of unstimulated PBMC 
showed that stronger responders had increased myeloid signatures, which were 
down-regulated upon stimulation with BCG (data not shown). This supports our 
hypothesis that the degree of inflammation seen in the two groups of infants is 
driven by myeloid cells, as discussed in chapter 3. 
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Cytokine as well as cytotoxic T cell gene sets were also up-regulated in cluster 
2 compared to cluster 1. This is in agreement with what we observed at the 
protein level where BCG-specific T cells were higher in cluster 2 compared to 
cluster 1. This might suggest that inflammation observed in cluster 2 is driven by 
BCG-specific T cells while in cluster 1 it is driven by myeloid, cells hence two 
different modules of inflammation in both clusters.  
IPA analysis showed enrichment of a network of genes involved in 
enhancement of cell growth and proliferation. Interestingly, this pathway was 
central to IFN-γ, which was up-regulated in stronger responders compared to 
weaker responders. This further supports the observation made at the protein 
level, whereby higher frequencies of IFN--producing CD4+ T cells were 
detected in stronger BCG responders compared to weaker responders. To 
support this finding, there was a strong significant positive correlation between 
IFN- mRNA expression and IFN--producing CD4+ T cells as well as between 
CXCL9 mRNA expression (a protein specifically induced by IFN-) and IFN--
producing CD4+ T.  
Further mechanistic investigations were performed to better understand the 
biology of this clustering. However, we could not find any other significant 
differentially expressed pathway that was relevant to this study. Nevertheless, 
the fact that we identified a pathway largely dominated by IFN-γ in cluster 2 
infants compared to cluster 1 backs up the CD4+ T cell data. In addition, the 
strong correlation between IFN-γ mRNA expression and CD4+ T cells making 
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4.5) Conclusion  
Together, our data suggests that immune responses elicited by BCG 
vaccination are heterogeneous and that this differential responsiveness to BCG 
should be taken into account in the discovery of potential correlates of 
protection and/or risk of TB disease. We therefore sought to validate these 
findings in an independent cohort of BCG vaccinated infants. 
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CHAPTER 5: VALIDATION OF CORRELATES OF RISK OF TB DISEASE IN 
DIFFERENTIAL BCG RESPONDERS 
In this chapter, all Fluidigm, flow cytometry and quantitative real-time PCR 
experiments and analyses were done by Samuel Njikan. Fluidigm analyses 




In the previous chapters, we report that gene expression patterns of BCG-
stimulated PBMCs in BCG-vaccinated infants separated them into 2 groups, 
which associated with differential response to BCG vaccination in 10-week old 
infants. Accounting for this differential response was a prerequisite for 
identification of host correlates of risk of TB disease following BCG vaccination. 
For the first time, we identified candidate correlates of prospective risk of TB 
disease in healthy infants, which could later translate into correlates of risk. 
However, several exploratory analyses, involving bioinformatics and systems 
biology approaches where used to mine our high dimensional data set. There is 
always a high chance of false positive discoveries in these analysis steps, 
especially considering the small sample size and the small changes in gene 
expression profiles between the conditions under study [266]. A validation of the 
results identified in the training set (samples on which results were generated) is 
therefore important to negate the likelihood of false positive discoveries. 
Validation involves measuring the outcomes identified in the training set on an 
independent set of samples (validation set). Quantitative real time PCR (qRT-
PCR) can be used to validate microarray results, since it allows   measurement 
of only the most differentially expressed genes identified by microarray. 
Because this method is a relatively low throughput, we used a multiplex 
microfluidic qRT-PCR (Fluidigm) platform for validation. This technique allows 
simultaneous performance of up to 9216 qPCR reactions from 96 different 
samples and 96 different transcripts in a single experiment. 
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We aimed to identify biomarkers of clustering and validate prospective 
correlates of risk of TB disease in a second cohort of BCG vaccinated infants. 
For the application of validated correlates of risk of TB disease in clinical trials, 
performing global gene expression by microarray may be intensive and 
expensive. Therefore, measuring a few genes by real time PCR or routine 
immunological assays will be very practical in such trials. For the identification of 
these markers, we used two different approaches. The first approach was 
hypothesis driven, where we applied frequencies of BCG-specific CD4+ T cells 
and the expression of CXCL9 (MIG) mRNA as markers of differential BCG 
response in the validation set. This was based on the fact that: i) stronger BCG 
responders in the training set had higher frequencies of BCG-specific T cells 
compared to weaker BCG responders, ii) stronger BCG responders had higher 
expression of the IFN-γ-inducible gene pathway which correlated with the 
magnitude of IFN-γ-expressing CD4+ T cells compared to weaker responders.  
The second approach was unbiased, where we applied a gene expression 
signature identified by microarray as a classifier for differential BCG response in 
the validation set, with minor attention to underlying biological meaning. We 
then sought to validate the correlates of risk of TB disease in stronger and 
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5.2) Materials and Methods 
5.2.1) Study participants  
Another group of 10-week old infants vaccinated with BCG at birth enrolled into 
the RCT study at the SATVI field site in the Worcester area, near Cape Town, 
were included as study participants for this experiment (see section 2.2.1) [56]. 
Exclusion and inclusion criteria were identical to the previous group (section 
2.2.1) with the exception of the factors below.  
5.2.2) Participant follow up and TB case definition 
As for the training cohort, blood was collected from healthy infants at 10 weeks 
of age, who were followed up for a period of 2 years to identify those who 
developed TB disease. Community-wide passive surveillance systems identified 
patients with possible TB disease and children with symptoms suggestive of TB 
disease, or from households where an adult had TB disease [56]. These infants 
were admitted to a dedicated research ward for clinical examination, chest 
radiography, tuberculin skin testing, two early morning gastric aspirations and 
two sputum inductions for M.tb smear and culture [56]. All infants admitted to 
the research ward were also tested for HIV infection: a positive antibody test 
resulted in exclusion. 
Cases for the validation study were culture negative for M.tb but had a strong 
positive chest x-ray and clinical and/or epidemiological evidence of TB (probable 
TB, n=29). Controls included infants who were living in the same endemic 
community but did not meet criteria for TB investigation (community controls, 
n=55). 
5.2.3) Whole blood assay and intracellular cytokine staining 
See section 2.2.3 
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5.2.4) Lymphoproliferation assay  
Cryopreserved PBMC (see section 2.2.4) were thawed in 12.5% v/v AB serum 
in RPMI containing 10g/mL DNase (Sigma-Aldrich). Lymphoproliferation assay 
was performed as described in section 2.2.5. as described above.  
5.2.5) Cytotoxic marker assay 
See section 2.2.6 
5.2.6) PBMC isolation and stimulation for primer/probe qualification and 
optimisation of Fluidigm gene expression panel 
For optimisation experiments, fresh PBMCs from healthy donors were isolated 
as described in section 2.2.4. Cells (1X106 cells/ml) were then cultured with 
BCG at an MOI of 0.18 (5 vials) or left unstimulated (5 vials) for 12hrs at 37°C. 
Following incubation, 3 vials each unstimulated cells were combined with BCG 
stimulated cells and used for primer qualification, to ensure uniform 
representation of transcripts present in both unstimulated and stimulated cells. 
The remaining 2 vials each of BCG stimulated and unstimulated cells were 
separately used for optimising the fluidigm gene expression panel.  
For infant samples used for validation, cryopreserved PBMCs were thawed, 
washed in RPMI 1640 and rested for 6 hours at 106 cells in RPMI 1640 
containing 10% AB serum and 1% L-glutamine at 37°C and 5% CO2. After 
resting, PBMC were then incubated in culture with BCG at an MOI of 0.18 for 12 
hours at 37°C and 5% CO2.  Phorbol 12-myristate-13 acetate (PMA, 1µg/mL) 
and Ionomycin (5µg/mL) were used as positive control while medium alone 
served as negative control.  
5.2.7) RNA Extraction for optimisation experiments and validation samples 
Following the incubation period, cells were harvested and RNA extracted from 
combined and non combined cells (optimisation experiments), using the 
QIAamp RNA Blood Mini Kit (Qiagen) according to the manufacturer’s 
instructions. 
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5.2.8) cDNA synthesis and Quantitative real-time PCR (qPCR) for CXCL9 
expression 
Complementary DNA (cDNA) was synthesised from the extracted RNA using 
Omniscript RT Kit (Qiagen), according to the manufacturer’s instructions with 
Oligo dT12-18 primers (Invitrogen).  
Quantitative real time PCR (qPCR) was performed using SensiMixTMSYBR No-
ROX (Bioline; USA) containing 2X SensiMixTMSYBR No-ROX solution and 
50mM MgCl2 solution on a Rotor-GeneTM6000 (Corbett) with the following 
primers: 
CXCL9-F: 5’-TCCCATGAAGAAAGGGAACGGTGA-3’  
CXCL9-R: 5’-AGAGGCTAACTGGGCACCAATCAT-3’  
HPRT-F: 5’-TGGAGTCCTATTGACATCGCCAGT-3’ 
HPRT-R: 5’-AACAACAATCCGCCCAAAGGGAAC-3’ 
The thermal cycling conditions used for the qPCR were as follows:  
Activation step of 95°C for 15mins 
Denaturation step 94°C for 15sec 
Annealing 60°C for 20sec 
Elongation 72°C for 15sec 
The house keeping gene HPRT was used to control for variation in cDNA 
quantity between samples and all reactions were performed in triplicate. 
5.2.9) Generation of standard curve 
A standard curve for each primer pair was generated by quantifying and 
purifying each transcript with a gel purification kit (Qiagen) and diluting the PCR 
products. Briefly, a conventional PCR was performed for each gene and the 
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PCR product run on a 2% agarose gel in 1XTAE buffer. The resulting PCR 
bands were excised and purified with a gel purification kit (Qiagen) according to 
the manufacturer’s instructions. The product was then quantified using a 
nanodrop and several aliquots of six 10-fold serial dilutions (six standards) were 
made and stored at -20°C. A standard curve and amplification efficiency were 
determined by performing a qPCR on 1 aliquot each of the six standards and 
saved. All six standards could not be run for every single experiment to 
determine the standard curve due to limited space on the Rotor-GeneTM6000 
(Corbett). To overcome this, 2 of the 6 standards were run for each experiment 
and the saved standard curve for each gene was imported for downstream 
analyses.  
5.2.10) Selection of differentially expressed genes 
To identify gene classifiers of differential response to BCG vaccination and risk 
of TB disease, selection of genes differentially expressed between stronger and 
weaker BCG responders and between cases and controls in stronger 
responders respectively was performed. Two methods were used to identify 
genes differentially expressed between the various groups of infants. Firstly, k-
means cluster analysis (centroid-based clustering) which uses an optimal 
shrinkage threshold to build a centroid was used to identify differentially 
expressed genes. The optimal threshold that gave the lowest error rate after 
cross-validation was chosen. Secondly, LIMMA analysis and an empirical Bayes 
method were used to identify genes differentially expressed between groups of 
infants as in section 3.2.1b. The genes were then sorted and ranked firstly by 
adjusted p value with 0.00001 and 0.05 used as a cut-off value for response to 
BCG vaccination and risk of TB disease, respectively. Genes were then sorted 
and ranked by log fold change (FC) in gene expression with FC>2 and 1.4 used 
as cut-off for response to BCG vaccination and risk of TB disease, respectively. 
Priority was given to the top most differentially expressed genes ranked by p-
value and fold change using LIMMA analysis and centroid analysis.  
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5.2.11) TaqMan Gene Expression (GE) assay qualification and optimisation 
of a multiplex gene expression system (Fluidigm) 
5.2.11.1) TaqMan GE assay selection  
Primer/probes (TaqMan GE assays) for Fluidigm (Fluidigm Corporation, USA) 
were selected online from the list of TaqMan primer/probes that have been 
qualified for qPCR (Life Technologies, www.lifetechnologies.com). Criteria in 
order of priority for primer/probe selection included: 1) Probe sequence for 
Fluidigm must span the same region and/or be located on the same reference 
gene sequence as probes used for microarray to confirm similar expression 
profiles between microarray and Fluidigm. 2) Primer/probe sequence must span 
exon junctions to ensure amplification of mRNA and not genomic DNA. 3) 
Recommended primer/probe by Life Technologies. 4) An amplicon length of not 
more than 140bp. 5) Readily available assays (inventoried). However, not all 4 
criteria could be met for all assays at all times so selection was prioritised on all 
assays that met the first criterion and any of the other 3. 
5.2.11.2) cDNA synthesis for optimisation and Fluidigm experiments 
RNA was reverse transcribed into cDNA using the superscript II reverse 
transcriptase kit according to the manufacturer’s instructions with Oligo dT12-18 
primers. Briefly, up to 100ng of RNA was mixed with Oligo dT15 primers and 
dNTP mix. Where necessary, low TE buffer was added to have a volume of 
12µl. The mixture was heated for 5mins at 65°C. This was followed by quick 
chilling on ice and the addition of 4µl of 5X first strand buffer, 2µl of 0.1M DTT, 
0.5µl RNase out and 0.5µl distilled water. The reaction was gently mixed and 
incubated for 2mins at 42°C. Following this incubation period, 1µl of superscript 
II RT was added and the reaction incubated for another 50mins at 42°C. Finally, 
the reaction was deactivated by heating at 70°C for 15mins and reaction volume 
made up to 100µl with low TE buffer. 
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5.2.11.3) Quality control of cDNA 
After cDNA synthesis, a conventional PCR was performed using TaqMan 
universal PCR master mix to ensure that the cDNA synthesis step was 
successful. This was done on one cDNA sample from each batch of samples 
reverse transcribed at the same time. The B2M transcript was amplified as a 
housekeeping gene.  Table 8 below gives a summary of PCR set up, modified 
from an ABI biosystems protocol. 
 
Table 8: PCR set up for quality control of cDNA 
 
Reaction component Volume/ well  Final concentration 
(1X) 
TaqMan Universal 
PCR Master mix 
10 µl 1X 
TaqMan GE assay  1 µl 1X 
cDNA 4 µl  
Low TE buffer 5 µl  
Total volume 20 µl  
 
Following set up, PCR was performed using a Rotor-GeneTM6000 (Corbett). 
Table 9 below shows the thermal cycling condition used for amplification, 
recommended by ABI biosystems. 
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Table 9: Thermal cycling conditions for quality control of cDNA 
 
Initial setup 40 cycles each 
Denature Annealing/Extension 
Hold 1 Hold 2 Cycle 
UNG activation 
2 mins at 50°C 
10 mins at 95°C 15 sec at 95°C 1 min at 60°C 
  
5.2.11.4) Preamplification of cDNA 
To overcome issues of low template numbers when distributing cDNA into the 
96 wells in the microfluidic chambers so that amplification of all 96 TaqMan GE 
assays is possible, a preamplification (preamp) of the cDNA was usually done 
prior to running the samples on the Biomark HD system [329]. The preamp was 
performed using Fermentas PCR and TaqMan assay master mixes. Firstly, 0.2X 
TaqMan assay master mix was prepared by combining all TaqMan GE assays 
and doing a 1:100 dilution with nuclease free water. The preamp setup and 
thermal cycling conditions are shown in Tables 10 and 11, respectively. Number 
of optimal preamp cycles was pre-determined as described in section 5.2.11.6. 
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Table 10: PCR set up for preamp of cDNA 
 
Reaction component Volume/ well  Final concentration  
Fermentas PCR 
Master Mix 
5 µl 2X 
TaqMan assay mix 2.5 µl 0.2X 
cDNA 2.5 µl  
Total volume 10 µl  
 
Table 11: Thermal cycling conditions for preamp of cDNA 
 
 16 cycles each  
Denature Annealing/Extension 
Activation Cycle Hold 
10 mins at 95°C 15 sec at 95°C 4 mins at 60°C Indefinite at 4°C 
 
5.2.11.5) Assay qualification 
A piecewise assay qualification method [329] (Figure 34) was used for 
qualification of TaqMan GE assays for final analysis. Briefly, a 12-point, two-fold 
serial dilution of bulk RNA generated from combination of BCG stimulated and 
unstimulated cells (section 5.2.7) was performed. Each RNA dilution was 
replicated eight times, reverse transcribed, preamplified and run on the Biomark 
HD system. Expression threshold (Et =40-Ct) values were plotted against 
amount of RNA (expressed as a log scale). Parameters assessed were 1) 
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Linearity of RNA (input RNA is proportional to final signal), 2) Efficiency of 
TaqMan GE assays (signal doubles with every PCR cycle). 
As shown in Figure 34, a step-wise evaluation of ≥5 consecutive RNA dilutions 
starting from the highest dilution in each replicate was done. The linear least-
squares correlation (r2) for each segment was calculated between the 
amplification cycles (Et) and the log of the RNA amount. To determine if the 
relationship between the signal and the amount of RNA was linear, the slope 
was calculated. A slope of 3.32 (1/Log210) indicates a linear relationship and 
100% efficient amplification. The efficiency (E) was calculated using the formula:  
E=101/slope – 1. For assays to qualify, at least one of the segments in any 
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Figure 34: Piecewise assay qualification (Adapted from Dominguez et al., 2013). 
Assay qualification using 12 serial dilutions of RNA replicated 8 times, searching for segments 
(≥5 consecutive serial dilutions) with efficient amplification (slope between 3.1 - 3.6) and linearity 
(r2≥0.97). Assay was qualified if these criteria were met in at least 1 segment. 
 
The piecewise assay qualification method was used to qualify only TaqMan GE 
assays for differential BCG responsiveness. Prior to the publication of this 
method, we had developed an in house assay qualification method, which we 
used to qualify TaqMan GE assays for risk of TB disease. Briefly, cryopreserved 
PBMCs generated from blood bank samples were thawed, washed in RPMI 
1640 and rested for 6 hours at 106 cells in RPMI 1640 containing 10% AB serum 
and 1% L-glutamine at 37°C and 5% CO2. After resting, PBMC were then 
incubated in culture with BCG at an MOI of 0.18 for 12 hours at 37°C and 5% 
CO2.  Phorbol 12-myristate-13 acetate (PMA, 1µg/mL) and Ionomycin (5µg/mL) 
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or Lipopolysaccharide (LPS 0.15µg/mL) were used as positive controls while 
medium alone served as negative control. RNA was extracted as described 
above and cDNA transcribed as described in section 5.2.11.2. Firstly, a 
conventional qPCR was performed on each transcript individually on the light 
cycler using the experimental set up in Table 8 and amplification cycle in Table 
9. This was followed by performing a multiplex qPCR on the Fluidigm using the 
experimental set up in Tables 12 and 13 and amplification cycle in Table 14.  
Parameters assessed in both conventional and multiplex qPCR were: 1) 
Difference in ΔCt values between any two or more conditions (to confirm 
differential expression across stimulation conditions), 2) Log fold change of 
Δ∆Ct > 2 or <0.5 between BCG and/or positive controls over the unstimulated 
condition. For assays to qualify, they had to meet at least 1 of the above criteria.   
5.2.11.6) Optimal experimental conditions for Fluidigm 
Bulk RNA generated from combined and non combined cells (section 5.2.7) was 
reverse transcribed, preamplified and run on the Fluidigm system. The optimal 
conditions tested were 1) number of preamp cycles (14, 16 and 18 cycles) and 
2) preamp cDNA dilution (five 2 fold serial dilutions, no dilution - 1:16 dilution). 
Optimal experimental conditions were defined by the minimum number of 
preamp cycles and the maximum dilution of preamp cDNA that resulted in the 
following outcomes: (1) Optimal Ct values should reflect a wide dynamic range, 
preferably clustered with a median of all assays at 20-30 cycles, and with as few 
failed assays as possible; (2) ΔCt calculated using the geometric mean of the 
housekeeping genes should fluctuate as little as possible across cDNA dilutions.  
5.2.12) Fluidigm 96.96 qPCR profiling 
After determination of optimal experimental conditions, qPCR was performed 
using the Fluidigm system according to the manufacturer’s instructions. Firstly, 
the chip was primed by injecting the control line fluid in each of the 
accumulators and running the prime script (136x) in the integrated fluidic circuit 
(IFC). This was followed by preparing both assay and sample mixes as shown 
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in Tables 12 and 13 respectively. 5µl each of both assay and sample mixes 
were loaded into the various inlets on the primed chip and mixed by running the 
load mix script (136X) on the IFC controller to mix samples and assays together 
on the chip. After mixing of samples and assays, the chip was placed in the 
Biomark instrument and amplification was performed using the standard GE 
96X96 thermal cycling conditions recommended by the manufacturer shown in 
Table 14. Data was captured and analysed using the Fluidigm Real-Time PCR 
analysis software according to the manufacturer’s guidelines.  
 
Table 12: Assay mix 
 
Reagent Volume/well Concentration 
20X TaqMan GE Assay 3 µl 1X 
Assay Loading Reagent 
(Fluidigm, PN85000736) 
3 µl 1X 
Total volume 6 µl 10X 
 
Table 13: Sample Mix 
 
Reagent Volume/well Concentration 
 TaqMan Universal Master Mix 
(ABI, PN 4304437) 
3 µl 1X 
Sample Loading Reagent 
(Fluidigm, PN85000735) 
0.3 µl 1X 
Pre-amplified cDNA 2.7 µl  
Total volume 6 µl  
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Table 14: Thermal cycling conditions for 96.96 GE profiling 
 
Thermal Mix UNG and Hot start PCR (40 cycles) 
50°C 70°C 25°C 50°C 95°C 95°C 60°C 
120 sec 1800 sec 600 120 sec 600 sec 15 sec 60 sec 
 
5.2.13) Data Analysis 
5.2.13.1) Flow cytometry analyses 
See section 2.2.9 
For assessment of differences between cases and controls in stronger and 
weaker responders separately, a Mann-Whitney U test was performed, using 
Prism 4.0 (GraphPad Software Inc.).  
5.2.13.2) Logistic regression analysis to determine response to BCG 
vaccination 
This analysis was performed in collaboration with William Msemburi (MRC, 
South Africa) and later with Nkosilesisa Mpofu (University of Cape Town, South 
Africa). STATA was used for all logistic regression analyses. Firstly, data were 
tested for normality using the Shapiro Wilk test for normal distribution. For use 
of parametric test to compare differences between response groups, all data 
were log transformed. Baseline distributions and summary statistics of individual 
variables (univariate data exploration) with respect to the two response groups 
were conducted through the use of histograms, means and confidence intervals. 
Histograms as well as box and whiskers were used for graphical illustrations of 
the data distribution. 
Following this analysis, univariate and multivariate model building using all T cell 
outcomes was performed and the model with the best overall correct 
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classification when benchmarked to the classification by clustering analysis was 
chosen. 
5.2.13.3) qPCR analysis 
Real time PCR analysis software on the Rotor-gene 6000 and light cycler 
machines were used for data analysis. The average Ct of three replicates was 
used for each sample. For the sample to be included for analysis, the % 
variation of each replicate from the known standard and the replicate Ct 
standard deviation must be ≤10% and 0.5 respectively. Quantification was 
calculated using the Pfaffl relative quantification method [330] and the cut-off for 
response was considered a fold increase of ≥1. 
5.2.13.4) Fluidigm analysis 
The Real-Time PCR analysis software on the Fluidigm instrument was used to 
generate amplification curves, heat maps and Ct values for each reaction 
according to the recommendations from the manufacturers. The quality 
threshold was set at 0.65 while Linear Derivative method was used for baseline 
correction. The Auto Global method was used to determine the Ct threshold. All 
failed assays (no amplification or quality threshold below 0.65) were excluded 
from analysis. Data was exported directly from the software into an excel 
spreadsheet for further analyses. 
Raw expression values were pre-processed and quantile normalised as earlier 
described. The Partial Least Square-Discriminant Analysis (PLS-DA) from 
Bioconductor's Classification for Microarrays (CMA) package was used to 
classify stronger and weaker BCG responders as well as cases and controls in 
stronger BCG responders. This is a two-step procedure which involves 
dimension reduction and classifier fitting. In the dimension reduction step, a 
latent component (K) is constructed using PLS by treating the categorical 
variable (stronger and weaker BCG responders / cases and controls) as a 
continuous variable by assigning a dummy code (0, 1). Construction of K 
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component is followed by prediction of response classes (stronger and weaker 
BCG responders / cases and controls) using LDA. 
 




Enrolment of infants was performed as described in Figure 8A from section 
2.3.1. Similar to the training set, different groups and numbers of participants 
were used for different assays reported in this chapter. Infants included into this 
part of the study were from both training and validation sets. For infants in the 
training set, on which microarray analyses were performed, a total of 26 were 
identified as definite TB (microbiological confirmation) and were included as 
cases and 18 were identified as household controls (see section 2.2.2 for 
definitions).  Because there were not enough culture positive infants to be 
included in the validation set, a total of 29   identified as probable TB, were 
assigned as TB cases (see section 2.2.2 for definition). Controls in the validation 
set were community controls that were never investigated for TB (n=55). 
However, because not all infant samples were always available for the different 
analyses, slightly different numbers of participants were included in different 
analyses in the validation set. Figure 35 below shows the summary of the 












Figure 35: Participant enrolment into the different groups and cohorts of the study. 
Cases and controls included in the different assays and different cohorts of the study. A) 
Samples on which microarray analysis was performed in the training cohort (n=44). Among 
these 44 samples, there were 26 cases and 18 household controls. All 18 controls had gene 
expression data however due to sample availability, not all 18 controls were from the initial 55 
controls. B) Samples on which logistic regression, CXCL9 and gene expression analyses were 
performed in the validation cohort. Highlighted in red are cases and black are controls in each of 
the analyses. Number of samples available for analyses of frequencies of cytokine and cytotoxic 
BCG-specific T cells in both cohorts. 
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5.3.2)  T cell markers of differential response to BCG 
5.3.2.1) Logistic regression model to define differential response to BCG 
vaccination 
We showed in the previous chapter that frequencies of CD4+ T cells expressing 
the cytokines IL-2, IFN-γ and TNF-α were different between the two clusters in 
the training set. In addition to this, other T cell functions as well as secreted 
mediators were associated with clustering in the training set. Clustering in the 
training set was therefore linked to differential response to BCG vaccination. We 
sought to investigate if these markers could be used to define differential 
response to BCG vaccination whenever global gene expression profiles are not 
available. For this, we developed a logistic regression model to identify the best 
functional markers for differential response to BCG vaccination in the training 
that would then be validated in a test set.   
Logistic regression will predict the odds of an infant to be a stronger or weaker 
responder to BCG vaccination, as defined by PBMC gene expression clustering 
profiles, based on one or more of the functional outcomes measured using other 
assays.  
Firstly, we tested the whole data set for normal distribution. This was to 
determine which statistical test to use for comparing the two groups of 
responders to BCG vaccination. Data were not normally distributed, 
necessitating the use of a non-parametric test for analysis. The Shapiro Wilk 
test was used to assess normality of the different outcomes (Table 15). This test 
calculates the probability that the outcomes measured are normally distributed. 
It is based on the null hypothesis that sample data are not significantly different 
from the normal population. P-values < 0.05 indicate that data are not normally 
distributed while p-values >0.05 indicate normally distributed data. The Shapiro 
Wilk tests statistic and departure from normality are represented by W and V 
parameters, respectively. For normally distributed data the median value of V 
should be between 1.2 and 2.4. The Z score is represented by z while 
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probability for accepting or rejecting the null hypothesis is represented by p>z. 
Table 11 shows p values of <0.05 (last column).  
 
Table 15: Shaprio Wilk test for normality of numerical values 
 
    Variable           |     Obs      W              V            z            p>z 
CD4+ Total IL-2   |       32    0.83447      5.261     3.433    0.00030 
CD4+ Total IFN-γ  |     32    0.87020      4.126     2.930    0.00169 
CD4+ Total TNF-α |    32    0.82753      5.482     3.518    0.00022 
 
However, data was log transformed and a normality test performed again. The 
results showed that all log transformed data were normally distributed (Table 
16). We therefore decided to use the log transformed data and parametric 
analyses for comparison between the two groups of infants. Table 11 shows 
normality of log transformed values using Shapiro Wilk test (p>0.05). 
 
Table 16: Shapiro Wilk test for normality of log transformed values 
 
    Variable                   |     Obs      W              V            z        p>z 
Log CD4+ Total IL-2     |     32    0.96275      1.284     0.349    0.36337 
Log CD4+ Total IFN-γ  |     32    0.95053      1.572     0.936    0.17471 
Log CD4+ Total TNF-α |     32    0.97744      1.717    -0.687    0.75406 
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To identify the best T cell markers for differential response to BCG vaccination 
in the training set, we applied both univariate and multivariate logistic regression 
model building. We first looked at the performance of each outcome individually 
and then used combinations of significant outcomes.  
Our results showed that the univariate analysis yielded models were statistically 
significant in correctly classifying differential response to BCG vaccination 
(Table 17). However, the sensitivity and specificity of these models as well as 
the overall correct classification when benchmarked to global gene expression 
profiles, were variable (Table 17). Outcomes significantly different between 
stronger and weaker responders included frequencies of CD4+ T cells 
expressing total IFN-γ, total TNF-α and total IL-2, as well as plasma levels of IL-
2 and TGF-α. 
We went forward to perform multivariate analyses on these outcomes, which 
showed better sensitivities, specificities as well as overall correct classification 
(Table 17). However, the probability to correctly classify BCG response using 
multivariate analyses was not statistically significant (p>0.05). Since we needed 
to accurately classify our infants into the different response groups, we used the 
model that gave us the best overall classification irrespective of statistical 
significance. Looking at the overall correct classification into stronger and 
weaker responders, a model that included CD4+ T cells expressing total IFN-γ, 
TNF-α and IL-2 gave the best classification (90.63 %) (Table 18). The sensitivity 
and specificity of this model were 97.74% and 84.62% respectively. Multivariate 
analysis of analysis of soluble IL-2 and TGF-α did not yield better classification 
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Table 17:  Univariate logistic regression model for marker of differential 
response to BCG vaccination in the training cohort 
 




CD4 Total TNF-α  0.024  100.00%  68.4%  81.2%  73 
CD4 Total IFN-γ  0.035  53.9%  79.0%  68.8%  73 
CD4 Total IL-2  0.035  69.2%  73.9%  71.9%  73 
Soluble IL-2  0.029  92.3%  57.9%  71.9%  42 
Soluble TGF-α  0.066  97.4%  53.8%  78.1%  42 
 
Table 18: Multivariate logistic regression model for marker of differential 
response to BCG vaccination in the training cohort 
 







0.558 84.62% 97.74% 90.63% 72 
Soluble IL- 2, 
TGF-α 
0.633 84.6% 68.4% 75.0% 43 
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Using this model, 3 out of the 32 infants used to build the model were 
misclassified (Table 19). Two out of 13 weaker responders and 1 out of 19 
stronger responders were misclassified (Table 19) when benchmarked to the 
clustering analysis. We therefore used this model to define differential response 
to BCG vaccination in the validation cohort.  
 
Table 19: Multivariate logistic regression model for marker of differential 
response to BCG vaccination in the training cohort 
 
5.3.1.2) Validation of T cell correlates of risk of TB in infants with 
differential response to BCG defined by logistic regression model 
To validate correlates of risk of TB disease identified in the training set in an 
independent cohort of infants, we had to first identify differential responders to 
BCG vaccination. Using the logistic model, which incorporates the frequencies 
of CD4+ T cells expressing total IFN-γ, TNF-α and IL-2, we classified infants 
from the validation cohort into stronger and weaker BCG responders (Figure 
36). Our result shows that stronger responders had a significantly higher 
frequency of total CD4 T cells expressing any combination of IFN-γ, TNF-α and 
IL-2 compared to weaker responders. Validation of correlates of risk was then 
undertaken in the two groups of infants separately.  
 











11 2 13 
Stronger 
responders 
1 18 19 
Total 12 20 32 




Figure 36: Logistic regression model for differential response to BCG stimulation in 
validation set. 
Whole blood was incubated with BCG for 12 hours and cytokine detected using an intracellular 
cytokine assay and flow cytometry. Infants were classified into stronger or weaker responders 
using a logistic regression model incorporating the frequencies of CD4+ T cells expressing total 
IFN-γ, TNF-α and IL-2. Higher frequencies of CD4+ T cells producing total IFN-γ, TNF-α and IL-2  
were observed in stronger (blue, n=22) compared to weaker responders (green, n=33). Mann 
Whitney U-test was used to assess differences between the two groups. Horizontal line and 
whiskers on graph denote median and interquartile range, respectively. 
 
To validate T cell correlates of prospective risk of TB disease identified in the 
training set, we assessed frequencies of BCG-specific CD4+ T cells producing 
IL-17. These cells were found to be more abundant in cases compared to 
controls in stronger responders in the training set. We found no differences 
between cases and controls in stronger responders in the validation set (Figure 
37).  
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Figure 37: Frequency of BCG-specific CD4+ T cells producing IL-17.  
Whole blood was incubated with BCG for 12 hours and cytokine detected using an intracellular 
cytokine assay and flow cytometry. Logistic regression model incorporating the frequencies of 
total CD4+ T cells producing IFN-γ, TNF-α and IL-2 was used to define differential response to 
BCG vaccination. In stronger responders, frequencies of CD4+ cells expressing IL-17 were not 
different between cases (red) and controls (black). The Mann Whitney test was used to asses 
differences between two groups. All p values were >0.05. Horizontal line and whiskers on graph 
denotes median and interquartile range, respectively. Weaker responders, cases n= 13 and 
controls n=20. Stronger responders, cases n=9 and controls n=13. 
 
Next we sought to validate differences in BCG-specific CD4+ T cell cytotoxic 
potential observed between cases and controls in differential BCG responders 
in the training set. In the training set, cases in weaker responders had higher 
frequencies of BCG-specific CD4+ T cells producing granulysin, granzyme B 
and perforin together, granulysin and granzyme B together as well as granzyme 
B and perforin together compared to controls. However, we found the opposite 
in the validation set. In weaker responders, controls were associated with higher 
frequencies of BCG specific CD4+ T cells producing granulysin, granzyme B 
and perforin together (Figure 38A) as well as granzyme B and perforin together 
(Figure 38C). There was no difference in CD4+ T cells producing granulysin and 
granzyme B together between cases and controls (Figure 38B).  
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In stronger responders in the training set, controls showed higher frequencies of 
CD4+ T cells producing perforin only. There was no difference between cases 
and controls when this marker was assessed in stronger responders in the 
validation set (Figure 38D).  
In the training set, controls in stronger responders had higher frequencies of 
BCG-specific CD4+T cells producing granulysin and granzyme B as well as 
granzymeB and perforin when compared to controls in weaker responders. 
However, this could not be validated since no difference was observed in the 


















Figure 38: Cytotoxic capacity of BCG-specific CD4+ T cells. 
PBMCs were stimulated with BCG or left unstimulated for 3 days and flow cytometry was used 
to detect BCG-specific CD4+ T cells expressing granzyme B, granulysing and/or perforin. BCG-
specific T cells were defined by subtracting the unstimulated values from the BCG stimulated 
values. Logistic regression model incorporating the frequencies of total CD4+ T cells expressing 
total IFN-γ, TNF-α and IL-2 was used to define differential response to BCG vaccination. 
Frequencies of BCG-specific CD4+ T cells expressing A) granulysin, granzyme B and perforin 
together; B) granulysin and granzyme B together; C) granzyme B and perforin together; D) 
perforin only are shown. The Mann Whitney test was used to assess differences between two 
groups. Horizontal line and whiskers on graphs denote median and interquartile range, 
respectively. Only p values <0.05 were considered significant (highlighted in purple). Weaker 
responders, cases n= 12 and controls n=20. Stronger responders, cases n=9 and controls n=13 
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Using a logistic regression model, we were able to define differential response 
to BCG vaccination. However, correlates of risk of TB disease in differential 
BCG responders identified in the training set could not be validated in the test 
set using this model. We therefore decided to assess differential response to 
BCG vaccination using a different marker and further validate correlates of risk 
of TB in differential BCG responders defined by this new marker.  
5.3.2) CXCL9 expression to define differential response to BCG 
vaccination 
IFN-γ was one of the most differentially expressed genes between stronger and 
weaker BCG responders in the training set (Figure 39A). In addition, an IFN-
inducible signature was one of the main pathways differentially expressed in 
stronger versus weaker responders. We therefore hypothesised that measuring 
IFN or IFN-induced transcripts could differentiate stronger and weaker BCG 
responders in the validation set. As earlier mentioned, the frequency of BCG-
specific IFN-γ-producing cells is very low, making it difficult to measure the 
expression of this gene by qPCR. CXCL9 (MIG) is specifically induced by IFN-γ 
and is expressed in large amounts in myeloid cells, thereby allowing for a more 
sensitive analysis. This gene was also differentially expressed between stronger 
and weaker BCG responders (Figure 39B) and was best able to discriminate 
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Figure 39: IFN-γ and CXCL9 gene expression between weaker and stronger responders in 
training set. 
PBMCs were stimulated with BCG or not for 12 hours, RNA was extracted, transcribed to cDNA 
and microarray analysis performed as described in the method section. BCG-UNS data show 
difference in A) IFN-γ and B) CXCL9 gene expression between weaker (green, n=20) and 
stronger (blue, n=24) BCG responders. Horizontal lines and whiskers on graphs show median 
and interquartile range, respectively. Mann-Whitney test was used to compare differences 
between the two groups.  
 
 
We therefore investigated the expression of CXCL9 transcript as a potential 
marker for differential response to BCG vaccination in the validation set. We 
measured the expression of this transcript by qPCR and used the Pfaffl method 
to quantify its expression.  
To determine the efficiency of the amplification of CXCL9 and the housekeeping 
gene HPRT to be used for the quantification of these genes, we amplified both 
genes using a conventional PCR and run products on a 2% agarose gel. Figure 
40A shows the expected band sizes for both CXCL9 (92bp) and HPRT (197bp). 
After confirmation of specific amplification, PCR bands were excised purified 
and six 10 fold serial dilutions made to generate a standard curve for each 
gene. A qPCR was performed to determine the efficiency of amplification of 
each transcript. Results show that the efficiencies of CXCL9 and HPRT 
amplification were 100% and 92% respectively (Figure 40B and C). The slopes 
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for both amplification curves were 3.318 and 3.526 respectively (Figure 40B and 
C). A linearity (r2) ≥0.999 was obtained for both genes indicating that the final 




Figure 40: Efficiency of CXCL9 and HPRT amplification. 
Ethidium bromide stained agarose gel (2%) showing A) the expected band sizes of CXCL9 
(MIG) (92bp) and HPRT (197bp) amplification. Standard curve of CXCL9 B) and HPRT C) 
showing efficiency of amplification and linearity. Lane 1 was loaded with a 1KB DNA ladder. 
 
The absolute quantification of gene expression using a standard reference 
curve requires that a good dilution curve for both the gene of interest and 
reference gene be included in each qPCR run. However, one of the 
disadvantages of using this method is that it requires extra 18 wells for each 
gene, significantly reducing the amount of samples that can be analysed in a 
single experiment. To overcome this, we ran 5 qPCR experiments on 5 different 
days and calculated the average of the efficiencies across the different days. 
Table 20 shows an average efficiency of 97.2% and 95.6% for CXCL9 and 
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HPRT respectively. We next calculated the coefficient of variation (CV) across 
the different experiments to ensure consistent results across different days. A 
CV of 6.1% and 3.7% was obtained for CXCL9 and HPRT respectively (Table 
21).  We therefore used these efficiencies for all our PCR experiments, without 
including all samples to generate a full standard curve in each run. 
Nevertheless, we included at least 2 of 6 standards in all 20 PCR runs to 
monitor for inter-assay variability. Variability ranged between 2.6% - 3.3% for 
CXCL9 and 1.8% - 2.2% for HPRT (Table 21). 





CXCL9 97.2% 5.9 6.1% 
HPRT 95.6% 3.5 3.7% 
 
















CXCL9 Standard 1 19.2 0.5 2.6% 
Standard 2 20.9 0.7 3.3% 
HPRT Standard 1 16.5 0.3 1.8% 
Standard 2 18.4 0.4 2.2% 
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In infant samples, a strong response to BCG vaccination was defined by a 
CXCL9 relative expression of ≥1 (calculated according to Pfaffl method above; 
Figure 41), which means up-regulation of this IFN-inducible gene upon BCG 
stimulation. As observed in the training set, about half of the infants were 
classified as stronger responders, according to CXCL9 expression in the 
validation set.  
 
 
Figure 41: Differential response to BCG stimulation stratified by CXCL9 expression in the 
validation cohort. 
PBMCs were stimulated with BCG or left unstimulated for 12 hours. RNA was extracted and 
transcribed to cDNA followed by qPCR on CXCL9 and HPRT (reference gene). Pfafll method 
was used for quantification and a CXCL9 fold change ≥1 was used as cut-off for differential 
response. Stronger responders (blue, n=22) and weaker responders (green, n=19) 
 
Using this cut-off, 10/24 (sensitivity=42%) weaker responders and 8/17 
(specificity=47%) stronger responders were correctly classified when 
benchmarked to the logistic regression model in the validation set 
(accuracy=43%) (Table 22). Therefore there was little agreement between these 
2 biomarkers of BCG responsiveness. 
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Table 22: Misclassification rate based on CXCL9 gene expression 
 
5.3.5) Validation of T cell correlates of risk of TB disease in differential 
BCG responders defined by CXCL9 gene expression 
Following infant categorisation into differential BCG responders based on 
CXCL9 gene expression in the validation set, we sought to validate potential T 
cell correlates of risk of TB disease identified in the training set.    
In the training set, frequencies of BCG-specific CD4+ T cells expressing IL-17 
were higher in cases compared to controls in stronger BCG responders defined 
by clustering of gene expression profiles (Figure 20). However, there was no 
difference when this outcome was measured between cases and controls in 

















10 9 19 
Stronger 
responders 
14 8 22 
Total 24 17 41 
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Figure 42: Frequency of BCG-specific CD4+ T cells expressing IL-17. 
Whole blood was incubated with BCG for 12 hours and cytokine detected using an intracellular 
cytokine staining assay and flow cytometry. CXCL9 expression was used to define differential 
response to BCG vaccination in validation set. Frequencies of total CD4+ T cells expressing IL-
17, were not different between cases (red) and controls (black) in stronger and weaker BCG 
responders.  Mann Whitney test was used to asses differences between the two groups and all 
p values were >0.05. Horizontal lines and whiskers on graphs represent median and 
interquartile range, respectively. Weaker responders, cases n= 7 and controls n=12. Stronger 
responders, cases n=8 and controls n=14. 
 
 
We next assessed the cytotoxic capacity of CD4+ and CD8+ T cells between 
cases and controls in differential BCG responders defined by CXCL9 gene 
expression in the validation cohort.  
In weaker BCG responders defined by clustering in the training set, CD4+ T 
cells from cases showed higher combined expression of granulysin, granzyme B 
and perforin (Figure 21A), granulysin and granzyme B (Figure 21B) as well as 
granzyme B and perforin, compared to controls (Figure 21C). These differences 
were not observed in the validation set between cases and controls when 
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CXCL9 gene expression was used as a marker for differential response to BCG 
vaccination (Fig 43A-C). 
In the training set, controls were associated with increased frequencies of CD4+ 
T cells producing perforin only (Fig 21D) compared to cases in stronger 
responders.  Again, no difference in CD4+ T cells producing perforin only was 
observed between cases and controls in stronger BCG responders in the 




















Figure 43: Cytotoxic capacity of  BCG-specific CD4+ T cells. 
PBMCs were stimulated with BCG or left unstimulated for 3 days and flow cytometry was used 
to detect BCG-specific CD4+ T cells producing granzyme B, granulysing and/or perforin. BCG-
specific T cells were defined by subtracting the unstimulated value from the BCG stimulated 
value. CXCL9 gene expression was used to define differential response to BCG vaccination in 
validation set. Frequencies of CD4+ T cells producing A) granulysin, granzyme B  and perforin 
together, B) granulysin and granzymeB together, C) granzyme B and perforin together and D) 
perforin between cases (red) and controls (black) in weaker and stronger BCG responders.  
Mann Whitney test was used to asses differences between two groups. Only p values <0.05 
were considered significant (purple). Horizontal lines and whiskers on graphs denote median 
and interquartile range, respectively. Weaker responders, cases n= 7 and controls n=9. 
Stronger responders, cases n=7 and controls n=10. 
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Taken together, our results show that no T cell correlate of risk of TB disease 
could be validated when differential response to BCG vaccination was defined 
by CXCL9 gene expression.  
 5.3.6) Gene classifiers of differential response to BCG vaccination and 
risk of TB disease  
The measurement of frequencies of BCG-specific T cells and the expression of 
a single transcript (CXCL9) as markers of differential response to BCG 
vaccination did not allow validation of correlates of risk of TB disease in BCG 
vaccinated infants. These two approaches were based on our interpretation of 
differential BCG responsiveness. We decided to implore an unbiased approach 
to identify a gene expression signature for differential response to BCG and risk 
of TB disease. K-means cluster analysis, LIMMA analysis and an empirical 
Bayes method were used to identify the most differentially expressed genes 
measured by microarray between stronger and weaker BCG responders as well 
as between cases and controls in stronger responders in the training set. Two 
gene classifiers of 89 genes (differential BCG response) and 54 genes (risk of 
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AADACL1 CD163 EEPD1 IL12B MPP1 SLC37A2 
ACP5 CD33 ENG IL19 NUP214 SLCO2B1 
AIF1 CD36 FBP1 IL1A PLD3 SNAI3 
ALDH1A2 CD69 FCGRT IL1F9 PLOD1 SORT1 
APOC1 CD84 FCN1 IL6 PLXDC2 TLR4 
APOE CEBPA FLJ22662 INDO PPARG TNF 
AVPI1 CKB FLVCR2 IRAK2 PTGER4 TNFRSF21 
C12orf59 COTL1 FPR3 KCNK13 PTGS2 ZMIZ2 
C1orf162 CSF2 G6PD LIPA RGS1 TNFAIP6 
C4orf18 CTSB GJB2 LMNA RHOBTB3  
CAMK1 CTSC GPNMB LYZ RIPK2  
CARD9 CTSD GSN MCOLN2 RPS6KA1  
CASP1 DDEF2 HEXB MITF RTN3  
CcL1 DHRS9 HK3 MMP1 SH3BGRL3  
CCL20 DUSP23 HSD3B7 MNDA SLC25A37  
CCL4L1 EBI3 IL10 MOBKL2B SLC29A3  
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To assess the performance of these classifiers, a 10-fold cross validation using 
Bioconductor's PAMR package was performed on samples from the training set. 
The overall error rate for the classifier of differential response to BCG was 0.03 
and risk of TB disease was 0.2. 
 
5.3.7) Assay qualification 
The efficiency of TaqMan GE assays is usually tested by the manufacturer for 
use in qPCR reactions. However, we qualified these assays for use in our 
system by assessing their ability to detect difference in gene expression 
between different conditions using an in house qualification system, before 
publication of a primer qualification procedure [329]. PBMCs were stimulated 
with BCG, LPS, PMA and Ionomycin or left unstimulated for 12 hours. RNA was 
ACP2 CD14 FGR INDO MFSD1 PVRL2 
ADORA2A CD82 FLJ11286 KCNN4 NDP PVRL2 
ALCAM CLDN15 GCN5L2 KIAA1598 NDP RNF19B 
ALDH3B1 CTSZ HCK KIF1B PCMTD2 S100A8 
ASAP1 CYP27A1 HNMT LRCH4 PILRA SART2 
BMP6 DNAJC3 HNRPH1 LRP10 PILRA SFRS5 
C17ORF56 EBF IL12B LTBR PMS2L5 SLAMF7 
SMG1 SPSB3 STMN3 TNFAIP6 TNIP1 UBA7 
CCL1 ENO3 IL4I1 LYN PRKDC SLC16A3 
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extracted, transcribed to cDNA and a conventional qPCR performed for each 
transcript. For assays to qualify, the difference in the ΔCt values between 
unstimulated and stimulated samples had to be statistically significant (p<0.05) 
and/or the fold change of the ΔΔCt had to be ≥2 or ≤0.5. Figure 44A (CTSZ) and 
B (CD82) show representative assays that qualified using statistical 
significance. Figure 44C shows a summary of all assays that qualified using the 
two parameters. The left y-axis shows ΔCt p-values between the stimulation 
conditions. Assays that qualified had a p-value of <0.05 (below the black dotted 
line) (Figure 44C). The right y-axis shows the fold change between the 
unstimulated and any of the stimulated conditions denoted as ΔΔCt values. 
Assays that qualified had a ΔΔCt value of either ≥2 or ≤0.5 (above 2 or below 
0.5 denoted by the green dotted lines respectively) (Figure 44C). Based on 











Figure 44: Qualification of TaqMan GE assays for risk of TB disease by conventional 
qPCR. 
PBMCs were stimulated with BCG, LPS, PMA and Ionomycin (P&I) or left unstimulated (UNS) 
for 12hrs. RNA was extracted, transcribed to cDNA and a conventional qPCR performed. A) 
CTSZ and B) CD82 show examples of assays that qualified using the statistical significant 
method. ANOVA was used to assess differences between the three conditions and a student-t-
test used to compare difference between any two conditions. Data points represent mean and 
SD of three replicates. C) Summary of all assays that qualified using any of the methods. Left y-
axis denotes p values obtained from ΔCt between the unstimulated and any stimulated condition 
(black circles) and cut-off for qualification denoted by black dashed line (p<0.05). Right y-axis 
denotes fold change between the unstimulated and any stimulated condition as ΔΔCt (green 
circles) and cut-off for qualification denoted by green dashed lines (≥2 and ≤0.5). X-axis shows 
all genes tested. 
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However, the Fluidigm is significantly different from these standard qPCR 
reactions in that it involves the use of smaller volumes of reactions and different 
conditions. We therefore further qualified these assays by performing a 
multiplex qPCR using all transcripts on the same samples used for the 
conventional qPCR and assessed the same parameters. Figure 45 shows 
assessment of ΔCt p-value (left y-axis) and ΔΔCt (right y-axis) for all transcripts. 
For assays to qualify, they had to be either below the black line and/or not 
between the green lines (Figure 45). A total of 54 assays passed using this 
method. For final inclusion for analysis, priority was given to assays that 
qualified using this method. 
 
 
Figure 45: Qualification of TaqMan GE assays for risk of TB disease by Fluidigm. 
PBMCs were stimulated with BCG, LPS, PMA and Ionomycin (P&I) or left unstimulated (UNS) 
for 12hrs. RNA was extracted, transcribed to cDNA and Fluidigm run performed on all 
transcripts. Left y-axis denotes p values obtained from ΔCt between the unstimulated and any 
stimulated condition (black circles) and cut-off for qualification denoted by black dashed line 
(p<0.05). Right y-axis denotes fold change between the unstimulated and any stimulated 
condition as ΔΔCt (green circles) and cut-off for qualification denoted by green dashed lines (≥2 
and ≤0.5). X-axis shows all genes tested. 
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To determine optimal cDNA dilution to be used for Fluidigm, a 2 fold serial 
dilution of the cDNA was done eight times starting from the neat (undiluted 
cDNA) to 1:128 dilution. We then compared median ΔCt of all 96 genes across 
the different cDNA dilutions. Theoretically, the median ΔCt should not fluctuate 
across different cDNA dilutions. Our results showed little or no fluctuation 
between the median ΔCt across the different cDNA dilutions (Figure 46).  
 
Figure 46: cDNA dilution series after preamplification. 
Eight 2-fold serial dilutions of preamplified cDNA.  Genes were normalized over the geometric 
mean of 4 housekeeping genes (B2M, HPRT, GAPDH, HBB) and ΔCt showed little fluctuation.  
Boxes represent the interquartile range, whiskers represent the maximum and minimum values 
and the horizontal lines in the boxes represent the median 
 
In order to avoid too much or little dilution of cDNA to be able to detect specific 
amplification, we finally chose the 1:16 dilution. Assays that qualified using both 
platforms were included for analysis. We qualified 74% (54/73) of TaqMan GE 
assays to assess risk of TB disease. 
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The inhouse qualification system was used to qualify the gene signature for risk 
of TB disease. For the signature of differential response to BCG vaccination, a 
piecewise qualification method was used to assess the efficiency of these 
probes [329]. A wide range of RNA concentrations starting from 50ng, 
generated from a mixture of stimulated and unstimulated cells was used 
because transcript abundance and/or expression upon stimulation was not 
known. A total of 12 dilutions of RNA and 8 replicates of each dilution were run 
for assay qualification.  For assays to qualify, at least 1 piecewise segment  
must have a linearity of ≥0.97 and efficiency between 90-110% (slope between 
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Figure 47: Piecewise method for assay qualification. 
Representative primer/probe for qualification. 12 serial dilutions of bulk RNA (combined from 
stimulated and unstimulated cells) were run on the Fluidigm system in 8 replicates. Primer/probe 
with any 5 or more consecutive RNA dilutions in any of the replicates that has an r2 =0.97 and 
slope=3.1-3.6 qualified for inclusion in analysis. Regions with red ring denote the best linearity 
for each replicate.  Expression threshold (Et) =40 – Ct. 
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Figure 48 summarises qualification results for all primer/probe sets tested with 
this method. The left y-axis denotes the slope of the amplifiction curve (red 
closed circles) and should be between 3.1-3.6 (red dashed lines). The right y-
axis denotes the linearity of the amplification R2 (blue open circles) and the cut-
off for qualification is shown by the blue dashed line (R2 ≥ 0.97). For assays to 
qualify, they must be between the red lines and on/above the blue line (Figure 
48). There was no transcript amplification obserevd in any sample using 3 
primer/probes. Using this method, we qualified 84% (75/89) of the primer/probes 
used to assess differential responsiveness to BCG vaccination 
 
Figure 48: Qualification of TaqMan GE assays for differential response to BCG 
vaccination by Fluidigm. 
Twelve serial dilutions of bulk RNA (combined from stimulated and unstimulated cells) were run 
on the Fluidigm system in 8 replicates using all primer-probe sets. The left y-axis shows the 
slope of the curve (red circles) and the acceptable range (3.1-3.6) denoted by red dashed lines. 
Right  y-axis shows linearity (R2, blue open circles) and cut-off ≥0.97 denoted by blue dashed 
lines. X-axis shows all genes tested. 
 
5.3.8) Optimal pre-amplification and cDNA dilution 
In the Biomark HD system each sample is split and distributed to 96 microfluidic 
PCR chambers. For rare transcripts to be evenly distributed across the 96 
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chambers, at least 4096 transcripts of each sample are needed requiring at 
least 12 cycles of pre-amplification if the original cDNA comprises of only 1 
transcript [329]. We sought to determine how many cycles of pre-amplification 
and which preamplifed cDNA dilution will allow amplification of most gene 
transcripts (least failed assays), widest dynamic range of Ct values (clustered 
preferably between 20-30 Cts) and lowest variation of the ΔCt calculated using 
the geometric mean of the housekeeper genes.  
We investigated three different numbers of amplification cycles starting with 
different amounts of RNA and five two-fold serial dilutions of the pre-amplified 
cDNA. We observed amplification of most transcripts using either of 14, 16 and 
18 pre-amplification cycles with the different starting amounts of RNA (Figure 
49). However, more assays failed with higher amount of RNA. Subsequent 
analyses were therefore performed with starting amounts of RNA between 
0.195ng and 6.25ng.   
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Figure 49: Percentage pass rate of TaqMan assays. 
Twelve serial dilutions of bulk RNA (combined from stimulated and unstimulated cells) were 
transcribed to cDNA, preamplified and run on the Fluidigm system. Number of preamplification 
cycles shown in A) 14 (blue), B)16 (black) or C) 18 (red) .  
 
We next calculated the percentage pass rate of all primer/probes for each 
preamplification cycle. This was done by taking the average pass rate of RNA 
dilutions between 0.195ng and 6.25ng for each preamplification cycle. Results 
show that 16 cycles of preamplification yielded the highest primer/probe pass 
rate (90%) compared to 14 (80%) and 18 (83%) cycles (Figure 50). We 
therefore chose the 16 cycles of preamplification to investigate the optimal 
cDNA dilutions. 




Figure 50: TaqMan GE pass rate with different preamplification cycles. 
Average TaqMan GE assay pass rate with different starting amount of RNA (6.25ng-0.195ng) 
with different preamplification cycles. Blue (14 cycles), Black (15 cycles) and Red (18 cycles). 
 
After 16 cycles of preamplification, a 1:5 dilution of the cDNA was made in low 
TE buffer. Starting from this dilution (neat cDNA), 4 other 2-fold serial dilutions 
were made with the highest dilution being 1:16. Calculating the ΔCt of the 
different cDNA dilutions showed no fluctuations in the median (Figure 51).  
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Figure 51: cDNA dilution series after 16 cycles of preamplification. 
Five 2-fold dilutions of cDNA after 16 cycles of preamplification. Genes were normalized with the 
geometric mean of 6 housekeeping genes (B2M, HPRT, GAPDH, RPS13, RPS20 and RPL27) 
and ΔCt shows little fluctuation. Boxes represent the interquartile range, whiskers represent the 
maximum and minimum values and the horizontal lines in the boxes represent the median..  
 
Although all dilutions showed no fluctuations in the medians, we chose the 1:16 
dilution of the preamplified cDNA to ensure dilution of any residual primer/probe 
used for preamplification in order to detect specific amplification.  
In conclusion, we chose to use 16 cycles of pre-amplification and 1:16 dilution of 
the preamplified cDNA for Fluidigm experiments.  
   
5.3.9) Confirmation of same direction of gene expression profiles between 
microarray and the fluidigm 
Following assay qualification and obtaining the optimal experimental conditions, 
we wanted to confirm if genes selected for differential response to BCG 
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vaccination as well as risk of developing TB disease have the same direction of 
gene expression when measured by microarray and Fluidigm in the training set. 
For this, we had to use RNA samples from the training set on which microarray 
experiments were performed. No PBMC samples were left from these 
participants therefore we used available RNA samples previously generated for 
microarray analysis. In microarray experiments, RNA is usually amplified (RNA 
transcribed to cDNA and back to RNA) to increase its yield. At the time of this 
analysis, we could include original amplified RNA for a subset of samples 
(n=12). For the other samples (n=15), we used non-amplified RNA. Whenever 
possible, we ran both amplified and non-amplified RNA from the same 
participant (n=11), to estimate the influence of RNA amplification on gene 
expression profiles. Both amplified RNA and non amplified RNA from samples in 
the training set were thawed, reverse transcribed to cDNA and samples run on 
the Fluidigm system using the experimental conditions described above. 
Before running samples on the Fluidigm, we determined the RNA yield and 
quality generated from samples in both the training and validation sets. RNA 
quality is a very critical and important component in gene expression 
experiments. Following RNA extraction, samples were measured using an ND 
2000 spectrophotometer (NanodropTM) to determine the concentration and the 
purity, as a 260/280 ratio read out. Our results showed a median purity of 1.89 
and 1.87 for training and validation sets respectively (Figure 52A).  More than 
95% of all samples in both training and validation sets were within the 
acceptable RNA purity range of 1.8-2.0 (Figure 52A). The median RNA yield 
was 27.3ng/µl and 27.9ng/µl for training and validation samples respectively 
(Figure 52B).  
 
Chapter 5: Validation of Correlates of Risk of TB Disease in Differential BCG Responders  Page 172 
 
 
Figure 52: Quality control of RNA. 
Prior to running samples on the Fluidigm, RNA quality and concentration from both training and 
validation samples were determined on the nanodrop. A) Quality denoted by 260/280 ratio with 
the acceptable range denoted by black dashed lines (1.8-2.0). B) Concentration measured in 
ng/µl. 
 
5.3.9.1) Data Normalisation 
Normalisation of qPCR data is the first and one of the most critical steps in data 
analysis. Housekeeping genes are often used to normalise qPCR data because 
of the assumption that their expression across different samples and conditions 
does not change. Quantile normalisation is another method used for data 
normalisation and it assumes that all samples have similar levels of transcript 
abundance. This method is mostly used for normalisation of microarray data 
and it works by transforming all the arrays to have a common distribution of 
intensities through averaging the quantiles across each sample. We sought to 
determine which of these two normalisation methods will be most appropriate 
for use in our data analysis.  
Firstly we chose housekeeping genes based on their universal use (HPRT, 
GAPDH, G6PD, B2M, HBB) and from published literature [331] (OAZI, RPL27, 
RPS13 and RPS20). We then used a Mann Whitney test to compare the median 
expression of these genes between the unstimulated and BCG conditions in the 
training set. Genes with no differential expression between the two conditions 
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were retained as housekeeping genes. Results show that G6PD was 
differentially expressed between the two conditions (p<0.001) and was 
excluded. However, we only had space for 7 housekeeping genes and so we 
needed to exclude 1 more. OAZ1 was excluded because it was closest to 
significance of the remaining genes. Therefore of the 9 genes assessed, two 




Figure 53: Selection of housekeeping genes. 
Median gene expression of housekeeping genes in unstimulated (UNS) and BCG stimulated 
PBMCs. Mann Whitney test was used to compare the two conditions. P-values highlighted in 
purple and green are genes that were excluded as housekeeping genes.  
 
We next compared different normalisation methods to use for data analysis. We 
observed that quantile normalisation yielded the least variability in normalisation 
of our data compared to using the geometric mean of several housekeeping 
genes for normalisation (Figure 54). The average CV with quantile normalisation 
was 7.35% while normalising with the geometric mean of 2, 3 or 5 
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housekeeping genes yielded a %CV of more than 15% (Figure 54). We also 
noted that normalising the data with the raw intensities of all gene expression 
levels also resulted in higher variability (13.65%) compared to quantile 
normalisation (Figure 54).  
 













13.5 16.17 16.78 15.96 7.35 15.41
 
Figure 54: Normalisation of Fluidigm qRT-PCR data. 
Different normalisation techniques tested for data normalisation. There was less variation with 
quantile normalisation (yellow bar) (7.35%) compared to the use of the geometric mean of 2 
(green), 3 (red) and 5 (orange) housekeeping genes.  
 
Based on these data, quantile normalisation was used for all subsequent 
analyses.     
 
5.3.9.2) Comparison between amplified and non-amplified RNA 
Because we did not know how amplification of RNA would affect gene 
expression profiles compared to non amplified RNA, we compared the gene 
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expression profiles between cDNA generated from amplified RNA and non 
amplified RNA to see if these samples could be analysed together. Following 
background subtraction (BCG-UNS), the median gene expression of all 
transcripts was determined for both RNA types. The medians and interquartile 
ranges were plotted for each RNA type and samples were excluded if the 
median gene expression across RNA types was different. A total of 5 samples 
were excluded from analysis based on this criterion (samples highlighted in red) 
(Figure 55).  
 
 
Figure 55: Comparison between amplified and non amplified RNA. 
PBMCs were stimulated with BCG or not for 12 hours and RNA extracted. RNA was either 
amplified (amplified RNA, left boxes) or not (non amplified RNA, right boxes) and synthesised to 
cDNA. Samples were run on Fluidigm and median gene expression of all genes was compared 
between the two types of RNA. Boxes in each column show the amplified and non amplified 
RNA respectively and denote median and interquartile range.  
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Our results show that after exclusion of samples that had a significant difference 
in gene expression when both RNA types were analysed,  it was possible to 
analyse samples with both RNA types together. For subsequent analyses with 
samples containing both RNA types, an average expression for each gene 
across the two available samples was used. 
5.3.9.3) Correlation between Fluidigm and microarray 
The Fluidigm system and microarray platform used to measure gene expression 
profiles operate on different principles. The detection technology of these 
platforms is different, implying that these two platforms might detect transcript 
levels differently. We therefore investigated whether differentially expressed 
transcripts detected by microarray were correlated with transcript levels 
measured by Fluidigm. Primer/probes for differential BCG responsiveness and 
risk of TB disease that passed qualification (75 and 54 respectively) were 
measured by Fluidigm using the same samples on which the microarray was 
performed. Spearman correlation was performed on fold change (FC) values on 
transcripts measured by both platforms. For differential response to BCG, the 
fold change was calculated by subtracting the unstimulated values from the 
BCG stimulated values while for risk of TB disease, the values from control 
samples were subtracted from case values.  
Using a FC>1.3 and a p value of 0.05, 27/75 transcripts from the classifier of 
differential response to BCG were either up-regulated or down-regulated when 
measured by both microarray and Fluidigm (r=0.89) (Figure 56). Following this 
analysis, a 10-fold cross validation was performed using Bioconductor's PAMR 
package to assess the performance of these genes in the training set. A total of 
two samples were misclassified using these 27 genes with a misclassification 
rate of 0.057. The sensitivity and specificity of this classification were 0.95 and 
0.93 respectively. 




Figure 56: Correlation between mRNA transcript detection by microarray and Fluidigm to 
determine differential response to BCG vaccination. 
RNA from training cohort on which microarray was performed were run on the Fluidigm using 
optimised experimental conditions and assays that passed qualification). Blue line and grey 
shade denote fitted values and confidence interval. Fold change (FC)= BCG-UNS. 
Amongst stronger responders, only 12 of the 54 transcripts from the classifier of 
risk of TB disease were either up-regulated or down-regulated when measured 
by microarray and Fluidigm (r=0.96) (Figure 57) with a FC>1.3 and p-value of 
0.05. Upon cross-validation in the training set, a total of three samples were 
misclassified using these 12 genes with a misclassification rate of 0.136. The 
sensitivity and specificity of this classification were 0.83 and 0.90 respectively.  
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Figure 57: Correlation between mRNA transcript detection microarray and Fluidigm to 
determine differential response in cases and controls. 
Samples from training cohort on which microarray was performed were run on the Fluidigm 
using optimised experimental conditions and assays that passed qualification Blue line and grey 
shade denote fitted values and confidence interval. Fold change (FC)= Cases-controls  
 
We therefore locked down our classifier to 27 genes for differential response to 
BCG vaccination and 12 genes for risk of TB disease to be measured in the 
validation cohort (Table 25).  
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Table 25: Genes that correlated between microarray and Fluidigm 
 
Differential response to BCG Risk of TB disease 
ACP5 CCL20 CKB MMP1 EEPD1 PVRL2 ACP2 
RGS1 SORT1 CSF2 IRAK2 ENG UNC84A BMP6 
INDO TNFAIP6 NUP214 IL1F9 SLC25A37 PCMTD2 CYP27A1 
LIPA IL6 SH3BGRL3 CAMK1  KIF1B PILRA 
C4orf18 CTSD FBP1 PTGS2  ENO3 ITK 
EBI3 G6PD CEBPA RIPK2  SFRS5 S100A8 
 
5.3.10) Validation of correlates of risk of TB disease in differential BCG 
responders defined by gene expression signature 
In the validation set, differential response to BCG vaccination was defined by 
frequencies of BCG-specific CD4+ T cells expressing total IFN-γ, TNF-α and IL-
2 identified by a logistic regression model and the expression of CXCL9 
transcript. In stronger responders identified with these markers, T cell correlates 
of risk of TB disease identified in the training cohort could not be validated in the 
validation set. We now aimed to validate these correlates in infants with 
differential response to BCG defined by a gene signature.  
Firstly, to assign infants as either a weaker or stronger BCG responder using 
the 27 gene classifier in the validation cohort, partial least square-discriminant 
analysis (PLS-DA) in Bioconductor's CMA package was used. Using this 
method, 32 infants were classified as stronger responders while 16 were 
classified as weaker responders in the validation set (Figure 58). There were 10 
cases and 22 controls among the stronger responders while there were 8 cases 
and 8 controls among the weaker BCG responders (Figure 58).   




Figure 58: Distribution of cases and controls among stronger and weaker BCG 
responders defined by 27 gene classifier in the validation cohort measured by Fluidigm. 
PLS-DA was performed on 27 genes to assign infants into the two BCG response groups. 
Cases (red) and controls (black) within BCG weaker (green) and stronger (blue) responders. 
 
We next assessed the performance of this 27 gene classifier in the validation 
cohort. Since there was no microarray analysis done in this cohort, the 
performance of this classifier was benchmarked to the frequencies of a 
combination of CD4+ T cells expressing total IFN-γ, TNF-α and IL-2 identified as 
markers of differential BCG response by a logistic regression model. This model 
had been previously shown to accurately classify 90% of infants correctly when 
benchmarked to microarray classification However, there were only 39 samples 
on which we had both gene expression and ICS data. The accuracy to correctly 
classify a stronger responder was 56.3% and a weaker responder was 26.1%, 
with the overall accuracy being 38.5% (Table 26).  
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  Table 26: Classification rate of gene signature of BCG responsiveness 
 











6 7 13 
Stronger 
responders 
17 9 26 
Total 23 16 39 
 
We next assessed correlates of risk of TB disease identified in the training set. 
In the training set, cases in stronger responders showed increased frequency of 
CD4+ IL-17 producing cells compared to controls. Using the 27-gene classifier 
for BCG responsiveness, we identified stronger and weaker BCG responders in 
the validation cohort. In the stronger responders, there was no difference 
between cases and controls when we compared the frequency of BCG specific 
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Figure 59: Frequencies of BCG-specific CD4+ T cells producing IL-17. 
Whole blood was incubated with BCG for 12 hours and cytokines were detected using an 
intracellular cytokine staining assay and flow cytometry. A 27-gene signature was used to define 
differential response to BCG vaccination in the validation set. In stronger responders, 
frequencies of BCG-specific CD4+ cells producing IL-17 were not different between cases (red) 
and controls (black). The Mann Whitney test was used to compare differences between  two 
groups. All p values were >0.05. Horizontal lines and whiskers on graph denote median and 
interquartile range, respectively. Weaker responders, cases n= 7 and controls n=6. Stronger 
responders, cases n=7 and controls n=19. 
 
We next assessed the cytotoxic capacity of CD4+ and CD8+ T cells between 
cases and controls in differential BCG responders defined by the 27 gene 
classifier in the validation cohort.  
In weaker BCG responders defined by clustering in the training set, CD4+ T 
cells from cases showed higher combined expression of granulysin, granzyme B 
and perforin (Figure 21A), granulysin and granzyme B (Figure 21B) as well as 
granzyme B and perforin compared to controls (Figure 21C). However, there 
were no differences in any of these combinations when we defined differential 
response to BCG using the 27 gene classifier (Figure 60A -C). 
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Controls in stronger responders were associated with increased frequency of 
CD4+ T cells producing perforin only (Figure 21D) compared to cases in the 





















Figure 600: Cytotoxic capacity of BCG-specific CD4+ T cells. 
PBMCs were stimulated with BCG or left unstimulated for 3 days and flow cytometry was used 
to detect BCG-specific CD4+ T cells expressing granzyme B, granulysing and/or perforin. BCG-
specific T cells were defined by subtracting the unstimulated value from the BCG stimulated 
value. A 27 gene classifier was used to define differential response to BCG vaccination in the 
validation set. Frequencies of CD4+ T cells producing of A) granulysin, granzyme B  and 
perforin together, B) granulysin and granzyme  B  together, C) granzyme B and perforin 
together and D) perforin only.  Cases (red) and controls (black) in weaker and stronger BCG 
responders.  The Mann Whitney test was used to assess differences between the two groups. 
All p were values> 0.05.  Horizontal lines on graphs denote median while whiskers denote 
interquartile, range. Weaker responders, cases n= 8 and controls n=8. Stronger responders, 
cases n=9 and controls n=20. 
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Following the finding that no T cell correlate of risk of TB disease could be 
validated in infants with differential response to BCG as defined by the 27-gene 
classifier, we sought to validate the gene classifier for risk of TB disease 
identified in the training set. Infants were again divided into weaker and stronger 
BCG responders using the 27-gene classifier and in stronger responders only, 
we assessed the performance of the 12-gene classifier of risk of TB disease. 
There overall accuracy of classification was 69% with a sensitivity and 
specificity of 30% and 86.4% respectively (Table 27). 
 
Table 27: Classification rate of gene signature of risk of TB disease 
 
                   
 
Logistic regression 
Cases Controls Total 
Gene classifier 
Cases 3 3 6 
Controls 7 19 26 
Total 10 22 32 







Chapter 5: Validation of Correlates of Risk of TB Disease in Differential BCG Responders  Page 186 
 
5.4) Discussion 
In the training set, correlates of risk of TB disease were identified when infants 
who either had strong or weak recall response to BCG vaccination were 
separated. These correlates were absent if response to BCG vaccination was 
not taken into account. Because the identification of these correlates involved 
in-depth analysis and data mining with the measurement of multiple outcomes, 
validation in an independent cohort was necessary. However, microarrays 
cannot be done on the scale of a clinical trial for the application of such validate 
correlates of risk. For this reason, we investigated the use of intracellular 
cytokine staining as well as quantitative real time PCR to assess the 
performance of three different biomarkers of differential response to BCG 
vaccination for the validation of correlates of risk of TB disease. Using a logistic 
regression model we identified a T cell classifier of differential response to BCG 
vaccination in the training set. This classifier involved the use of a combination 
of the frequencies of BCG-specific CD4+ T cells producing total IFN-γ, TNF-α 
and IL-2. Although there was no statistical significance in differentiating between 
the two groups when this classifier was used, it gave the overall best prediction 
and classification when compared to clustering analysis in the training set. The 
lack of significance is an important limitation in the study because the probability 
of classifying differential response to BCG could be due to chance. 
Nevertheless, we had a good rationale for using this marker to define differential 
response to BCG vaccination. As earlier mentioned, the magnitude of Th1 
responses is used in most TB vaccine trials to determine immunogenicity [64, 
323, 324]. Also, in a systems biology analysis of immune responses induced by 
a novel HIV vaccine, Zak et al also used the magnitude of T cell responses to 
identify higher and lower responders to MRKAd5/HIV vaccine [325]. However, in 
this study T cell responses were defined as serum cytokines and chemokines 
produced by CD8+ T cells [325] as opposed to Th1 cytokines produced by 
CD4+ T cells measured in whole blood in our study.  For a vaccine to be 
considered immunogenic, CD4+ T cells expressing these cytokines should be 
higher in vaccinees compared to placebo recipients. However, we do not know if 
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Th1 responses will translate into vaccine-induced protection. In the training set, 
there was good agreement between frequencies of Th1 cells measured by flow 
cytometry and clustering of gene expression profiles measured by microarray. 
This suggests that routine measurement of Th1 responses is a good proxy for 
the more complex PBMC response to Th1 inducing vaccines. This is further 
supported by the strong correlation between IFN-γ mRNA expression measured 
by microarray and the frequency of IFN-γ-expressing CD4+ T cells. Soares et al 
showed that BCG responses post-vaccination in babies peaks at 6-10 weeks 
[191]. Since BCG responses were measured during the peak response in our 
study, this might account for the synchronization between inflammation and Th1 
responses observed. It would be important to determine if this association 
between this early inflammation and the magnitude of Th1 cells also holds true 
when the memory response, months after vaccination is measured. Based on 
these data which suggest that magnitude of Th1 cells is a good classifier of 
BCG responsiveness, we used the frequencies of BCG-specific CD4+ T cells 
producing total IFN-γ, TNF-α and IL-2 in the validation set to separate infants 
into weaker and stronger BCG responders.   
In a second analysis, we used mRNA expression of CXCL9 gene as a marker 
for differential response to BCG stimulation in the validation set. Based on the 
microarray data generated in the training set, IFN-γ itself and pathways 
including IFN--inducible genes were among the most differentially expressed 
genes between weaker and stronger BCG responders. Since we were able to 
show that measuring the protein expression of this cytokine was also 
significantly higher in stronger responders compared to weaker responders, we 
wanted to investigate the use of this transcript in the validation set to define 
differential response to BCG vaccination. Validation of microarray results can be 
done by qPCR of the most differentially expressed genes. We used the 
expression of CXCL9, which is a gene specifically induced by IFN-γ, to define 
differential response to BCG vaccination. Brice et al showed that CXCL9 
measurement is a more sensitive measurement of biocative IFN-γ than IFN-γ 
itself [332]. CXCL9 has been examined as an alternative marker for 
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immunogenicity [333] and has been used in several studies to define vaccine 
immunogenicity [332, 334, 335]. For example, in a trial of a candidate malaria 
vaccine, Berthoud et al showed that CXCL9 was a more sensitive measure than 
IFN-γ in detecting antigen-specific T cell responses [334]. Therefore, we defined 
differential response to BCG vaccination in the validation cohort using the 
expression of this gene. Similar to what was observed in the training set with the 
clustering analysis, there was a 50% split of the infants into stronger and weaker 
responders using CXCL9. Nevertheless, when we benchmarked the 
classification by CXCL9 to the logistic regression model, there was little 
agreement between the two markers. Also there was a poor correlation between 
CXCL9 mRNA expression and frequency of IFN-γ-expressing CD4+ T cells in 
the validation set (Appendix 1) even though there was a good correlation 
between the two in the training set. Technical issues such as RNA quality, 
viability of PBMCs, storage age of samples as well as assay used, could be the 
reasons for this observation. The RNA quality of most of the samples was within 
the acceptable range as determined by the 260/280 and the median viability of 
the thawed PBMCs was 84% (Appendix 2). The most probable reason for this 
disparity could be the different platforms used to measure CXCL9 expression in 
the training and validation sets. In the training set, CXCL9 mRNA expression 
was measured by microarray while in the validation set, qRT-PCR was used for 
the measurement of this transcript. These two platforms operate on slightly 
different technologies in mRNA detection.  
Our hypothesis-driven approaches to define differential response to BCG 
vaccination did not allow validation of correlates of risk of TB disease. The use 
of a single gene might be suboptimal in defining differential response. We 
therefore also sought to use a gene expression signature rather than the 
expression of a single gene to define this differential response. Several studies 
have used unbiased systems biology approaches as to define vaccine 
immunogenicity [325, 327, 336-338]. Recently, Tan et al used this approach and 
identified a gene set to developing predictors of vaccine outcome and showed 
that enrichment of signatures corresponding to proliferating B cells accurately 
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defined antibody responses to influenza vaccine [327]. A similar approach was 
used by Henn et al, who showed that a plasma cell gene signature correlated 
with influenza vaccine responses [338]. In HIV, Zak et al, identified an innate 
immune signature that was up-regulated post-vaccination compared to pre-
vaccination with the MRKAd5/HIV vaccine, and this signature correlated with the 
magnitude of CD8+ T cells [325]. We identified a gene signature of differential 
BCG response in the training set and used a high throughput qRT-PCR system 
(Fluidigm) to measure the expression of these genes in the validation set. This 
platform allows measurement of 96 transcripts from 96 different samples. As 
part of the optimisation process, we qualified each primer/probe for inclusion in 
analysis. Primer/probe qualification is a very important quality control step in 
qRT-PCR. We applied the piecewise qualification process described by 
Dominguez et al [329]. Hu et al had applied this qualification process to non 
human primates (NHP) and found cross-reactivity between NHP specific 
primers and human mRNA, and vice versa [339]. In our study, not all 
primer/probes could be qualified using this system but the overall qualification 
rate was similar to those reported in these two other studies. One of the 
possible reasons for failure in qualification could be the fact that Applied 
Biosystems uses a different qualification platform: these assays are tested 
individually using a conventional qRT-PCR. In our qualification experiments, we 
multiplexed these assays and ran them on the Fluidigm.  
The gene expression signature of risk of TB disease in differential BCG 
responders did not validate in the validation set. We tried to investigate the 
possible reasons for this observation. Firstly, we assessed the cDNA quality in 
the validation set. We had shown that running samples from the training set 
using the Fluidigm allowed identification of a locked-down classifier of 27 genes 
for differential BCG response and 12 genes for risk of TB disease. Poor cDNA 
quality has a negative effect on downstream gene expression results [340, 341].  
However, we observed no difference in cDNA quality or amplification between 
samples generated from the training and validation set. Possible reasons to 
account for the lack of correlation could be: i) Not enough transcripts from the 
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initial classifiers were applied in the validation set due to lack of correlation 
between microarray and Fluidigm, resulting in a loss of predictive power. ii)  
Different definitions of cases and controls in the training and validation sets. In 
the training set, all cases were infants with definite TB (microbiological 
confirmation) and controls were household controls. In the validation set, cases 
were identified as probable TB (no microbiological confirmation but strong 
clinical and epidemiological features) and controls were community controls that 
were never investigated for TB disease. Importantly, at the time of blood 
collection for analysis (10 weeks of age) all infants were healthy, and therefore 
the difference in TB diagnosis would not have influenced the analyses at 10 
weeks of age. Regardless, our study design was suboptimal, which may have 
contributed to undermining successful validation. 
Our results suggest that the T cell outcomes we measured do not robustly 
predict who is at risk of developing TB disease. Our results also suggest that 
frequencies of BCG-specific Th1 CD4+ T cells appear to correlate to BCG recall 
responsiveness (e.g. immunogenicity) [191], but not with reduced risk of 
developing TB disease. These observations support the previous observation 
that frequencies of Th1 cells do not correlate with risk of TB in infants [175]. A 
correlation between extent of disease measured on chest X-ray and 
immunological/genetic finding would have given a good insight on these 
correlates. However, at the time when these infants were diagnosed with TB, 
there was no grading system yet on disease severity on chest X-ray. In addition, 
the sample size for definite TB cases was too small for this analysis as there will 
be a lot of variation to come to a final conclusion.  
Prospective biomarker studies rely on robust clinical case definition, appropriate 
sample size, adequate samples and technology [342]. Our study however had 
important limitations and therefore data should be interpreted with caution. 
Some of the limitations and lessons learned in this study include: 
I) Sample sizes used for analysis. Not all participant samples were always 
available for all analyses. The microarray analysis on which clustering of gene 
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expression profiles was identified included 44 samples. This had to be further 
divided into stronger and weaker responders before evaluating differences 
between cases and controls in each sample. However, classical sample size 
calculations are challenging for such complex analyses, as these cannot rely on 
precise assumptions and effect of sizes are not known [343]. The sample sizes 
used in this study were based on availability of samples and our previous 
experience conducting similar immunology and systems biology studies, as well 
as cost and feasibility considerations. 
II) The definition of participants in training and validation (test) sets. Cases and 
controls in both sets of the study had different clinical and epidemiological 
definitions. However, all analyses were performed on samples collected at 10 
weeks of age, well before TB disease or exposure occurred, when all 
participants were healthy and there was no evidence of household exposure to 
TB. Moreover, if a biomarker of prospective risk of TB disease will be identified 
and validated, its broad applicability to the general population cannot rely on 
strict definitions. Regardless, an ideal study design would include identical 
clinical and epidemiological definitions for training and validation set with 
samples randomly split selected for each set. 
III) Validation strategy. We applied three different strategies to validate what we 
observed when gene expression profiles were analysed by microarray. Different 
assay platforms operate on different technologies and generate data with 
different sensitivities, dynamic ranges as well as limit of detection. Performing a 
validation using the same technique would greatly reduce variability in results. 
However, the initial finding becomes more reliable if it can be confirmed with 
another technique. 
IV) Analysis plan. Before starting such studies, pre-defined analysis strategies 
including cut offs should be locked-down. This helps in determining how feasible 
the study is, as well as addressing possible limitations up front, while eliminating 
potential bias as the analyses proceed.  
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5.5) Conclusions 
This is the first study of its kind that has investigated prospective correlates of 
risk of TB disease in infants with differential response to BCG vaccination. We 
showed that although frequencies of BCG-specific Th1 cells did not correlate 
with risk of developing TB disease, they indeed correlated with a broader 
measurement of immune recall response to BCG, when differential 
responsiveness is taken into account, and therefore represent a solid tool to 
assess vaccine-induced immunogenicity. We also showed that inflammatory, 
myeloid and interferon gene pathways were associated with risk of TB disease 
in infants who were either stronger or weaker responders to BCG vaccination. 
Several studies have also shown this in TB disease patients compared to latent 
individuals. In our study, all infants were healthy at time of analysis and the fact 
that we also observe the same finding suggests that it will be interesting to 
further investigate this. In addition, the implication that the same immune 
response pattern can be both beneficial and pathological may have hindered 
identification of correlates of risk in other studies. Given the complex nature of 
the immune response to mycobacteria, we propose that other T cell functions, 
cross-talk between adaptive and innate immunity as well as variability in 
vaccine-induced responses  be included in future studies of correlates of risk of 
TB disease. Findings from such studies will help significantly in the possible 
identification of these correlates and contribution in the field of TB vaccinology. 






s/tbdefinitions.aspx. 2012 (Accessed 15th February 2013). . 
2. Lawn, S.D., et al., Impact of HIV infection on the epidemiology of 
tuberculosis in a peri-urban community in South Africa: the need for age-
specific interventions. Clin Infect Dis, 2006. 42(7): p. 1040-7. 
3. Lawn, S.D., et al., Short-term and long-term risk of tuberculosis 
associated with CD4 cell recovery during antiretroviral therapy in South 
Africa. AIDS, 2009. 23(13): p. 1717-25. 
4. Griffiths-Chu, S., et al., Characterization of immature T cell 
subpopulations in neonatal blood. Blood, 1984. 64(1): p. 296-300. 
5. Kollmann, T.R., et al., Neonatal innate TLR-mediated responses are 
distinct from those of adults. J Immunol, 2009. 183(11): p. 7150-60. 
6. Marais, B.J., et al., The natural history of childhood intra-thoracic 
tuberculosis: a critical review of literature from the pre-chemotherapy era. 
Int J Tuberc Lung Dis, 2004. 8(4): p. 392-402. 
7. WHO, Global Tuberculosis Report 2013 (Accessed 15th February 2014). 
http://apps.who.int/iris/bitstream/10665/75938/1/9789241564502_eng.pdf
, 2013. 
8. Moyo, S., et al., Age-related tuberculosis incidence and severity in 
children under 5 years of age in Cape Town, South Africa. Int J Tuberc 
Lung Dis, 2010. 14(2): p. 149-54. 
9. Lawn, S.D. and M.P. Nicol, Xpert(R) MTB/RIF assay: development, 
evaluation and implementation of a new rapid molecular diagnostic for 
tuberculosis and rifampicin resistance. Future Microbiol, 2011. 6(9): p. 
1067-82. 
10. Lee, E. and R.S. Holzman, Evolution and current use of the tuberculin 
test. Clin Infect Dis, 2002. 34(3): p. 365-70. 
11. Ranganathan, S., T. Connell, and N. Curtis, Interferon-gamma release 
assays in children--no better than tuberculin skin testing? J Infect, 2007. 
54(4): p. 412-3; author reply 414-5. 
12. Ewer, K., et al., Comparison of T-cell-based assay with tuberculin skin 
test for diagnosis of Mycobacterium tuberculosis infection in a school 
tuberculosis outbreak. Lancet, 2003. 361(9364): p. 1168-73. 
13. Connell, T.G., et al., Enhanced ex vivo stimulation of Mycobacterium 
tuberculosis-specific T cells in human immunodeficiency virus-infected 
persons via antigen delivery by the Bordetella pertussis adenylate 
cyclase vector. Clin Vaccine Immunol, 2007. 14(7): p. 847-54. 
14. Mahomed, H., et al., Comparison of mantoux skin test with three 
generations of a whole blood IFN-gamma assay for tuberculosis 
infection. Int J Tuberc Lung Dis, 2006. 10(3): p. 310-6. 
References   Page 194 
 
15. Machingaidze, S., et al., The utility of an interferon gamma release assay 
for diagnosis of latent tuberculosis infection and disease in children: a 
systematic review and meta-analysis. Pediatr Infect Dis J, 2011. 30(8): p. 
694-700. 
16. Sadatsafavi, M., et al., A statistical method was used for the meta-
analysis of tests for latent TB in the absence of a gold standard, 
combining random-effect and latent-class methods to estimate test 
accuracy. J Clin Epidemiol, 2010. 63(3): p. 257-69. 
17. Chegou, N.N., et al., Tuberculosis assays: past, present and future. 
Expert Rev Anti Infect Ther, 2011. 9(4): p. 457-69. 
18. Zar, H.J., Chronic lung disease in human immunodeficiency virus (HIV) 
infected children. Pediatr Pulmonol, 2008. 43(1): p. 1-10. 
19. Olivieri, D., R. D'Ippolito, and A. Chetta, Induced sputum: diagnostic 
value in interstitial lung disease. Curr Opin Pulm Med, 2000. 6(5): p. 411-
4. 
20. Ruiz Jimenez, M., et al., "Induced sputum versus gastric lavage for the 
diagnosis of pulmonary tuberculosis in children". BMC Infect Dis, 2013. 
13(1): p. 222. 
21. Connell, T.G., H.J. Zar, and M.P. Nicol, Advances in the diagnosis of 
pulmonary tuberculosis in HIV-infected and HIV-uninfected children. J 
Infect Dis, 2011. 204 Suppl 4: p. S1151-8. 
22. Zeka, A.N., S. Tasbakan, and C. Cavusoglu, Evaluation of the GeneXpert 
MTB/RIF assay for rapid diagnosis of tuberculosis and detection of 
rifampin resistance in pulmonary and extrapulmonary specimens. J Clin 
Microbiol, 2011. 49(12): p. 4138-41. 
23. Trebucq, A., et al., Xpert(R) MTB/RIF for national tuberculosis 
programmes in low-income countries: when, where and how? Int J 
Tuberc Lung Dis, 2011. 15(12): p. 1567-72. 
24. Van Rie, A., et al., Xpert((R)) MTB/RIF for point-of-care diagnosis of TB 
in high-HIV burden, resource-limited countries: hype or hope? Expert Rev 
Mol Diagn, 2010. 10(7): p. 937-46. 
25. Hatherill, M., et al., Induced sputum or gastric lavage for community-
based diagnosis of childhood pulmonary tuberculosis? Arch Dis Child, 
2009. 94(3): p. 195-201. 
26. Zar, H.J., et al., Induced sputum versus gastric lavage for microbiological 
confirmation of pulmonary tuberculosis in infants and young children: a 
prospective study. Lancet, 2005. 365(9454): p. 130-4. 
27. WHO, Treatment of Tuberculosis Guidelines, 4th Edition 2011 (Accessed 
2nd April 2013). 
http://whqlibdoc.who.int/publications/2010/9789241547833_eng.pdf, 
2011. 
28. WHO, Guidance for national tuberculosis programmes on the 
management of tuberculosis in children. Geneva. 2006. 
29. CDC, (Accessed 2nd April 2013). 
http://www.cdc.gov/tb/topic/treatment/ltbi.htm, 2012. 
30. Tuberculosis, I.a., (Accessed 2nd April 2013). http://www.tbfacts.org/tb-
treatment.html, 2012. 
References   Page 195 
 
31. Yoshiyama, T., et al., Development of acquired drug resistance in 
recurrent tuberculosis patients with various previous treatment outcomes. 
Int J Tuberc Lung Dis, 2004. 8(1): p. 31-8. 
32. NIAID, (Accessed 2nd April 2013). 
http://www.niaid.nih.gov/topics/tuberculosis/Understanding/Pages/treatm
ent.aspx, 2012. 
33. Hatherill, M., Prospects for elimination of childhood tuberculosis: the role 
of new vaccines. Arch Dis Child, 2011. 96(9): p. 851-6. 
34. Rodrigues, L.C., V.K. Diwan, and J.G. Wheeler, Protective effect of BCG 
against tuberculous meningitis and miliary tuberculosis: a meta-analysis. 
Int J Epidemiol, 1993. 22(6): p. 1154-8. 
35. Rodrigues, L.C. and P.G. Smith, Tuberculosis in developing countries 
and methods for its control. Trans R Soc Trop Med Hyg, 1990. 84(5): p. 
739-44. 
36. Colditz, G.A., et al., Efficacy of BCG vaccine in the prevention of 
tuberculosis. Meta-analysis of the published literature. JAMA, 1994. 
271(9): p. 698-702. 
37. Ottenhoff, T.H. and S.H. Kaufmann, Vaccines against tuberculosis: 
where are we and where do we need to go? PLoS Pathog, 2012. 8(5): p. 
e1002607. 
38. Hesseling, A.C., et al., The risk of disseminated Bacille Calmette-Guerin 
(BCG) disease in HIV-infected children. Vaccine, 2007. 25(1): p. 14-8. 
39. Comstock, G.W., Identification of an effective vaccine against 
tuberculosis. Am Rev Respir Dis, 1988. 138(2): p. 479-80. 
40. Davids, V., et al., The effect of bacille Calmette-Guerin vaccine strain and 
route of administration on induced immune responses in vaccinated 
infants. J Infect Dis, 2006. 193(4): p. 531-6. 
41. Ritz, N., et al., To TST or not to TST: is tuberculin skin testing necessary 
before BCG immunisation in children? Vaccine, 2012. 30(8): p. 1434-6. 
42. Sutherland, I. and V.H. Springett, Effectiveness of BCG vaccination in 
England and Wales in 1983. Tubercle, 1987. 68(2): p. 81-92. 
43. Ponnighaus, J.M., et al., Efficacy of BCG vaccine against leprosy and 
tuberculosis in northern Malawi. Lancet, 1992. 339(8794): p. 636-9. 
44. Mangtani, P., et al., Protection by BCG vaccine against tuberculosis: a 
systematic review of randomized controlled trials. Clin Infect Dis, 2014. 
58(4): p. 470-80. 
45. Brahmajothi, V., et al., Association of pulmonary tuberculosis and HLA in 
south India. Tubercle, 1991. 72(2): p. 123-32. 
46. Jouanguy, E., et al., Interferon-gamma-receptor deficiency in an infant 
with fatal bacille Calmette-Guerin infection. N Engl J Med, 1996. 335(26): 
p. 1956-61. 
47. Jouanguy, E., et al., Partial interferon-gamma receptor 1 deficiency in a 
child with tuberculoid bacillus Calmette-Guerin infection and a sibling with 
clinical tuberculosis. J Clin Invest, 1997. 100(11): p. 2658-64. 
48. Goldfeld, A.E., et al., Association of an HLA-DQ allele with clinical 
tuberculosis. JAMA, 1998. 279(3): p. 226-8. 
References   Page 196 
 
49. Shey, M.S., et al., Single nucleotide polymorphisms in toll-like receptor 6 
are associated with altered lipopeptide- and mycobacteria-induced 
interleukin-6 secretion. Genes Immun, 2010. 11(7): p. 561-72. 
50. Randhawa, A.K., et al., Association of human TLR1 and TLR6 deficiency 
with altered immune responses to BCG vaccination in South African 
infants. PLoS Pathog, 2011. 7(8): p. e1002174. 
51. Young, S.L., et al., Environmental strains of Mycobacterium avium 
interfere with immune responses associated with Mycobacterium bovis 
BCG vaccination. Infect Immun, 2007. 75(6): p. 2833-40. 
52. Fine, P.E., Bacille Calmette-Guerin vaccines: a rough guide. Clin Infect 
Dis, 1995. 20(1): p. 11-4. 
53. Elias, D., et al., Poor immunogenicity of BCG in helminth infected 
population is associated with increased in vitro TGF-beta production. 
Vaccine, 2008. 26(31): p. 3897-902. 
54. Rook, G.A., K. Dheda, and A. Zumla, Do successful tuberculosis 
vaccines need to be immunoregulatory rather than merely Th1-boosting? 
Vaccine, 2005. 23(17-18): p. 2115-20. 
55. Hatherill, M., et al., The potential impact of helminth infection on trials of 
novel tuberculosis vaccines. Vaccine, 2009. 27(35): p. 4743-4. 
56. Hawkridge, A., et al., Efficacy of percutaneous versus intradermal BCG in 
the prevention of tuberculosis in South African infants: randomised trial. 
BMJ, 2008. 337: p. a2052. 




58. McShane, H., et al., Recombinant modified vaccinia virus Ankara 
expressing antigen 85A boosts BCG-primed and naturally acquired 
antimycobacterial immunity in humans. Nat Med, 2004. 10(11): p. 1240-
4. 
59. Tameris, M.D., et al., Safety and efficacy of MVA85A, a new tuberculosis 
vaccine, in infants previously vaccinated with BCG: a randomised, 
placebo-controlled phase 2b trial. Lancet, 2013. 381(9871): p. 1021-8. 
60. Martin, C., Tuberculosis vaccines: past, present and future. Curr Opin 
Pulm Med, 2006. 12(3): p. 186-91. 
61. Hess, J., et al., Mycobacterium bovis Bacille Calmette-Guerin strains 
secreting listeriolysin of Listeria monocytogenes. Proc Natl Acad Sci U S 
A, 1998. 95(9): p. 5299-304. 
62. Grode, L., et al., Increased vaccine efficacy against tuberculosis of 
recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that 
secrete listeriolysin. J Clin Invest, 2005. 115(9): p. 2472-9. 
63. Desel, C., et al., Recombinant BCG DeltaureC hly+ induces superior 
protection over parental BCG by stimulating a balanced combination of 
type 1 and type 17 cytokine responses. J Infect Dis, 2011. 204(10): p. 
1573-84. 
References   Page 197 
 
64. Abel, B., et al., The novel tuberculosis vaccine, AERAS-402, induces 
robust and polyfunctional CD4+ and CD8+ T cells in adults. Am J Respir 
Crit Care Med, 2010. 181(12): p. 1407-17. 
65. Smaill, F., et al., A human type 5 adenovirus-based tuberculosis vaccine 
induces robust T cell responses in humans despite preexisting anti-
adenovirus immunity. Sci Transl Med, 2013. 5(205): p. 205ra134. 
66. Vogel, F.R., Improving vaccine performance with adjuvants. Clin Infect 
Dis, 2000. 30 Suppl 3: p. S266-70. 
67. Day, C.L., et al., Induction and regulation of T-cell immunity by the novel 
tuberculosis vaccine M72/AS01 in South African adults. Am J Respir Crit 
Care Med, 2013. 188(4): p. 492-502. 
68. van Dissel, J.T., et al., Ag85B-ESAT-6 adjuvanted with IC31 promotes 
strong and long-lived Mycobacterium tuberculosis specific T cell 
responses in naive human volunteers. Vaccine, 2010. 28(20): p. 3571-81. 
69. Billeskov, R., et al., The HyVac4 subunit vaccine efficiently boosts BCG-
primed anti-mycobacterial protective immunity. PLoS One, 2012. 7(6): p. 
e39909. 
70. Parida, S.K. and S.H. Kaufmann, Novel tuberculosis vaccines on the 
horizon. Curr Opin Immunol, 2010. 22(3): p. 374-84. 
71. Marais, B.J., Childhood turberculosis: reflections from the front line. 
Pediatr Ann, 2004. 33(10): p. 695-8. 
72. Wood, R., et al., Burden of new and recurrent tuberculosis in a major 
South African city stratified by age and HIV-status. PLoS One, 2011. 
6(10): p. e25098. 
73. Brennan, M.J. and J. Thole, Tuberculosis vaccines: a strategic blueprint 
for the next decade. Tuberculosis (Edinb), 2012. 92 Suppl 1: p. S6-13. 
74. Hanekom, W.A., et al., SATVI - after 10 years closing in on a new and 
better vaccine to prevent tuberculosis. S Afr Med J, 2012. 102(6): p. 438-
41. 
75. Poland, G.A., Variability in immune response to pathogens: using 
measles vaccine to probe immunogenetic determinants of response. Am 
J Hum Genet, 1998. 62(2): p. 215-20. 
76. Poland, G.A., et al., Heterogeneity in vaccine immune response: the role 
of immunogenetics and the emerging field of vaccinomics. Clin 
Pharmacol Ther, 2007. 82(6): p. 653-64. 
77. Sinha, P., et al., The major histocompatibility complex haplotypes dictate 
and the background genes fine-tune the dominant versus the cryptic 
response profile of a T-cell determinant within a native antigen: relevance 
to disease susceptibility and vaccination. Scand J Immunol, 2007. 65(2): 
p. 158-65. 
78. Ovsyannikova, I.G., et al., HLA supertypes and immune responses to 
measles-mumps-rubella viral vaccine: findings and implications for 
vaccine design. Vaccine, 2007. 25(16): p. 3090-100. 
79. Ovsyannikova, I.G., et al., The contribution of HLA class I antigens in 
immune status following two doses of rubella vaccination. Hum Immunol, 
2004. 65(12): p. 1506-15. 
References   Page 198 
 
80. van Eden, W., et al., HLA-DR3 associated genetic control of response to 
multiple skin tests with new tuberculins. Clin Exp Immunol, 1983. 52(2): 
p. 287-92. 
81. Ottenhoff, T.H., et al., Evidence for an HLA-DR4-associated immune-
response gene for Mycobacterium tuberculosis. A clue to the 
pathogenesis of rheumatoid arthritis? Lancet, 1986. 2(8502): p. 310-3. 
82. Fitzgerald, J.C., et al., A simian replication-defective adenoviral 
recombinant vaccine to HIV-1 gag. J Immunol, 2003. 170(3): p. 1416-22. 
83. Casimiro, D.R., et al., Comparative immunogenicity in rhesus monkeys of 
DNA plasmid, recombinant vaccinia virus, and replication-defective 
adenovirus vectors expressing a human immunodeficiency virus type 1 
gag gene. J Virol, 2003. 77(11): p. 6305-13. 
84. Harro, C.D., et al., Safety and immunogenicity of adenovirus-vectored 
near-consensus HIV type 1 clade B gag vaccines in healthy adults. AIDS 
Res Hum Retroviruses, 2009. 25(1): p. 103-14. 
85. Buchbinder, S.P., et al., Efficacy assessment of a cell-mediated immunity 
HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-
controlled, test-of-concept trial. Lancet, 2008. 372(9653): p. 1881-93. 
86. McElrath, M.J., et al., HIV-1 vaccine-induced immunity in the test-of-
concept Step Study: a case-cohort analysis. Lancet, 2008. 372(9653): p. 
1894-905. 
87. Targonski, P.V. and G.A. Poland, Pneumococcal vaccination in adults: 
recommendations, trends, and prospects. Cleve Clin J Med, 2007. 74(6): 
p. 401-6, 408-10, 413-4. 
88. Cook, I.F., Sexual dimorphism of humoral immunity with human vaccines. 
Vaccine, 2008. 26(29-30): p. 3551-5. 
89. Kagina, B.M., et al., Delaying BCG vaccination from birth to 10 weeks of 
age may result in an enhanced memory CD4 T cell response. Vaccine, 
2009. 27(40): p. 5488-95. 
90. Burl, S., et al., Delaying bacillus Calmette-Guerin vaccination from birth 
to 4 1/2 months of age reduces postvaccination Th1 and IL-17 responses 
but leads to comparable mycobacterial responses at 9 months of age. J 
Immunol, 2010. 185(4): p. 2620-8. 
91. Lutwama, F., et al., Distinct T-cell responses when BCG vaccination is 
delayed from birth to 6 weeks of age in Ugandan infants. J Infect Dis, 
2014. 209(6): p. 887-97. 
92. Landrum, M.L., et al., Hepatitis B vaccination and risk of hepatitis B 
infection in HIV-infected individuals. AIDS, 2010. 24(4): p. 545-55. 
93. Hung, C.C., et al., A 5-year longitudinal follow-up study of serological 
responses to 23-valent pneumococcal polysaccharide vaccination among 
patients with HIV infection who received highly active antiretroviral 
therapy. HIV Med, 2010. 11(1): p. 54-63. 
94. Walzl, G., et al., Immunological biomarkers of tuberculosis. Nat Rev 
Immunol, 2011. 11(5): p. 343-54. 
95. Ernst, J.D., The immunological life cycle of tuberculosis. Nat Rev 
Immunol, 2012. 12(8): p. 581-91. 
References   Page 199 
 
96. Wolf, A.J., et al., Mycobacterium tuberculosis infects dendritic cells with 
high frequency and impairs their function in vivo. J Immunol, 2007. 
179(4): p. 2509-19. 
97. Kang, D.D., et al., Profiling early lung immune responses in the mouse 
model of tuberculosis. PLoS One, 2011. 6(1): p. e16161. 
98. Jo, E.K., Mycobacterial interaction with innate receptors: TLRs, C-type 
lectins, and NLRs. Curr Opin Infect Dis, 2008. 21(3): p. 279-86. 
99. Harding, C.V. and W.H. Boom, Regulation of antigen presentation by 
Mycobacterium tuberculosis: a role for Toll-like receptors. Nat Rev 
Microbiol, 2010. 8(4): p. 296-307. 
100. Chen, Y.C., et al., Toll-like receptor 2 gene polymorphisms, pulmonary 
tuberculosis, and natural killer cell counts. BMC Med Genet, 2010. 11: p. 
17. 
101. Caws, M., et al., The influence of host and bacterial genotype on the 
development of disseminated disease with Mycobacterium tuberculosis. 
PLoS Pathog, 2008. 4(3): p. e1000034. 
102. Ferwerda, G., et al., NOD2 and toll-like receptors are nonredundant 
recognition systems of Mycobacterium tuberculosis. PLoS Pathog, 2005. 
1(3): p. 279-85. 
103. Reiling, N., et al., Cutting edge: Toll-like receptor (TLR)2- and TLR4-
mediated pathogen recognition in resistance to airborne infection with 
Mycobacterium tuberculosis. J Immunol, 2002. 169(7): p. 3480-4. 
104. Abel, B., et al., Toll-like receptor 4 expression is required to control 
chronic Mycobacterium tuberculosis infection in mice. J Immunol, 2002. 
169(6): p. 3155-62. 
105. Branger, J., et al., Toll-like receptor 4 plays a protective role in pulmonary 
tuberculosis in mice. Int Immunol, 2004. 16(3): p. 509-16. 
106. Branger, J., et al., Role of Toll-like receptor 4 in gram-positive and gram-
negative pneumonia in mice. Infect Immun, 2004. 72(2): p. 788-94. 
107. Drennan, M.B., et al., Toll-like receptor 2-deficient mice succumb to 
Mycobacterium tuberculosis infection. Am J Pathol, 2004. 164(1): p. 49-
57. 
108. Sugawara, I., et al., Mycobacterial infection in TLR2 and TLR6 knockout 
mice. Microbiol Immunol, 2003. 47(5): p. 327-36. 
109. Holscher, C., et al., Containment of aerogenic Mycobacterium 
tuberculosis infection in mice does not require MyD88 adaptor function 
for TLR2, -4 and -9. Eur J Immunol, 2008. 38(3): p. 680-94. 
110. Dorhoi, A., et al., Activation of the NLRP3 inflammasome by 
Mycobacterium tuberculosis is uncoupled from susceptibility to active 
tuberculosis. Eur J Immunol, 2012. 42(2): p. 374-84. 
111. Flynn, J.L., Mutual attraction: does it benefit the host or the bug? Nat 
Immunol, 2004. 5(8): p. 778-9. 
112. Flynn, J.L., J. Chan, and P.L. Lin, Macrophages and control of 
granulomatous inflammation in tuberculosis. Mucosal Immunol, 2011. 
4(3): p. 271-8. 
References   Page 200 
 
113. Barry, C.E., 3rd, et al., The spectrum of latent tuberculosis: rethinking the 
biology and intervention strategies. Nat Rev Microbiol, 2009. 7(12): p. 
845-55. 
114. Rustad, T.R., et al., Hypoxia: a window into Mycobacterium tuberculosis 
latency. Cell Microbiol, 2009. 11(8): p. 1151-9. 
115. Divangahi, M., S.M. Behar, and H. Remold, Dying to live: how the death 
modality of the infected macrophage affects immunity to tuberculosis. 
Adv Exp Med Biol, 2013. 783: p. 103-20. 
116. Wang, T.T., et al., Cutting edge: 1,25-dihydroxyvitamin D3 is a direct 
inducer of antimicrobial peptide gene expression. J Immunol, 2004. 
173(5): p. 2909-12. 
117. Martineau, A.R., et al., Neutrophil-mediated innate immune resistance to 
mycobacteria. J Clin Invest, 2007. 117(7): p. 1988-94. 
118. Liu, P.T., et al., Toll-like receptor triggering of a vitamin D-mediated 
human antimicrobial response. Science, 2006. 311(5768): p. 1770-3. 
119. Liu, P.T., et al., Cutting edge: vitamin D-mediated human antimicrobial 
activity against Mycobacterium tuberculosis is dependent on the 
induction of cathelicidin. J Immunol, 2007. 179(4): p. 2060-3. 
120. Krutzik, S.R., et al., IL-15 links TLR2/1-induced macrophage 
differentiation to the vitamin D-dependent antimicrobial pathway. J 
Immunol, 2008. 181(10): p. 7115-20. 
121. Dorhoi, A., S.T. Reece, and S.H. Kaufmann, For better or for worse: the 
immune response against Mycobacterium tuberculosis balances 
pathology and protection. Immunol Rev, 2011. 240(1): p. 235-51. 
122. Davis, J.M. and L. Ramakrishnan, The role of the granuloma in 
expansion and dissemination of early tuberculous infection. Cell, 2009. 
136(1): p. 37-49. 
123. Cambier, C.J., et al., Mycobacteria manipulate macrophage recruitment 
through coordinated use of membrane lipids. Nature, 2014. 505(7482): p. 
218-22. 
124. Chackerian, A.A., et al., Dissemination of Mycobacterium tuberculosis is 
influenced by host factors and precedes the initiation of T-cell immunity. 
Infect Immun, 2002. 70(8): p. 4501-9. 
125. Khader, S.A., et al., Interleukin 12p40 is required for dendritic cell 
migration and T cell priming after Mycobacterium tuberculosis infection. J 
Exp Med, 2006. 203(7): p. 1805-15. 
126. Blomgran, R., et al., Mycobacterium tuberculosis inhibits neutrophil 
apoptosis, leading to delayed activation of naive CD4 T cells. Cell Host 
Microbe, 2012. 11(1): p. 81-90. 
127. Velmurugan, K., et al., Mycobacterium tuberculosis nuoG is a virulence 
gene that inhibits apoptosis of infected host cells. PLoS Pathog, 2007. 
3(7): p. e110. 
128. Miller, J.L., et al., The type I NADH dehydrogenase of Mycobacterium 
tuberculosis counters phagosomal NOX2 activity to inhibit TNF-alpha-
mediated host cell apoptosis. PLoS Pathog, 2010. 6(4): p. e1000864. 
129. Wallgren, A., BCG inoculation and BCG vaccination. Am J Dis Child, 
1948. 76(5): p. 485-91. 
References   Page 201 
 
130. Poulsen, A., Some clinical features of tuberculosis. 1. Incubation period. 
Acta Tuberc Scand, 1950. 24(3-4): p. 311-46. 
131. Lin, P.L., et al., Sterilization of granulomas is common in active and latent 
tuberculosis despite within-host variability in bacterial killing. Nat Med, 
2014. 20(1): p. 75-9. 
132. Reiley, W.W., et al., ESAT-6-specific CD4 T cell responses to aerosol 
Mycobacterium tuberculosis infection are initiated in the mediastinal 
lymph nodes. Proc Natl Acad Sci U S A, 2008. 105(31): p. 10961-6. 
133. Wolf, A.J., et al., Initiation of the adaptive immune response to 
Mycobacterium tuberculosis depends on antigen production in the local 
lymph node, not the lungs. J Exp Med, 2008. 205(1): p. 105-15. 
134. Marino, S. and D.E. Kirschner, The human immune response to 
Mycobacterium tuberculosis in lung and lymph node. J Theor Biol, 2004. 
227(4): p. 463-86. 
135. Mogues, T., et al., The relative importance of T cell subsets in immunity 
and immunopathology of airborne Mycobacterium tuberculosis infection 
in mice. J Exp Med, 2001. 193(3): p. 271-80. 
136. Gill, W.P., et al., A replication clock for Mycobacterium tuberculosis. Nat 
Med, 2009. 15(2): p. 211-4. 
137. Ford, C.B., et al., Use of whole genome sequencing to estimate the 
mutation rate of Mycobacterium tuberculosis during latent infection. Nat 
Genet, 2011. 43(5): p. 482-6. 
138. Kwan, C.K. and J.D. Ernst, HIV and tuberculosis: a deadly human 
syndemic. Clin Microbiol Rev, 2011. 24(2): p. 351-76. 
139. Diedrich, C.R., et al., Reactivation of latent tuberculosis in cynomolgus 
macaques infected with SIV is associated with early peripheral T cell 
depletion and not virus load. PLoS One, 2010. 5(3): p. e9611. 
140. Pancholi, P., et al., Sequestration from immune CD4+ T cells of 
mycobacteria growing in human macrophages. Science, 1993. 
260(5110): p. 984-6. 
141. Cooper, A.M., T cells in mycobacterial infection and disease. Curr Opin 
Immunol, 2009. 21(4): p. 378-84. 
142. Aaron, L., et al., Tuberculosis in HIV-infected patients: a comprehensive 
review. Clin Microbiol Infect, 2004. 10(5): p. 388-98. 
143. North, R.J. and Y.J. Jung, Immunity to tuberculosis. Annu Rev Immunol, 
2004. 22: p. 599-623. 
144. Flynn, J.L. and J. Chan, Immunology of tuberculosis. Annu Rev Immunol, 
2001. 19: p. 93-129. 
145. Warren, R.M., et al., Patients with active tuberculosis often have different 
strains in the same sputum specimen. Am J Respir Crit Care Med, 2004. 
169(5): p. 610-4. 
146. Glynn, J.R., et al., High rates of recurrence in HIV-infected and HIV-
uninfected patients with tuberculosis. J Infect Dis, 2010. 201(5): p. 704-
11. 
147. Lillebaek, T., et al., Stability of DNA patterns and evidence of 
Mycobacterium tuberculosis reactivation occurring decades after the 
initial infection. J Infect Dis, 2003. 188(7): p. 1032-9. 
References   Page 202 
 
148. Geldmacher, C., et al., Early depletion of Mycobacterium tuberculosis-
specific T helper 1 cell responses after HIV-1 infection. J Infect Dis, 2008. 
198(11): p. 1590-8. 
149. Harris, J. and J. Keane, How tumour necrosis factor blockers interfere 
with tuberculosis immunity. Clin Exp Immunol, 2010. 161(1): p. 1-9. 
150. Wallis, R.S., Mycobacterial disease attributable to tumor necrosis factor-
alpha blockers. Clin Infect Dis, 2008. 47(12): p. 1603-5; author reply 
1605-6. 
151. Clay, H., H.E. Volkman, and L. Ramakrishnan, Tumor necrosis factor 
signaling mediates resistance to mycobacteria by inhibiting bacterial 
growth and macrophage death. Immunity, 2008. 29(2): p. 283-94. 
152. Nadkarni, S., C. Mauri, and M.R. Ehrenstein, Anti-TNF-alpha therapy 
induces a distinct regulatory T cell population in patients with rheumatoid 
arthritis via TGF-beta. J Exp Med, 2007. 204(1): p. 33-9. 
153. Bruns, H., et al., Anti-TNF immunotherapy reduces CD8+ T cell-mediated 
antimicrobial activity against Mycobacterium tuberculosis in humans. J 
Clin Invest, 2009. 119(5): p. 1167-77. 
154. Vallerskog, T., G.W. Martens, and H. Kornfeld, Diabetic mice display a 
delayed adaptive immune response to Mycobacterium tuberculosis. J 
Immunol, 2010. 184(11): p. 6275-82. 
155. Jick, S.S., et al., Glucocorticoid use, other associated factors, and the 
risk of tuberculosis. Arthritis Rheum, 2006. 55(1): p. 19-26. 
156. Cattamanchi, A., et al., Interferon-gamma release assays for the 
diagnosis of latent tuberculosis infection in HIV-infected individuals: a 
systematic review and meta-analysis. J Acquir Immune Defic Syndr, 
2011. 56(3): p. 230-8. 
157. Lewinsohn, D.A., M.C. Gold, and D.M. Lewinsohn, Views of immunology: 
effector T cells. Immunol Rev, 2011. 240(1): p. 25-39. 
158. Torrado, E. and A.M. Cooper, IL-17 and Th17 cells in tuberculosis. 
Cytokine Growth Factor Rev, 2010. 21(6): p. 455-62. 
159. Feng, C.G. and W.J. Britton, CD4+ and CD8+ T cells mediate adoptive 
immunity to aerosol infection of Mycobacterium bovis bacillus Calmette-
Guerin. J Infect Dis, 2000. 181(5): p. 1846-9. 
160. Chan, S.H., C. Benoist, and D. Mathis, In favor of the selective model of 
positive selection. Semin Immunol, 1994. 6(4): p. 241-8. 
161. Cooper, A.M., et al., Interleukin 12 (IL-12) is crucial to the development of 
protective immunity in mice intravenously infected with mycobacterium 
tuberculosis. J Exp Med, 1997. 186(1): p. 39-45. 
162. Sahiratmadja, E., et al., Association of polymorphisms in IL-12/IFN-
gamma pathway genes with susceptibility to pulmonary tuberculosis in 
Indonesia. Tuberculosis (Edinb), 2007. 87(4): p. 303-11. 
163. Gomez-Reino, J.J., et al., Treatment of rheumatoid arthritis with tumor 
necrosis factor inhibitors may predispose to significant increase in 
tuberculosis risk: a multicenter active-surveillance report. Arthritis 
Rheum, 2003. 48(8): p. 2122-7. 
164. Singh, S.B., et al., Human IRGM induces autophagy to eliminate 
intracellular mycobacteria. Science, 2006. 313(5792): p. 1438-41. 
References   Page 203 
 
165. Keane, J., et al., Infection by Mycobacterium tuberculosis promotes 
human alveolar macrophage apoptosis. Infect Immun, 1997. 65(1): p. 
298-304. 
166. Lalvani, A. and K.A. Millington, T Cells and Tuberculosis: Beyond 
Interferon-gamma. J Infect Dis, 2008. 197(7): p. 941-3. 
167. Forbes, E.K., et al., Multifunctional, high-level cytokine-producing Th1 
cells in the lung, but not spleen, correlate with protection against 
Mycobacterium tuberculosis aerosol challenge in mice. J Immunol, 2008. 
181(7): p. 4955-64. 
168. Darrah, P.A., et al., Multifunctional TH1 cells define a correlate of 
vaccine-mediated protection against Leishmania major. Nat Med, 2007. 
13(7): p. 843-50. 
169. Day, C.L., et al., Functional capacity of Mycobacterium tuberculosis-
specific T cell responses in humans is associated with mycobacterial 
load. J Immunol, 2011. 187(5): p. 2222-32. 
170. Harari, A., et al., Dominant TNF-alpha+ Mycobacterium tuberculosis-
specific CD4+ T cell responses discriminate between latent infection and 
active disease. Nat Med, 2011. 17(3): p. 372-6. 
171. Caccamo, N., et al., Analysis of Mycobacterium tuberculosis-specific CD8 
T-cells in patients with active tuberculosis and in individuals with latent 
infection. PLoS One, 2009. 4(5): p. e5528. 
172. Harrington, L.E., P.R. Mangan, and C.T. Weaver, Expanding the effector 
CD4 T-cell repertoire: the Th17 lineage. Curr Opin Immunol, 2006. 18(3): 
p. 349-56. 
173. Liang, S.C., et al., Interleukin (IL)-22 and IL-17 are coexpressed by Th17 
cells and cooperatively enhance expression of antimicrobial peptides. J 
Exp Med, 2006. 203(10): p. 2271-9. 
174. Peng, R., et al., The IL-17F sequence variant is associated with 
susceptibility to tuberculosis. Gene, 2013. 515(1): p. 229-32. 
175. Kagina, B.M., et al., Specific T cell frequency and cytokine expression 
profile do not correlate with protection against tuberculosis after bacillus 
Calmette-Guerin vaccination of newborns. Am J Respir Crit Care Med, 
2010. 182(8): p. 1073-9. 
176. Scriba, T.J., et al., Distinct, specific IL-17- and IL-22-producing CD4+ T 
cell subsets contribute to the human anti-mycobacterial immune 
response. J Immunol, 2008. 180(3): p. 1962-70. 
177. Sutherland, J.S., et al., Pattern and diversity of cytokine production 
differentiates between Mycobacterium tuberculosis infection and disease. 
Eur J Immunol, 2009. 39(3): p. 723-9. 
178. Matthews, K., et al., Predominance of interleukin-22 over interleukin-17 at 
the site of disease in human tuberculosis. Tuberculosis (Edinb), 2011. 
91(6): p. 587-93. 
179. Gopal, R., et al., IL-23-dependent IL-17 drives Th1-cell responses 
following Mycobacterium bovis BCG vaccination. Eur J Immunol, 2012. 
42(2): p. 364-73. 
References   Page 204 
 
180. Cruz, A., et al., Cutting edge: IFN-gamma regulates the induction and 
expansion of IL-17-producing CD4 T cells during mycobacterial infection. 
J Immunol, 2006. 177(3): p. 1416-20. 
181. Khader, S.A., et al., IL-23 and IL-17 in the establishment of protective 
pulmonary CD4+ T cell responses after vaccination and during 
Mycobacterium tuberculosis challenge. Nat Immunol, 2007. 8(4): p. 369-
77. 
182. Khader, S.A., et al., IL-23 compensates for the absence of IL-12p70 and 
is essential for the IL-17 response during tuberculosis but is dispensable 
for protection and antigen-specific IFN-gamma responses if IL-12p70 is 
available. J Immunol, 2005. 175(2): p. 788-95. 
183. Umemura, M., et al., IL-17-mediated regulation of innate and acquired 
immune response against pulmonary Mycobacterium bovis bacille 
Calmette-Guerin infection. J Immunol, 2007. 178(6): p. 3786-96. 
184. Gopal, R., et al., Unexpected role for IL-17 in protective immunity against 
hypervirulent Mycobacterium tuberculosis HN878 infection. PLoS Pathog, 
2014. 10(5): p. e1004099. 
185. Ordway, D.J., et al., Mycobacterium bovis BCG-mediated protection 
against W-Beijing strains of Mycobacterium tuberculosis is diminished 
concomitant with the emergence of regulatory T cells. Clin Vaccine 
Immunol, 2011. 18(9): p. 1527-35. 
186. Jaron, B., et al., Effect of attenuation of Treg during BCG immunization 
on anti-mycobacterial Th1 responses and protection against 
Mycobacterium tuberculosis. PLoS One, 2008. 3(7): p. e2833. 
187. Vankayalapati, R. and P.F. Barnes, Innate and adaptive immune 
responses to human Mycobacterium tuberculosis infection. Tuberculosis 
(Edinb), 2009. 89 Suppl 1: p. S77-80. 
188. Guyot-Revol, V., et al., Regulatory T cells are expanded in blood and 
disease sites in patients with tuberculosis. Am J Respir Crit Care Med, 
2006. 173(7): p. 803-10. 
189. Canaday, D.H., et al., CD4(+) and CD8(+) T cells kill intracellular 
Mycobacterium tuberculosis by a perforin and Fas/Fas ligand-
independent mechanism. J Immunol, 2001. 167(5): p. 2734-42. 
190. Turner, J. and H.M. Dockrell, Stimulation of human peripheral blood 
mononuclear cells with live Mycobacterium bovis BCG activates cytolytic 
CD8+ T cells in vitro. Immunology, 1996. 87(3): p. 339-42. 
191. Soares, A.P., et al., Longitudinal changes in CD4(+) T-cell memory 
responses induced by BCG vaccination of newborns. J Infect Dis, 2013. 
207(7): p. 1084-94. 
192. Thiery, J., et al., Perforin pores in the endosomal membrane trigger the 
release of endocytosed granzyme B into the cytosol of target cells. Nat 
Immunol, 2011. 12(8): p. 770-7. 
193. Okada, S., et al., Intracellular mediators of granulysin-induced cell death. 
J Immunol, 2003. 171(5): p. 2556-62. 
194. Kaspar, A.A., et al., A distinct pathway of cell-mediated apoptosis 
initiated by granulysin. J Immunol, 2001. 167(1): p. 350-6. 
References   Page 205 
 
195. Stenger, S., et al., An antimicrobial activity of cytolytic T cells mediated 
by granulysin. Science, 1998. 282(5386): p. 121-5. 
196. Goping, I.S., et al., Granzyme B-induced apoptosis requires both direct 
caspase activation and relief of caspase inhibition. Immunity, 2003. 18(3): 
p. 355-65. 
197. Flynn, J.L., et al., Major histocompatibility complex class I-restricted T 
cells are required for resistance to Mycobacterium tuberculosis infection. 
Proc Natl Acad Sci U S A, 1992. 89(24): p. 12013-7. 
198. Chen, C.Y., et al., A critical role for CD8 T cells in a nonhuman primate 
model of tuberculosis. PLoS Pathog, 2009. 5(4): p. e1000392. 
199. Caruso, A.M., et al., Mice deficient in CD4 T cells have only transiently 
diminished levels of IFN-gamma, yet succumb to tuberculosis. J 
Immunol, 1999. 162(9): p. 5407-16. 
200. Scanga, C.A., et al., Depletion of CD4(+) T cells causes reactivation of 
murine persistent tuberculosis despite continued expression of interferon 
gamma and nitric oxide synthase 2. J Exp Med, 2000. 192(3): p. 347-58. 
201. Soares, A.P., et al., Bacillus Calmette-Guerin vaccination of human 
newborns induces T cells with complex cytokine and phenotypic profiles. 
J Immunol, 2008. 180(5): p. 3569-77. 
202. Lancioni, C., et al., CD8+ T cells provide an immunologic signature of 
tuberculosis in young children. Am J Respir Crit Care Med, 2012. 185(2): 
p. 206-12. 
203. Young, D.B., H.P. Gideon, and R.J. Wilkinson, Eliminating latent 
tuberculosis. Trends Microbiol, 2009. 17(5): p. 183-8. 
204. Alcais, A., et al., Tuberculosis in children and adults: two distinct genetic 
diseases. J Exp Med, 2005. 202(12): p. 1617-21. 
205. Alcais, A., et al., Life-threatening infectious diseases of childhood: single-
gene inborn errors of immunity? Ann N Y Acad Sci, 2010. 1214: p. 18-33. 
206. Brandli, O., The clinical presentation of tuberculosis. Respiration, 1998. 
65(2): p. 97-105. 
207. Lin, P.L. and J.L. Flynn, Understanding latent tuberculosis: a moving 
target. J Immunol, 2010. 185(1): p. 15-22. 
208. O'Garra, A., et al., The immune response in tuberculosis. Annu Rev 
Immunol, 2013. 31: p. 475-527. 
209. Medlar, E.M., The pathogenesis of minimal pulmonary tuberculosis; a 
study of 1,225 necropsies in cases of sudden and unexpected death. Am 
Rev Tuberc, 1948. 58(6): p. 583-611. 
210. Capuano, S.V., 3rd, et al., Experimental Mycobacterium tuberculosis 
infection of cynomolgus macaques closely resembles the various 
manifestations of human M. tuberculosis infection. Infect Immun, 2003. 
71(10): p. 5831-44. 
211. Mack, U., et al., LTBI: latent tuberculosis infection or lasting immune 
responses to M. tuberculosis? A TBNET consensus statement. Eur 
Respir J, 2009. 33(5): p. 956-73. 
212. Plotkin, S.A., Vaccines: correlates of vaccine-induced immunity. Clin 
Infect Dis, 2008. 47(3): p. 401-9. 
References   Page 206 
 
213. Tuaillon, E., et al., Detection of memory B lymphocytes specific to 
hepatitis B virus (HBV) surface antigen (HBsAg) from HBsAg-vaccinated 
or HBV-immunized subjects by ELISPOT assay. J Immunol Methods, 
2006. 315(1-2): p. 144-52. 
214. Coursaget, P., et al., Twelve-year follow-up study of hepatitis B 
immunization of Senegalese infants. J Hepatol, 1994. 21(2): p. 250-4. 
215. Potsch, D.V., et al., Vaccination against hepatitis B with 4-double doses 
increases response rates and antibodies titers in HIV-infected adults. 
Vaccine, 2012. 30(41): p. 5973-7. 
216. Reber, A. and J. Katz, Immunological assessment of influenza vaccines 
and immune correlates of protection. Expert Rev Vaccines, 2013. 12(5): 
p. 519-36. 
217. Ohmit, S.E., et al., Influenza hemagglutination-inhibition antibody titer as 
a correlate of vaccine-induced protection. J Infect Dis, 2011. 204(12): p. 
1879-85. 
218. Voordouw, A.C., et al., Evaluation of serological trials submitted for 
annual re-licensure of influenza vaccines to regulatory authorities 
between 1992 and 2002. Vaccine, 2009. 28(2): p. 392-7. 
219. CPMP, C.F.P.M.P., NOTE FOR GUIDANCE ON HARMONISATION OF 
REQUIREMENTS FOR INFLUENZA VIRUS. 1997, 2002. 
220. Kaufmann, S.H., Fact and fiction in tuberculosis vaccine research: 10 
years later. Lancet Infect Dis, 2011. 11(8): p. 633-40. 
221. Qin, L., et al., A framework for assessing immunological correlates of 
protection in vaccine trials. J Infect Dis, 2007. 196(9): p. 1304-12. 
222. Kaforou, M., et al., Detection of tuberculosis in HIV-infected and -
uninfected African adults using whole blood RNA expression signatures: 
a case-control study. PLoS Med, 2013. 10(10): p. e1001538. 
223. Berry, M.P., et al., An interferon-inducible neutrophil-driven blood 
transcriptional signature in human tuberculosis. Nature, 2010. 466(7309): 
p. 973-7. 
224. Dawany, N., et al., Identification of a 251 Gene Expression Signature 
That Can Accurately Detect M. tuberculosis in Patients with and without 
HIV Co-Infection. PLoS One, 2014. 9(2): p. e89925. 
225. Maertzdorf, J., et al., Human gene expression profiles of susceptibility 
and resistance in tuberculosis. Genes Immun, 2011. 12(1): p. 15-22. 
226. Ottenhoff, T.H., et al., Genome-wide expression profiling identifies type 1 
interferon response pathways in active tuberculosis. PLoS One, 2012. 
7(9): p. e45839. 
227. Cayabyab, M.J., L. Macovei, and A. Campos-Neto, Current and novel 
approaches to vaccine development against tuberculosis. Front Cell 
Infect Microbiol, 2012. 2: p. 154. 
228. Cassman, M., Barriers to progress in systems biology. Nature, 2005. 
438(7071): p. 1079. 
229. Kitano, H., Computational systems biology. Nature, 2002. 420(6912): p. 
206-10. 
230. Ideker, T., T. Galitski, and L. Hood, A new approach to decoding life: 
systems biology. Annu Rev Genomics Hum Genet, 2001. 2: p. 343-72. 
References   Page 207 
 
231. Mohr, S. and C.C. Liew, The peripheral-blood transcriptome: new insights 
into disease and risk assessment. Trends Mol Med, 2007. 13(10): p. 422-
32. 
232. Eisen, M.B. and P.O. Brown, DNA arrays for analysis of gene expression. 
Methods Enzymol, 1999. 303: p. 179-205. 
233. King, H.C. and A.A. Sinha, Gene expression profile analysis by DNA 
microarrays: promise and pitfalls. JAMA, 2001. 286(18): p. 2280-8. 
234. Pollock, J.D., Gene expression profiling: methodological challenges, 
results, and prospects for addiction research. Chem Phys Lipids, 2002. 
121(1-2): p. 241-56. 
235. Wang, Z., M. Gerstein, and M. Snyder, RNA-Seq: a revolutionary tool for 
transcriptomics. Nat Rev Genet, 2009. 10(1): p. 57-63. 
236. Cao, H., J. Yuen, and R.A. Hegele, Single nucleotide polymorphisms of 
the fukutin gene. J Hum Genet, 2001. 46(8): p. 487-9. 
237. Greenberg, S.A., DNA microarray gene expression analysis technology 
and its application to neurological disorders. Neurology, 2001. 57(5): p. 
755-61. 
238. Altman, R.B. and S. Raychaudhuri, Whole-genome expression analysis: 
challenges beyond clustering. Curr Opin Struct Biol, 2001. 11(3): p. 340-
7. 
239. Wyrick, J.J., et al., Genome-wide distribution of ORC and MCM proteins 
in S. cerevisiae: high-resolution mapping of replication origins. Science, 
2001. 294(5550): p. 2357-60. 
240. van 't Veer, L.J., et al., Gene expression profiling predicts clinical 
outcome of breast cancer. Nature, 2002. 415(6871): p. 530-6. 
241. Clarke, P.A., et al., Gene expression microarray analysis in cancer 
biology, pharmacology, and drug development: progress and potential. 
Biochem Pharmacol, 2001. 62(10): p. 1311-36. 
242. De Hertogh, B., et al., A benchmark for statistical microarray data 
analysis that preserves actual biological and technical variance. BMC 
Bioinformatics, 2010. 11: p. 17. 
243. Leung, Y.F. and D. Cavalieri, Fundamentals of cDNA microarray data 
analysis. Trends Genet, 2003. 19(11): p. 649-59. 
244. Quackenbush, J., Microarray data normalization and transformation. Nat 
Genet, 2002. 32 Suppl: p. 496-501. 
245. Lee, P.D., et al., Control genes and variability: absence of ubiquitous 
reference transcripts in diverse mammalian expression studies. Genome 
Res, 2002. 12(2): p. 292-7. 
246. Yang, Y.H., et al., Normalization for cDNA microarray data: a robust 
composite method addressing single and multiple slide systematic 
variation. Nucleic Acids Res, 2002. 30(4): p. e15. 
247. Qiu, X., H. Wu, and R. Hu, The impact of quantile and rank normalization 
procedures on the testing power of gene differential expression analysis. 
BMC Bioinformatics, 2013. 14: p. 124. 
248. Bolstad, B.M., et al., A comparison of normalization methods for high 
density oligonucleotide array data based on variance and bias. 
Bioinformatics, 2003. 19(2): p. 185-93. 
References   Page 208 
 
249. Gentleman, R.C., et al., Bioconductor: open software development for 
computational biology and bioinformatics. Genome Biol, 2004. 5(10): p. 
R80. 
250. Eisen, M.B., et al., Cluster analysis and display of genome-wide 
expression patterns. Proc Natl Acad Sci U S A, 1998. 95(25): p. 14863-8. 
251. Tavazoie, S., et al., Systematic determination of genetic network 
architecture. Nat Genet, 1999. 22(3): p. 281-5. 
252. Tamayo, P., et al., Interpreting patterns of gene expression with self-
organizing maps: methods and application to hematopoietic 
differentiation. Proc Natl Acad Sci U S A, 1999. 96(6): p. 2907-12. 
253. Kerr, M.K., M. Martin, and G.A. Churchill, Analysis of variance for gene 
expression microarray data. J Comput Biol, 2000. 7(6): p. 819-37. 
254. Long, A.D., et al., Improved statistical inference from DNA microarray 
data using analysis of variance and a Bayesian statistical framework. 
Analysis of global gene expression in Escherichia coli K12. J Biol Chem, 
2001. 276(23): p. 19937-44. 
255. Wu, T.D., Analysing gene expression data from DNA microarrays to 
identify candidate genes. J Pathol, 2001. 195(1): p. 53-65. 
256. Reiner, A., D. Yekutieli, and Y. Benjamini, Identifying differentially 
expressed genes using false discovery rate controlling procedures. 
Bioinformatics, 2003. 19(3): p. 368-75. 
257. Hakak, Y., et al., Genome-wide expression analysis reveals 
dysregulation of myelination-related genes in chronic schizophrenia. Proc 
Natl Acad Sci U S A, 2001. 98(8): p. 4746-51. 
258. Theilhaber, J., et al., Bayesian estimation of fold-changes in the analysis 
of gene expression: the PFOLD algorithm. J Comput Biol, 2001. 8(6): p. 
585-614. 
259. Ben-Dor, A., et al., Tissue classification with gene expression profiles. J 
Comput Biol, 2000. 7(3-4): p. 559-83. 
260. Akutsu, T., S. Miyano, and S. Kuhara, Inferring qualitative relations in 
genetic networks and metabolic pathways. Bioinformatics, 2000. 16(8): p. 
727-34. 
261. Liang, S., S. Fuhrman, and R. Somogyi, Reveal, a general reverse 
engineering algorithm for inference of genetic network architectures. Pac 
Symp Biocomput, 1998: p. 18-29. 
262. Friedman, N., et al., Using Bayesian networks to analyze expression 
data. J Comput Biol, 2000. 7(3-4): p. 601-20. 
263. Hartemink, A.J., et al., Using graphical models and genomic expression 
data to statistically validate models of genetic regulatory networks. Pac 
Symp Biocomput, 2001: p. 422-33. 
264. Firestein, G.S. and D.S. Pisetsky, DNA microarrays: boundless 
technology or bound by technology? Guidelines for studies using 
microarray technology. Arthritis Rheum, 2002. 46(4): p. 859-61. 
265. Benes, V. and M. Muckenthaler, Standardization of protocols in cDNA 
microarray analysis. Trends Biochem Sci, 2003. 28(5): p. 244-9. 
References   Page 209 
 
266. Mimmack, M.L., J. Brooking, and S. Bahn, Quantitative polymerase chain 
reaction: validation of microarray results from postmortem brain studies. 
Biol Psychiatry, 2004. 55(4): p. 337-45. 
267. Murphy, D., Gene expression studies using microarrays: principles, 
problems, and prospects. Adv Physiol Educ, 2002. 26(1-4): p. 256-70. 
268. Melin, J. and S.R. Quake, Microfluidic large-scale integration: the 
evolution of design rules for biological automation. Annu Rev Biophys 
Biomol Struct, 2007. 36: p. 213-31. 
269. Spurgeon, S.L., R.C. Jones, and R. Ramakrishnan, High throughput 
gene expression measurement with real time PCR in a microfluidic 
dynamic array. PLoS One, 2008. 3(2): p. e1662. 
270. Ramakrishnan, R., et al., Integrated Fluidic Circuits (IFCs) for digital 
PCR. Methods Mol Biol, 2013. 949: p. 423-31. 
271. Hanekom, W.A., et al., Novel application of a whole blood intracellular 
cytokine detection assay to quantitate specific T-cell frequency in field 
studies. J Immunol Methods, 2004. 291(1-2): p. 185-95. 
272. Apostolopoulos, V. and F.M. Marincola, Methods to measure vaccine 
immunity. Expert Rev Vaccines, 2010. 9(6): p. 545-6. 
273. Abu-Raddad, L.J., et al., Epidemiological benefits of more-effective 
tuberculosis vaccines, drugs, and diagnostics. Proc Natl Acad Sci U S A, 
2009. 106(33): p. 13980-5. 
274. Baran, J., et al., Three-color flow cytometry detection of intracellular 
cytokines in peripheral blood mononuclear cells: comparative analysis of 
phorbol myristate acetate-ionomycin and phytohemagglutinin stimulation. 
Clin Diagn Lab Immunol, 2001. 8(2): p. 303-13. 
275. Mao, J.H., et al., [Regulation of CD3, CD4 and CD8 expressions on 
PMA-activated human peripheral T cells]. Zhejiang Da Xue Xue Bao Yi 
Xue Ban, 2004. 33(2): p. 155-9. 
276. Fletcher, H.A., et al., Transcriptional profiling of mycobacterial antigen-
induced responses in infants vaccinated with BCG at birth. BMC Med 
Genomics, 2009. 2: p. 10. 
277. Golub, T.R., et al., Molecular classification of cancer: class discovery and 
class prediction by gene expression monitoring. Science, 1999. 
286(5439): p. 531-7. 
278. Bonnefoi, H., et al., Predictive signatures for chemotherapy sensitivity in 
breast cancer: are they ready for use in the clinic? Eur J Cancer, 2009. 
45(10): p. 1733-43. 
279. Pascual, V., D. Chaussabel, and J. Banchereau, A genomic approach to 
human autoimmune diseases. Annu Rev Immunol, 2010. 28: p. 535-71. 
280. Bean, A.G., et al., Structural deficiencies in granuloma formation in TNF 
gene-targeted mice underlie the heightened susceptibility to aerosol 
Mycobacterium tuberculosis infection, which is not compensated for by 
lymphotoxin. J Immunol, 1999. 162(6): p. 3504-11. 
281. Flynn, J.L., et al., Tumor necrosis factor-alpha is required in the 
protective immune response against Mycobacterium tuberculosis in mice. 
Immunity, 1995. 2(6): p. 561-72. 
References   Page 210 
 
282. Flynn, J.L., et al., IL-12 increases resistance of BALB/c mice to 
Mycobacterium tuberculosis infection. J Immunol, 1995. 155(5): p. 2515-
24. 
283. Flynn, J.L., et al., An essential role for interferon gamma in resistance to 
Mycobacterium tuberculosis infection. J Exp Med, 1993. 178(6): p. 2249-
54. 
284. Orme, I.M., The role of CD8+ T cells in immunity to tuberculosis infection. 
Trends Microbiol, 1993. 1(3): p. 77-8. 
285. Smith, S.M., et al., Human CD8+ CTL specific for the mycobacterial 
major secreted antigen 85A. J Immunol, 2000. 165(12): p. 7088-95. 
286. Silva, C.L. and D.B. Lowrie, Identification and characterization of murine 
cytotoxic T cells that kill Mycobacterium tuberculosis. Infect Immun, 2000. 
68(6): p. 3269-74. 
287. Kozakiewicz, L., et al., B cells regulate neutrophilia during 
Mycobacterium tuberculosis infection and BCG vaccination by 
modulating the interleukin-17 response. PLoS Pathog, 2013. 9(7): p. 
e1003472. 
288. Chen, R.T., et al., Measles antibody: reevaluation of protective titers. J 
Infect Dis, 1990. 162(5): p. 1036-42. 
289. Mathias, R.G., et al., The role of secondary vaccine failures in measles 
outbreaks. Am J Public Health, 1989. 79(4): p. 475-8. 
290. Casadevall, A. and L.A. Pirofski, The damage-response framework of 
microbial pathogenesis. Nat Rev Microbiol, 2003. 1(1): p. 17-24. 
291. Chen, J.J., Key aspects of analyzing microarray gene-expression data. 
Pharmacogenomics, 2007. 8(5): p. 473-82. 
292. Tavor, S., et al., The CXCR4 antagonist AMD3100 impairs survival of 
human AML cells and induces their differentiation. Leukemia, 2008. 
22(12): p. 2151-5158. 
293. Pomeroy, S.L., et al., Prediction of central nervous system embryonal 
tumour outcome based on gene expression. Nature, 2002. 415(6870): p. 
436-42. 
294. Shipp, M.A., et al., Diffuse large B-cell lymphoma outcome prediction by 
gene-expression profiling and supervised machine learning. Nat Med, 
2002. 8(1): p. 68-74. 
295. Joosten, S.A., H.A. Fletcher, and T.H. Ottenhoff, A helicopter perspective 
on TB biomarkers: pathway and process based analysis of gene 
expression data provides new insight into TB pathogenesis. PLoS One, 
2013. 8(9): p. e73230. 
296. Smyth, G.K., Limma: linear models for microarray data. In: Bioinformatics 
and Computational Biology Solutions using R and Bioconductor, R. 
Gentleman, V. Carey, S. Dusoit, R. Irizarry, W.Huber (eds). Springer, 
New York, 2005: p. 397-420. 
297. Tibshirani, R., et al., Diagnosis of multiple cancer types by shrunken 
centroids of gene expression. Proc Natl Acad Sci U S A, 2002. 99(10): p. 
6567-72. 
References   Page 211 
 
298. Subramanian, A., et al., Gene set enrichment analysis: a knowledge-
based approach for interpreting genome-wide expression profiles. Proc 
Natl Acad Sci U S A, 2005. 102(43): p. 15545-50. 
299. Chaussabel, D., et al., A modular analysis framework for blood genomics 
studies: application to systemic lupus erythematosus. Immunity, 2008. 
29(1): p. 150-64. 
300. Van Laere, S.J., et al., Identification of cell-of-origin breast tumor 
subtypes in inflammatory breast cancer by gene expression profiling. 
Breast Cancer Res Treat, 2006. 95(3): p. 243-55. 
301. Makretsov, N.A., et al., Hierarchical clustering analysis of tissue 
microarray immunostaining data identifies prognostically significant 
groups of breast carcinoma. Clin Cancer Res, 2004. 10(18 Pt 1): p. 6143-
51. 
302. Grossi, F., et al., Prognostic stratification of stage IIIA pN2 non-small cell 
lung cancer by hierarchical clustering analysis of tissue microarray 
immunostaining data: an Alpe Adria Thoracic Oncology Multidisciplinary 
Group study (ATOM 014). J Thorac Oncol, 2010. 5(9): p. 1354-60. 
303. Badsha, M.B., et al., Robust complementary hierarchical clustering for 
gene expression data analysis by beta-divergence. J Biosci Bioeng, 
2013. 116(3): p. 397-407. 
304. Sampson, B., et al., Hyperzincaemia and hypercalprotectinaemia: a new 
disorder of zinc metabolism. Lancet, 2002. 360(9347): p. 1742-5. 
305. Corbin, B.D., et al., Metal chelation and inhibition of bacterial growth in 
tissue abscesses. Science, 2008. 319(5865): p. 962-5. 
306. Gopal, R., et al., S100A8/A9 proteins mediate neutrophilic inflammation 
and lung pathology during tuberculosis. Am J Respir Crit Care Med, 
2013. 188(9): p. 1137-46. 
307. Areeshi, M.Y., et al., CD14 -159 C>T gene polymorphism with increased 
risk of tuberculosis: evidence from a meta-analysis. PLoS One, 2013. 
8(5): p. e64747. 
308. Wieland, C.W., et al., CD14 contributes to pulmonary inflammation and 
mortality during murine tuberculosis. Immunology, 2008. 125(2): p. 272-9. 
309. Homolka, J., et al., Evaluation of soluble CD 14 and neopterin as serum 
parameters of the inflammatory activity of pulmonary sarcoidosis. Clin 
Investig, 1992. 70(10): p. 909-16. 
310. Hoheisel, G., et al., Increased soluble CD14 levels in BAL fluid in 
pulmonary tuberculosis. Chest, 1995. 108(6): p. 1614-6. 
311. Naranbhai, V., et al., Ratio of monocytes to lymphocytes in peripheral 
blood identifies adults at risk of incident tuberculosis among HIV-infected 
adults initiating antiretroviral therapy. J Infect Dis, 2014. 209(4): p. 500-9. 
312. Pitabut, N., et al., Potential function of granulysin, other related effector 
molecules and lymphocyte subsets in patients with TB and HIV/TB 
coinfection. Int J Med Sci, 2013. 10(8): p. 1003-14. 
313. Ameixa, C. and J.S. Friedland, Interleukin-8 secretion from 
Mycobacterium tuberculosis-infected monocytes is regulated by protein 
tyrosine kinases but not by ERK1/2 or p38 mitogen-activated protein 
kinases. Infect Immun, 2002. 70(8): p. 4743-6. 
References   Page 212 
 
314. Casarini, M., et al., Cytokine levels correlate with a radiologic score in 
active pulmonary tuberculosis. Am J Respir Crit Care Med, 1999. 159(1): 
p. 143-8. 
315. Sadek, M.I., et al., Chemokines induced by infection of mononuclear 
phagocytes with mycobacteria and present in lung alveoli during active 
pulmonary tuberculosis. Am J Respir Cell Mol Biol, 1998. 19(3): p. 513-
21. 
316. Kurashima, K., et al., Elevated chemokine levels in bronchoalveolar 
lavage fluid of tuberculosis patients. Am J Respir Crit Care Med, 1997. 
155(4): p. 1474-7. 
317. Yamada, Y., et al., Cytokines in pleural liquid for diagnosis of tuberculous 
pleurisy. Respir Med, 2001. 95(7): p. 577-81. 
318. Friedland, J.S., et al., Inhibition of ex vivo proinflammatory cytokine 
secretion in fatal Mycobacterium tuberculosis infection. Clin Exp 
Immunol, 1995. 100(2): p. 233-8. 
319. Fallon, J., et al., In vivo induction of massive proliferation, directed 
migration, and differentiation of neural cells in the adult mammalian brain. 
Proc Natl Acad Sci U S A, 2000. 97(26): p. 14686-91. 
320. Cliff, J.M., et al., Distinct phases of blood gene expression pattern 
through tuberculosis treatment reflect modulation of the humoral immune 
response. J Infect Dis, 2013. 207(1): p. 18-29. 
321. Rand, L., et al., Matrix metalloproteinase-1 is regulated in tuberculosis by 
a p38 MAPK-dependent, p-aminosalicylic acid-sensitive signaling 
cascade. J Immunol, 2009. 182(9): p. 5865-72. 
322. Yang, C.S., et al., ASK1-p38 MAPK-p47phox activation is essential for 
inflammatory responses during tuberculosis via TLR2-ROS signalling. 
Cell Microbiol, 2008. 10(3): p. 741-54. 
323. Hanekom, W.A., et al., Immunological outcomes of new tuberculosis 
vaccine trials: WHO panel recommendations. PLoS Med, 2008. 5(7): p. 
e145. 
324. Aagaard, C., et al., Protection and polyfunctional T cells induced by 
Ag85B-TB10.4/IC31 against Mycobacterium tuberculosis is highly 
dependent on the antigen dose. PLoS One, 2009. 4(6): p. e5930. 
325. Zak, D.E., et al., Merck Ad5/HIV induces broad innate immune activation 
that predicts CD8(+) T-cell responses but is attenuated by preexisting 
Ad5 immunity. Proc Natl Acad Sci U S A, 2012. 109(50): p. E3503-12. 
326. Querec, T.D., et al., Systems biology approach predicts immunogenicity 
of the yellow fever vaccine in humans. Nat Immunol, 2009. 10(1): p. 116-
25. 
327. Tan, Y., et al., Gene signatures related to B-cell proliferation predict 
influenza vaccine-induced antibody response. Eur J Immunol, 2014. 
44(1): p. 285-95. 
328. Teles, R.M., et al., Type I interferon suppresses type II interferon-
triggered human anti-mycobacterial responses. Science, 2013. 
339(6126): p. 1448-53. 
References   Page 213 
 
329. Dominguez, M.H., et al., Highly multiplexed quantitation of gene 
expression on single cells. J Immunol Methods, 2013. 391(1-2): p. 133-
45. 
330. Pfaffl, M.W., A new mathematical model for relative quantification in real-
time RT-PCR. Nucleic Acids Res, 2001. 29(9): p. e45. 
331. de Jonge, H.J., et al., Evidence based selection of housekeeping genes. 
PLoS One, 2007. 2(9): p. e898. 
332. Brice, G.T., et al., Expression of the chemokine MIG is a sensitive and 
predictive marker for antigen-specific, genetically restricted IFN-gamma 
production and IFN-gamma-secreting cells. J Immunol Methods, 2001. 
257(1-2): p. 55-69. 
333. Brahmbhatt, S., et al., Human T cell responses to peptides of the 
Mycobacterium leprae 45-kD serine-rich antigen. Clin Exp Immunol, 
2002. 128(1): p. 140-8. 
334. Berthoud, T.K., et al., MIG (CXCL9) is a more sensitive measure than 
IFN-gamma of vaccine induced T-cell responses in volunteers receiving 
investigated malaria vaccines. J Immunol Methods, 2009. 340(1): p. 33-
41. 
335. Abramo, C., et al., Monokine induced by interferon gamma and IFN-
gamma response to a fusion protein of Mycobacterium tuberculosis 
ESAT-6 and CFP-10 in Brazilian tuberculosis patients. Microbes Infect, 
2006. 8(1): p. 45-51. 
336. Pulendran, B., S. Li, and H.I. Nakaya, Systems vaccinology. Immunity, 
2010. 33(4): p. 516-29. 
337. Nakaya, H.I., S. Li, and B. Pulendran, Systems vaccinology: learning to 
compute the behavior of vaccine induced immunity. Wiley Interdiscip Rev 
Syst Biol Med, 2012. 4(2): p. 193-205. 
338. Henn, A.D., et al., High-resolution temporal response patterns to 
influenza vaccine reveal a distinct human plasma cell gene signature. Sci 
Rep, 2013. 3: p. 2327. 
339. Hu, S.L., Non-human primate models for AIDS vaccine research. Curr 
Drug Targets Infect Disord, 2005. 5(2): p. 193-201. 
340. Dumur, C.I., et al., Evaluation of quality-control criteria for microarray 
gene expression analysis. Clin Chem, 2004. 50(11): p. 1994-2002. 
341. Silvy, M., et al., Improvement of gene expression analysis by RQ-PCR 
technology: addition of BSA. Leukemia, 2004. 18(5): p. 1022-5. 
342. Mayeux, R., Biomarkers: potential uses and limitations. NeuroRx, 2004. 
1(2): p. 182-8. 
343. Bacchetti, P., S.G. Deeks, and J.M. McCune, Breaking free of sample 
size dogma to perform innovative translational research. Sci Transl Med, 
2011. 3(87): p. 87ps24. 
 




Appendix 1: Correlation between CXCL9 mRNA expression and IFN-γ-
expressing CD4+ T cells in the validation cohort. 
 
 
Correlation between CXCL9 mRNA expression and IFN-γ-expressing CD4+ T cells in the 
validation cohort. 
PBMCs were stimulated with BCG or left unstimulated for 12 hrs. RNA was extracted, 
transcribed to cDNA and CXCL9 expression was measured by convention qRT-PCR. Whole 
blood was incubated with BCG or left unstimulated for 12 hours and frequencies of IFN-γ-
expressing CD4+ T cells measured by intracellular cytokine staining assay and flow cytometry. 
Following background subtraction, correlation between CXCL9 mRNA expression and 










Appendix 2: Cell count and viability of thawed PBMCs from participants in 
the validation cohort. 
Study Number Total Number of cells 
(106) 
Viability (%) 
14365 7.2 72.22 
11438 8.5 90.58 
14383 7.9 69.62 
14401 5.4 77.77 
14423 6.3 60.31 
12984 7.2 79.16 
14483 6.2 79.03 
14516 10.1 85.14 
15224 8.5 74.11 
14437 8.6 86.04 
14978 14.6 82.87 
15259 5.5 80.00 
15594 14.2 81.54 
15641 13.2 77.27 
15666 6.8 80.88 
16292 25.9 92.66 
18508 7.4 81.08 
16016 18 87.77 
16098 31.2 84.93 
16204 36.2 85.54 
16647 28.3 88.33 
19021 11.9 81.51 
19391 36.4 86.78 
19530 37.2 80.08 
16491 12.3 74.79 
16562 5.2 78.84 
16663 25.1 82.02 
16849 6.8 82.35 
16859 10.1 79.20 
19563 11.7 89.74 
19636 27.6 90.94 
16872 27.2 83.45 
16926 35 90.00 
17058 29.1 91.06 
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 14496 8.1 93.82 
20016 22.3 86.99 
20096 46.7 88.86 
20700 23 87.82 
15137 15.6 84.61 
15686 14.2 77.46 
16185 13.5 93.33 
16969 7.6 89.47 
21580 13 90.76 
21668 7.7 81.81 
14637 13.8 79.71 
16984 25.1 87.64 
17038 35.6 89.88 
14557 18.1 91.16 
19210 33.2 90.36 
20466 32.5 87.69 
14341 25 90.00 
14530 25.6 83.98 
15769 8.9 88.76 
15881 9 78.88 
16149 18.2 84.61 
17029 7 71.42 
14552 22.3 82.95 
16292 23.5 79.57 
19061 25.3 86.95 
19573 10.6 79.24 
